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Pancreatic ductal adenocarcinoma (PDAC) is noted for its resistance to therapy and poor 
prognosis. PDAC is characterised by extensive local invasion and metastases at distant 
organs. Having previously shown that the cAMP cascade had regulatory effects on cell 
migration/invasion in PDAC cells, which are vital processes in metastasis formation, we 
decided to characterise the cAMP signalling machinery in PANC-1 cells. In this study we 
adopted a live-cell imaging approach taking advantage of genetically engineered probes that 
use Fӧrster resonance energy transfer (FRET) to reveal cAMP concentration and PKA activity 
at a single cell level. Using the Epac-based cAMP sensor H134 we found that PDE3 and PDE4 
are the principal cAMP destroyers, whereas β-adrenoceptors are the main physiological 
cAMP-cascade activators, in PANC-1 cells. Downstream, using Boyden chamber assays we 
found that PDE3 has the biggest role in cell migration under ‘basal’ conditions, whereas 
PDE4 has a bigger role in the presence of isoproterenol. However, isoproterenol on its own 
did not influence PANC-1 cell migration despite having the ability to increase cAMP 
concentration inside the cell. This part of the study puts forward PDE3 and PDE4 as potential 
targets for reducing migration/invasion of PDAC. In the second part of the study, we found 
that these cells have an efficient Ca2+ signalling system; in which ORAI1 is the main mediator 
of store-operated Ca2+ entry (SOCE) in PANC-1 cells. To explore the possibility of a Ca2+-
cAMP crosstalk in PANC-1 cells, we used the AKAR4 probe to measure PKA activity during 
Ca2+ responses. The application of neurotensin (NT), a well-known IP3-producing agonist in 
this cell type, induced a Ca2+ response which was accompanied by an increase in PKA 
activity. SOCE is likely to play an important role in this process since the activation of SOCE 
by thapsigargin-mediated store depletion consistently and robustly increased PKA activity. 
To further investigate the downstream roles of PKA signalling in PANC-1 cells we utilised 
immunofluorescence to visualise the distribution of PKA activity. Using antibodies specific 
for phosphorylated PKA substrates, we found that phosphorylated PKA substrates are 
preferentially concentrated in the nucleus; and notably at the leading edges of PANC-1 cells 
displaying a migratory phenotype. At the leading edges phosphorylated PKA substrates 
colocalised with actin-rich ruffles. Interestingly, utilising the rapamycin-inducible 
heterodimerisation system to reveal endogenous ER-PM junctions in migrating PANC-1 cells, 
we found that ER-PM junctions are also situated in close proximity to the leading edge. 
These results suggest that SOCE activates PKA responses in the region strategically 
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Chapter 1: Introduction 
1.1. Pancreatic ductal adenocarcinoma (PDAC) 
Pancreatic ductal adenocarcinoma is the cancer of the exocrine pancreas, representing 95% 
of all pancreatic cancers (the other being insulinoma, cancer of the endocrine pancreas). 
The development process from the exocrine pancreas into PDAC is complex, but a few 
critical stages are known. The first critical stage is the activating mutation of the Kras protein 
(G12D), resulting in a constitutively active KRAS pathway (Shi et al., 2013, Kruger et al., 
2014). This likely provides a driving force for the creation of a series of lesions, known as 
pancreatic intraepithelial neoplasia (PanINs1-3, graded by the severity of the lesions) 
(Maitra et al., 2005, Hruban et al., 2001, Kopp et al., 2012); and the mutated cells in the 
lesions start to remodel its surrounding environment, especially the stroma (Pylayeva-Gupta 
et al., 2012, Chu et al., 2007). Moreover, EGF has also been shown to accelerate the PanIN1-
3  PDAC progression parallel and independent of Kras signalling; implying that EGFR 
signalling is also involved (Navas et al., 2012). The second stage is the loss of the tumour 
suppressor gene p16, also early in the PanIN development either by promoter deletion or 
homozygous deletion (Deer et al., 2010, Cowgill and Muscarella, 2003). As the lesions 
amplify, they are also reported to extensively remodel their stroma and induce an 
inflammatory, immunosuppressive environment to avoid detection from the immune 
system (Pylayeva-Gupta et al., 2012). The final critical stage appears to be the loss of the 
tumour suppressor gene TP53, occurring in the final stages of the transformation from 
PanIN into PDAC (Moore et al., 2003). The loss of another tumour suppressor SMAD4 is also 
commonly reported in about 50% of invasive PDACs (Deer et al., 2010, Kruger et al., 2014). 
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It was traditionally assumed that PDAC is derived from pancreatic ductal epithelial cells. 
However, recently evidence is accumulating suggesting that this cancer may instead arise 
from differentiated acinar cells being ‘forced’ into a more ductal-like phenotype in a Kras-
dependent manner, in a process known as acinar-ductal metaplasia (Shi et al., 2013, Kopp et 
al., 2012). Nevertheless, ambiguity remains on the origin of PDAC and more study is 
required.  
 
Statistically PDAC is currently the 5th most common cause of cancer-related deaths in the UK 
and 4th in the USA, but has the worst survival rate of all cancers; with a median survival 
period of just 6 months and a 97% mortality rate within 5 years (Pylayeva-Gupta et al., 2012, 
Kern et al., 2011, Maitra and Hruban, 2008). This is mainly due to the disease being 
asymptomatic until presentation, by which point the cancer had already reached an 
advanced stage, making this cancer resistant to chemotherapy (Schuller and Al-Wadei, 
2010). The best possible treatment for this disease, pancreatectomy, is still relatively 
ineffective due to the aggressive and invasive nature of PDAC (Rissel et al., 2003). Like many 
other cancers, the main cause of death from PDAC is metastatic disease, and advanced 
stage PDAC clinically forms extensive secondary tumours; especially in the liver, lymphatic 
system and central nervous system (Rhim et al., 2012, Delcore et al., 1996). Therefore, 
information on the intracellular signalling pathways that contribute to their aggressive 
physiology is urgently needed to help reduce the mortality rate.  
 
1.2. G-protein coupled receptors (GPCR) system 
The GPCR is a massive family of seven-pass membrane receptors for first messengers, 
consisting of over 1000 different types and their genes comprises 1% of the genome 
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(Hermans, 2003). There are 3 different groups of GPCRs – Group A, consisting of receptors 
for classical neurotransmitters, prostaglandins, odour and rhodopsin; group B, including 
receptors for most hormones; and group C, which contains receptors for glutamate, GABA 
and Ca2+ ions (Wess, 1998). The GPCR complex is composed of four components: the 
receptor, which contains 7 transmembrane domains with the intracellular loops forming the 
GTP and GDP binding domain, hence its name (Kobilka, 2007). There, the receptor is 
coupled to a heterotrimeric G protein consisting of the Gα subunit and a Gβγ dimer (Neves 
et al., 2002, Hamm, 1998).  
 
There are 16 different genes encoding for Gα, 5 for Gβ and 12 for Gγ (Hamm, 1998, Neves et 
al., 2002, Cabrera-Vera et al., 2003); which contributes to the diversity of this receptor type 
and subsequent function. Gα is a GTPase that is structurally not dissimilar to the cytosolic 
small G-proteins like Ras and Rac (Cabrera-Vera et al., 2003). It contains a GTPase region, 
which mediates the hydrolysis of GTP into GDP; and a helical domain, important for keeping 
GTP in its binding pocket (Cabrera-Vera et al., 2003, Hamm, 1998). Gβ consists of a 7-blade 
β-propeller, and complexes strongly with the Gγ subunit via the coiled coil domain in the 
latter, and then all along the base of the Gβ-subunit (Cabrera-Vera et al., 2003, Hamm, 
1998). When the receptor is inactive, Gα is bound with GDP and is locked together with Gβγ; 
on ligand binding, a conformational change ensues in Gα causing an exchange of GTP for 
GDP and its resultant dissociation from the Gβγ subunits (Sprang, 1997, Hamm, 1998, 
Cabrera-Vera et al., 2003).  
 
Unbound Gα-GTP can mediate a wide range of functions in different cells. There are 4 main 
classes of Gα subunits grouped by the homology of their amino acid sequences (Suzuki et 
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al., 2009): Gαs, Gαi/o, Gαq/11, and Gα12/13, each further divided into subclasses (Cabrera-
Vera et al., 2003, Hermans, 2003, Neves et al., 2002) and carry out unique downstream 
effects. Gαs is possibly the best characterised subunit of this family, and it activates all 
membrane isoforms of adenylyl cyclases (AC) to produce cAMP in cells (Neves et al., 2002), 
of which β2-adrenergic receptors in cardiomyocytes (Mongillo and Zaccolo, 2006) and 
glucagon-like peptide (GLP) receptors in pancreatic β-cells (Tian et al., 2011a) are the best 
examples. Gαi, although initially found as the adenylyl cyclase inhibiting subunit (e.g. 
calcium sensing receptors and groups II and III metabotropic glutamate receptors in the 
brain) (Riccardi and Kemp, 2012, Moussawi and Kalivas, 2010, Neves et al., 2002), 
understanding in its roles has since diversified into the regulation of Ca2+ and K+ (also called 
Gαz) (Jeong and Ikeda, 1998) and the activation of PDE6 (transducin, Gαt) (Stryer, 1983) to 
name a few. Gαq is classically known to be PLCβ activators to trigger the IP3 signalling 
pathway; examples include the cholecystokinin receptor in pancreatic acinar cells (Murphy 
et al., 2008). The functions of Gα12/13, compared to others, is still not completely 
understood (Neves et al., 2002). Examples of this receptor type includes the thrombin and 
LPA receptor, and there is accumulating evidence that p115RhoGEF can be activated by this 
Gα subtype, resulting in the induction of the RhoA signalling cascade (Suzuki et al., 2009). 
The importance of Gα12/13 is the observation that Gα13 KO mice is embryonically lethal 
(Offermanns et al., 1997, Suzuki et al., 2009). Finally, it is important to mention here that 
crosstalk exists between the receptors coupled with different classes of Gα subunits; 
converging their signalling onto the same intracellular target; with the convergence of Gαq 
and Gα12/13 onto Rho being one such example (Hermans, 2003, Gu et al., 2002, Suzuki et 
al., 2009). Conversely, in many cases the receptor-Gα coupling is not rigid; meaning that a 
single GPCR can couple to multiple Gα isoforms in the same cell. For example, in the heart 
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β2-adrenergic receptors, mentioned above to conventionally couple to Gαs, was found to 
also couple to the AC- inhibitory Gαi/o subunits (Kilts et al., 2000). Furthermore, in the rat 
gonadotroph, gonadotrophin-releasing hormone (GnRH) receptors was found to couple 
with Gαq, Gαi and Gαs (Stanislaus et al., 1998) 
 
Independent of Gα, the Gβγ subunit can also activate signalling pathways by the virtue that 
it interacts with a wide range of proteins (Hermans, 2003, Cabrera-Vera et al., 2003). One of 
the more established functions of the Gβγ subunit is the activation of phospholipase Cβ 
(PLCβ), phospholipase D (PLD), Bruton’s tyrosine kinase (Btk). Additionally, the Gβγ subunit 
has been known to modulate the activity of ACs (Khan et al., 2013, Cabrera-Vera et al., 
2003); as it has been known to further potentiate the actions of the Gαs subunit on ACII, IV 
and VII, but inhibit that of ACI (Willoughby and Cooper, 2007). Hence, it is possible that after 
activation of a single GPCR, Gα and Gβγ can each deliver independent downstream signals; 
such as the inhibition of AC by Gαi/o and activation of PLC by Gβγ (Hermans, 2003).     
 
When GPCR signalling is no longer required it is turned off by the hydrolysis of GTP in the 
Gα-subunit, resulting in the re-stabilisation of interactions with the Gβγ subunit (Cabrera-
Vera et al., 2003, Hamm, 1998). This process can be accelerated by GTPase activating 
proteins (GAPs) such as regulators of G-protein signalling (RGS) proteins (Suzuki et al., 2009). 
In addition, chronic GPCR activation also results in β-arrestin mediated endocytosis of the 
receptors, resulting in its sequestration into the cell where they are mostly degraded; but 
evidence exists that they can carry on signalling in vesicles deep inside the cell (Irannejad 
and von Zastrow, 2014).      
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1.3. The Ca2+ signalling system  
In a typical mammalian system the intracellular concentration of free Ca2+ ([Ca2+]cyt) is kept 
at approximately 100nM in the cytosol, whereas in the extracellular fluid it stands at about 
5mM (Clapham, 2007). This creates a massive concentration gradient across the plasma 
membrane. Cells have taken advantage of this gradient to create specialised channels to 
allow Ca2+ entry into the cytosol at appropriate moments. Due to the steep gradient, Ca2+ 
will rush into the cell almost immediately upon channel opening, increasing [Ca2+]cyt by 
around 10 fold (Clapham, 2007). High [Ca2+]cyt is toxic to the cell, so intracellular Ca
2+ 
homeostasis has to be tightly controlled by efficient Ca2+ extruding mechanisms, namely 
Ca2+ pumps and Na+/Ca2+ exchangers at the plasma membrane to prevent the overload of 
this ion in physiological conditions (Kass and Orrenius, 1999, Nicotera et al., 1992, Pozzan et 
al., 1994). More importantly, inside the cell the mitochondria (Williams et al., 2013) and 
endoplasmic reticulum (ER) require elevated [Ca2+] for effective function, with [Ca2+]ER at 
approximately 400µM (Samtleben et al., 2013, LaFerla, 2002); so they act as intracellular 
Ca2+ stores. Therefore, cells have also evolved channels and pumps onto these organelles to 
maintain their own [Ca2+] and modulate [Ca2+]cyt. This flux of Ca
2+ into and out of cytosol 
from outside the cell and intracellular stores forms the basis of Ca2+ signalling in cells 
(Clapham, 2007).  
 
There are two types of cellular Ca2+ signalling: signalling in excitable and non-excitable cells. 
Excitable cells are cells that base their Ca2+ signalling on the charge difference across the 
plasma membrane (also known as the membrane potential). Ca2+ entry into excitable cells is 
mediated by voltage-sensitive channels on the PM such as the L-type Ca2+ channels that 
open in response to depolarisation. Examples of excitable cells include neurones and 
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pancreatic β-cells, which couples increases of [Ca2+] to vesiclular fusion and excretion of first 
messengers (Idevall-Hagren et al., 2010, Braun et al., 2008). Non-excitable cells, on the 
other hand, rely on the mobilisation of intracellular Ca2+ stores, predominantly from the ER, 
in response to extracellular first messengers followed by second messenger signalling (Van 
Den Brink et al., 1999). Examples of non-excitable cells include most epithelial cells including 
exocrine cells from the digestive system such as pancreatic acinar cells.  
 
Focusing on non-excitable cells, activation of the Ca2+ signalling cascade involve the binding 
of first messengers to receptors on the PM, most commonly GPCRs or receptor tyrosine 
kinases (RTKs) (Pannekoek et al.), resulting in the intracellular activation of phospholipase 
Cβ (PLCβ) or PLCγ respectively. PLC then cleaves phosphatidylinositol-4, 5-bisphosphate 
(PIP2), a component of the PM, into diacylglycerol (DAG) and inositol-3-trisphosphate (IP3), 
resulting in the latter being released into the cytosol, where it docks onto its receptor (IP3 
receptors, or IP3R) on the ER; ending in the release of calcium into the cytosol. IP3Rs are 
specialised, six-transmembrane spanning, tetrameric intracellular Ca2+ channels on the ER 
that open on IP3 binding and allow Ca
2+ to flow into the cytosol down the gradient 
(Clapham, 2007, Taylor and Tovey, 2010). In addition, also resident on the ER are ryanodine 
receptors (RyR), which have the same end-point function as IP3R but are activated directly 
by Ca2+, facilitating a process called Ca2+-induced Ca2+ release (CICR) (Clapham, 2007).   
 
1.3.1. Store operated calcium entry (SOCE) 
In stimulated non-excitable cells, cytosolic Ca2+ transients develop as a result of Ca2+ release 
from the ER; meaning that after multiple stimulations, ER Ca2+ stores would be cumulatively 
depleted in the long term, and would render the cell incapable of sustaining medium to 
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long-term Ca2+ signals. Furthermore, chronic Ca2+ depletion from the ER impedes its primary 
function of facilitating protein folding, resulting in ER stress (Rasheva and Domingos, 2009, 
Austin, 2009). Therefore, cells need mechanisms by which to replenish ER Ca2+ stores. This is 
carried out in a process known as store operated Ca2+ entry (SOCE), which causes the influx 
of Ca2+ into the cytosol, where sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) on 
the ER membrane pumps 2 Ca2+ ions back into the lumen in exchange for 1 molecule of ATP 
hydrolysed (Clapham, 2007). SOCE is mediated mainly by two components: Stromal 
interaction molecule on the ER, and ORAI proteins on the PM (Cahalan, 2009). The principal 
role of SOCE appears to be sustaining long-term Ca2+ signalling regulation of gene 
transcription, as reported in mast and leukaemia cells (Kar et al., 2012). The importance of 
SOCE is undisputed (the pathophysiological effects of the lack of SOCE are listed in Soboloff 
et al., 2012), but it is best exemplified in the immune system, where ORAI1 KO mice has 
impaired adaptive immune responses (Feske et al., 2012). 
 
1.3.1.1. Stromal interaction molecule (STIM) 
STIM is a type 1A single span multi-domain membrane protein that mainly populates the ER, 
although 10% of the molecules also localise to the PM. The N-terminal region of each 
monomer contains two EF-hand domains, followed by a sterile-α-motif (SAM); and these 
two domains are resident in the ER lumen (Soboloff et al., 2011). The N-terminus of the 
cytoplasmic region of STIM immediately after the transmembrane domain are made of 3 
coiled-coil (from N-terminal side, CC1, CC2 and CC3) regions formed mainly of α-helices 
(Soboloff et al., 2012, Cole et al., 2008). The combined CC2 and CC3 regions are also known 
as the STIM-ORAI activating region (SOAR) (Yuan et al., 2009). After CC3, towards the C-
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terminus comes the inhibitory domain (ID) followed by the Pro/Ser rich (PS) domain, before 
reaching the Lys-rich domain at the C-terminus (Soboloff et al., 2012, Lee et al., 2014).  
There are 2 different isoforms of STIM - STIM1 and STIM2, with the main difference being 
the properties of the luminal EF hand. The EF hand of STIM2 (Kd = 400µM) has a half the Ca
2+ 
affinity of that in STIM1 (Kd = 200µM) (Soboloff et al., 2012, Fahrner et al., 2013, Fahrner et 
al., 2009), lowering its SOCE activation threshold and hence activates at higher [Ca2+]ER 
(Parvez et al., 2008, Zhou et al., 2009). However, STIM2 are poor activators of ORAI channels 
due to the conformational change in the luminal domain being more sluggish after store 
depletion (Soboloff et al., 2012, Zhou et al., 2009, Parvez et al., 2008). A recent report 
suggests STIM2 to have a ‘housekeeping’ function to maintain a constant basal [Ca2+]ER, and 
is important for maintaining long term Ca2+ oscillations to regulate transcription (Kar et al., 
2012).  
 
At resting [Ca2+]ER, STIM normally exists as a dimer that is distributed throughout the ER 
(Soboloff et al., 2012). The dimerization interface is proposed to be at the CC regions in the 
cytoplasmic domain (Muik et al., 2009), where CC1 and the SOAR region from each 
monomer mutually interact with the former sterically inhibiting the latter (Yang et al., 
2012). In the ER lumen, only one N-terminal EF-hand binds Ca2+, which serves as a sensor for 
this ion; whereas the other remains hidden (Soboloff et al., 2012). After store depletion, 
Ca2+ detaches from the EF-hand, inducing a conformational change in the EF hand and SAM 
domains in such a way that favours their interaction within the dimer, resulting in the 
oligomerisation of STIM molecules (Covington et al., 2010, Muik et al., 2009). This clustering 
of EF-hand and SAM domains between dimers also translates a conformational change into 
the cytosolic domain, where CC1 would partially unfold into a ‘straightened’ configuration; 
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in the process releasing the autoinhibitory mechanism on the SOAR region (Soboloff et al., 
2012, Muik et al., 2011). This activated STIM oligomer then proceeds to localise to the PM, 
where it (SOAR regions of STIM oligomers) interacts with the cytoplasmic coiled-coil domain 
of ORAI channels to activate SOCE (Calloway et al., 2010). The stoichiometry of a STIM-ORAI 
complex is reported to be 2 STIM dimers for every ORAI subunit (Hoover and Lewis, 2011, 
Rothberg et al., 2013). It should be noted here, however, aside from ORAI, the transient 
receptor potential cation channel (TRPC) family of channels has also been touted to be 
mediators of SOCE in some cells, though this hypothesis is still debated (Salido et al., 2009, 
Ramsey et al., 2006). SOCE is turned off by one rapid and one slow process – Ca2+-
dependent inactivation (CDI), the rapid phase of inhibition, is caused by the increase of local 
[Ca2+] in the immediate vicinity of the intracellular side of ORAI, which prevents further Ca2+ 
entry (Zweifach and Lewis, 1995, Derler et al., 2009). CDI is also partly facilitated by 
calmodulin binding to ID region on the STIM C-terminus (Litjens et al., 2004). The slow phase 
is the dissociation of STIM clusters from ORAI as Ca2+ returns into the EF hand in the ER 
lumen (Shen et al., 2011). 
  
1.3.1.2. CRAC channels – ORAI subunits 
The full structure of the CRAC channel formed by ORAI is still not fully clear, as it has no 
homology to other Ca2+ channels (Fahrner et al., 2013). The conventional view was that the 
CRAC channel is a tetrameric structure, due to an overwhelming amount of evidence 
stockpiled. However, a recent crystallographic structure of a drosophila ORAI channel shows 
that the subunits of ORAI actually arrange themselves into a hexameric configuration 
around the pore, formed by three pairs of dimers, potentially making it a hexamer (Hou et 
al., 2012). Thankfully, more is known about the key structural elements of the ORAI 
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subunits. Each subunit contain 4 transmembrane domains (from the N-terminal, termed 
M1, M2, M3 and M4), with both termini in the cytoplasm (Fahrner et al., 2013, Fahrner et 
al., 2009). M1 of each subunit contributes to the pore, with both M1 and M4 containing 
extensions that protrude into the cytoplasm. The N-terminus contains proline/arginine rich 
regions and a polybasic motif, whereas the C-terminus contains a basic coiled-coil domain 
(Fahrner et al., 2009). The pore is impermeable to monovalent ions when other divalent 
ions are present, but is very selective for Ca2+ ions (Rothberg et al., 2013); this is mainly due 
to a ring of glutamate residues on the pore entrance, which acts as an ion filter. Beyond the 
entrance, the pore cavity is relatively hydrophobic, with the intracellular portion being 
positively charged contributed by the M1 extension, which may act as an electrostatic 
barrier at rest (Rothberg et al., 2013, McNally et al., 2012). At resting conditions, ORAI1 
display very low conductance, requiring millimolar concentrations of the ion for entry and 
only increasing on contact with STIM clusters (Hoth and Penner, 1993). This corresponds 
well to its physiological function as it makes sure that no Ca2+ enters the cell before STIM is 
activated.    
 
The electrophysiological property of this channel is defined by the small, inwardly rectifying 
current, termed ICRAC, it occurs following store depletion (Hoth and Penner, 1992). The exact 
manner in which STIM1 binds ORAI is still to be fully elucidated. However, there is 
substantial evidence that the CC2 basic region of the STIM SOAR domain interacts with the 
acidic C-terminal cytoplasmic tail of ORAI via electrostatic interactions (Park et al., 2009, 
Frischauf et al., 2008, Soboloff et al., 2012). STIM1 also interacts weakly with the N-terminal 
region of ORAI, thereby forming a bridge between the N and C-terminal ends (Frischauf et 
al., 2008, Soboloff et al., 2012, Park et al., 2009). A recent model suggests that STIM1 
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activates ORAI1 by widening the pore, thereby removing the electrostatic barrier formed by 
the M1 helices to allow full Ca2+ entry (Rothberg et al., 2013). This arrangement is further 
stabilised by the interaction between the STIM1 C-terminal Lys-rich motif and the plasma 
membrane, though it is not essential (Park et al., 2009).  
 
There are 3 different isoforms of ORAI - 1-3, with ORAI2 and 3 lacking the proline/arginine 
rich motifs on the N-terminus but carrying a more stable and extensive coiled-coil region 
than ORAI1 (Fahrner et al., 2013). All three isoforms exhibit the same functions in that they 
all bind STIM1 to mediate SOCE, but have different activation/inhibition, expression and 
pharmacological profiles (Fahrner et al., 2009, Lis et al., 2007, DeHaven et al., 2007). For 
example, ORAI3 has a much lower store-operated Ca2+ current but a much faster negative-
feedback mechanism (Shuttleworth, 2012a, Shuttleworth, 2012b); moreover, the well-
known SOCE inhibitor 2-APB potently inhibits ORAI1 but activates ORAI3 when applied at 
high concentrations (Shuttleworth, 2012b, Shuttleworth, 2012a). ORAI3 has also been 
implicated in some diseases, most notably in breast cancer, where a switch from ORAI1 to 
ORAI3 takes place on transformation from normal breast cells to malignancy (Motiani et al., 
2013a, Motiani et al., 2013b).  
 
1.3.1.3. Canonical Transient receptor potential channels (TRPC) 
TRPC channels are part of a wider group of Ca2+ channels that form a big family of TRP 
channels; when combined with TRPL, TRPP, TRPV, TRPM, TRPN and TRPA (Venkatachalam 
and Montell, 2007, Ramsey et al., 2006). The TRPC channel subfamily itself has 7 different 
isoforms, with TRPC2 not expressed in humans but present in rodents. They are further 
subdivided into four subsets based on biochemical and structural properties to TRPC1, TRPC 
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2, TRPC3/6/7, and TRPC4/5, each with differential expression in tissues (Venkatachalam and 
Montell, 2007). This diversity can be increased via heterodimerisation of different TRPC 
subunits (Cheng et al., 2013). The common property of these channels is that all isoforms 
can be activated by the PLC pathway, as they can all interact with IP3R (Ramsey et al., 2006). 
The best characterised function of TRPC channels is probably in the CNS, where different 
isoforms of TRPC channels work in tandem to assist in the homing of neuronal growth cones 
to extracellular cues (Ramsey et al., 2006). Unlike ORAI channels, they are not selective for 
Ca2+ as they are also permeable to other mono- and divalent ions, resulting in different 
current/voltage profiles (Cheng et al., 2013, Ramsey et al., 2006).  
 
Each monomer of TRPC channels contains six transmembrane domains, with the loop 
between TM5 and TM6 contributing to the pore (Vazquez et al., 2004). Both the N and C 
terminus protrude into the cytoplasm, forming extensive motifs and domains. The N-
terminal domain contains 3-4 ankyrin repeats, a coiled coil region (CC) and a caveolin 
interaction region, whereas the C-terminus contains a TRP signature motif (EWKFAR), a 
proline-rich motif, a CIRB (calmodulin and IP3R binding) region and a coiled coil domain 
(Vazquez et al., 2004, Ramsey et al., 2006). In TRPC4/5, the C-terminal has an extension; 
containing an extra PDZ domain, which may provide a link to PLCβ and the cytoskeletion via 
the adaptor protein NHERF (Vazquez et al., 2004). Although still ambiguous, each TRPC 
channel is likely formed by 4 subsunits (Clapham, 2007, Ramsey et al., 2006). The ankyrin 
repeats seem to be important for the trafficking of the channel to the PM, whereas the N-
terminal CC domain takes part in dimerisation; implying that the N-terminal region is 
important for the correct localisation of the channel (Vazquez et al., 2004). The C-terminal 
appears more regulatory, as the CIRB domain serves as a binding site for IP3R and 
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calmodulin; the CC domain in this region also serves as a binding site for calmodulin, but 
only in TRPC1 (Vazquez et al., 2004). Finally, the proline rich motif is a binding site for the 
anchoring/adaptor protein Homer, and is important for its coupling to IP3R for regulation 
(Vazquez et al., 2004). 
 
Despite the discovery that ORAI is the frontline mediator of SOCE, evidence for TRPC also 
contributing to this process still remains (Worley et al., 2007), with the most convincing 
isoform being TRPC1 (Kim et al., 2009). The KD of TRPC1 in HEK293 cells, Human 
submandibular gland cells, human lung epithelial and pulmonary smooth muscle cells all 
resulted in a reduction in SOCE (Vazquez et al., 2004, Cheng et al., 2013). Moreover, 
pancreatic acinar cells and salivary gland cells from TRPC1-/- mice had displayed impaired 
SOCE despite ORAI presence (Hong et al., 2011). Indeed, in various mammalian cell systems 
STIM1 is known to interact with the two aspartate residues on TRPCs in the C-terminal 
domain, specifically via the STIM N-terminal lys-rich motif (Zeng et al., 2008). Furthermore, 
the CC domains on both ends of TRPC subunits are putative interaction sites with STIM (Lee 
et al., 2014). Interestingly, for TRPC1 to mediate SOCE, ORAI must also be present; since it is 
required for the translocation of TRPC1-containing vesicles to the membrane (Cheng et al., 
2011). This suggests that ORAI is indeed the principle SOCE mediator, with TRPC1 
immediately recruited downstream as an ‘assistant’ to ORAI, playing a secondary role in 
sculpting the SOCE Ca2+ signalling signature (Cheng et al., 2011). Supporting this, it was 
proposed previously that ORAI is important for establishing Ca2+ oscillations, where TRPC1 
alters the amplitude and the frequency; resulting in the dependency of NFAT activation on 




1.3.2. Downstream and the end of Ca2+ signalling  
Downstream, increases in [Ca2+]cyt results in this ion being intercepted by cytosolic proteins 
that serve to relay this signal into physiological functions. Calmodulin (CaM) is the most 
common Ca2+ receptor immediately downstream of a rise in [Ca2+]cyt (Heist and Schulman, 
1998) which, when bound with 4 Ca2+ ions, binds to and activates a whole host of proteins. 
These include the CaM-dependent kinase family (CaMK), serine/threonine phosphatase 
calcineurin (CaN), myosin light chain kinases (MLCK) (Clapham, 2007), adenylyl cyclases (ACI 
and VIII), and phosphodiesterase 1 (PDE1) (Halls and Cooper, 2011, Willoughby and Cooper, 
2007). Independent of CaM, Ca2+ signalling also activates the serine/threonine kinase 
protein kinase C (PKC). There are 11 families of PKC, split into 3 groups: conventional, 
consisting of PKCα, βI, βII, and γ; novel consisting of PKCδ, ε, θ, and η, and atypical, 
consisting of PKCλ, ι and ζ. Conventional PKCs require both Ca2+ binding and DAG for 
activation, whereas the novel varieties only need DAG for activation (Fan et al., 2014, Griner 
and Kazanietz, 2007). In contrast, atypical PKCs respond to neither, instead relying on other 
lipid derived second messengers for activation (Fan et al., 2014, Griner and Kazanietz, 2007). 
The differential expression patterns of the PKC isoforms in different cells have been 
implicated in a wide range of diseases including cancer, diabetes and heart failure (Fan et 
al., 2014, Griner and Kazanietz, 2007, Mochly-Rosen et al., 2012);. Together, these proteins 
can mediate both short term and long term effects depending on the cell type and desired 
function (Berridge et al., 2003). Examples of short term Ca2+ mediated processes include 
vesicle fusion for secretion (Ca2+)(Petersen and Ueda, 1976), MLCK mediated cell migration 
(CaM) (Chen et al., 2014b), the modulation of the cAMP pathways (Ca2+ and CaM), and the 




Long-term Ca2+ signalling, sustained by SOCE as mentioned earlier, results in the activation 
of transcription factors NFAT, which is activated by CaN-mediated dephosphorylation 
required for its translocation into the nucleus (Parekh, 2011). NF-κB, on the other hand, is 
activated by its dissociation from its inhibitory complex with IKK-β in a process dependent 
on PKC-induced phosphorylation (Chen and Greene, 2004). NFAT and NF-κB are utilised by a 
wide range of cellular systems, where they determine cellular outcomes. This is especially 
true in the adaptive immune system, where both NFAT and NF-κB activation are required 
for the activation and proliferation of T-lymphocytes.   
 
Once signalling is complete, excess cytosolic Ca2+ is removed via the plasma membrane or 
transported into the ER (mentioned earlier). This is carried out by pumps and exchangers – 
plasma membrane Ca2+ ATPase (PMCA), the Na+-Ca2+ exchanger (NCX), and the Na+/Ca2+-K+ 
exchangers (NCKX) (Clapham, 2007). The pumps carry out Ca2+ removal in exchange for ATP 
hydrolysis, whereas exchangers take advantage of the overwhelming out/in Na+ gradient to 
export Ca2+ ions. NCX exchanges one Ca2+ ion for 3 Na+ ions. NCKX exports 1 Ca2+ ion and 1 
K+ ion in exchange for 4 Na+ ions (Clapham, 2007). Moreover, the mitochondrial Ca2+ 
uniporter also contributes to the removal of Ca2+ from the cytosol (Duchen, 2000).   
 
1.4. The  cAMP signalling system 
cAMP is an ubiquitous, organic second messenger that is created by 10 different isoforms of 
adenylyl cyclases and destroyed by phosphodiesterases. Downstream, cAMP activates three 
main classes of proteins – protein kinase A, exchange protein activated by cAMP and cyclic 
nucleotide-gated channel family. This pathway is also under spatiotemporal regulation by A-
27 
 
kinase adaptor proteins which anchor cAMP signalling components to specific areas of the 
cell where they mediate a wide range of functions.   
 
1.4.1. Adenylyl cyclase (AC) 
ACs is a family of enzymes that catalyse the cyclisation of ATP into a molecule of cAMP, with 
2 Mg2+ ions also required as co-factor. So far 9 (AC1-9) membrane-bound isoforms and one 
soluble isoform (sAC) have been discovered, each with different modes of regulation and 
differential expression in tissues. It is normal for cells to express more than one AC isoforms 
at the same time to perform non-redundant functions. AC4, 6, 7 and 9 have a widespread 
expression profile, whereas AC1 is predominantly found in the brain, and AC2 is also 
expressed in the lung as well as the brain; AC3 is principally expressed in olfactory 
epithelium and pancreas; AC5 is mostly found in the heart, and AC8 is expressed in the brain 
and pancreas (Willoughby and Cooper, 2007, Halls and Cooper, 2011). Experiments carried 
out in AC knock-out mice underline their importance to mammals: AC1 knockout (KO) mice 
have reduced long term potentiation (Halls and Cooper, 2011, Wu et al., 1995), whereas a 
lack of AC8 results in altered stress-induced anxiety (Schaefer et al., 2000) and defective 
spatial memory (Zhang et al., 2008b). AC5 KO mice have decreased left ventricular 
functions, but a longer lifespan and higher stress endurance (Yan et al., 2007, Vatner et al., 
2009, Vatner et al., 2013, Okumura et al., 2003), and the KO of the similar AC6 resulted in 
similar effects in the heart but also have independent effects to AC5 (Tang et al., 2008). AC3 
KO mice have attenuated responses to pheromones, resulting in the lack of behaviour 
towards other males as well as a striking obese phenotype (Wang et al., 2009). Lastly, sAC 
has been found to be vital for sperm motility in mice (Esposito et al., 2004). 
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Inside each cell, nearly all AC isoforms are localised on the plasma membrane and can form 
functional inter-isoform dimers (Willoughby and Cooper, 2007, Cooper and Tabbasum, 
2014, Halls and Cooper, 2011). The major exception from this is sAC, which has a cytosolic 
distribution and is activated by bicarbonate ions (Steegborn, 2014, Lefkimmiatis et al., 
2013). AC is a monomer consisting of 2 transmembrane clusters (TM1 and TM2 domains), 
with each cluster containing 6 transmembrane helices (Zhang et al., 1997). The two clusters 
are connected by an intracellular loop, which is split into C1a and C1b region (Tesmer and 
Sprang, 1998, Zhang et al., 1997). After TM2, the C-terminal tail is an intracellular tail, 
similarly spilt into the C2a and C2b region (Zhang et al., 1997). The ATP binding active site is 
formed by the association of C1a and C2a regions; and for that reason these two regions are 
the most conserved section of the enzyme (Tesmer and Sprang, 1998, Zhang et al., 1997).     
 
Physiologically, every isoform (except sAC) can be activated by GPCRs coupled to the Gαs 
subunit to produce cAMP, with Gαs-GTP binding to the N-terminal side of C1a in the 
C1a/C2a interface (Tang and Hurley, 1998). Aside from GPCRs, ACs is also the subject of 
stimulatory and inhibitory modulations from a whole host of elements of the cell including 
PKA (inhibits AC5/6), Gαi (inhibits all apart from AC2/4/7), Gβγ (mentioned earlier), and 
most notably the Ca2+ pathway which has already been described extensively (Cooper and 
Tabbasum, 2014, Halls and Cooper, 2011, Willoughby and Cooper, 2007). Intriguingly, all AC 
isoforms are sensitive to the Ca2+ signalling pathway, whether directly or by downstream 
effectors. For example, AC1 and AC8 are activated by Ca2+ via a calmodulin-dependent 
mechanism. AC8 is activated by the removal of the attached autoinhibitory calmodulin, 
whereas AC1 is activated by Ca2+-calmodulin binding, both via the C1b domain (Masada et 
al., 2009). In contrast, AC5 and AC6 are directly inhibited by submicromolar concentrations 
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of the Ca2+ ion itself by competing with Mg2+ (Mou et al., 2009). The rest of isoforms i.e. 
AC2, 3, 4 and 7, are not directly activated by Ca2+; but are instead effected by downstream 
mediators: AC2, 4 and 7 are activated by PKC, whereas AC3 and AC9 are inhibited by CaMKII 
and CaN repectively. Interestingly, ACs1, 5, 6, and 8 are preferentially activated by Ca2+ 
signals generated by store operated calcium entry, whilst being insensitive to global Ca2+ 
increases induced by ionophores such as ionomycin (Willoughby and Cooper, 2007, Cooper 
and Tabbasum, 2014). Thanks to the work of the Dermot Cooper lab, we now understand 
that this phenomenon is due to the localisation of Ca2+ sensitive ACs to specialised, 
cholesterol and sphingolipid-rich domains of the plasma membrane, called lipid rafts, where 
they interact with SOCE-mediating channels ORAI1 (in non-excitable cells) and L-type Ca2+ 
channels (in excitable cells) (Cooper and Tabbasum, 2014). Also, in a more recent account, 
the depletion of Ca2+ stores in the ER alone, and not SOCE, can increase cAMP levels in 
certain cell systems such as colonic crypt and airway epithelial cells; thought to be mediated 
by AC3 in a STIM1 dependent manner but not involving ORAI (Maiellaro et al., 2012, 
Lefkimmiatis et al., 2009). This effect had been called store operated cAMP signalling 
(SOcAMP), which can potentially provide a link between the status of the ER and cAMP 
signalling.  
 
ACs is under the control of protein components from different pathways at the same time. 
Therefore, although AC isoform-specific knock-out studies have been made in mice 
producing definitive phenotypes, very little is actually known as to the physiological 
outcome of Ca2+-induced cAMP production (Halls and Cooper, 2011). Studies on MIN6 
pancreatic β-cells suggests that Ca2+ is likely a fine-tuner tool for cAMP signalling, as it 
produced oscillations that synchronised with Ca2+ and downstream PKA activity to exert 
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temporal control on downstream proteins (Ni et al., 2011, Dyachok et al., 2006, Landa et al., 
2005).     
 
1.4.2. Phosphodiesterase (PDEs) 
PDEs is a group of enzymes that catalyses the conversion of cAMP into 5’-AMP, which 
effectively ‘switches off’ the pathway (Francis et al., 2011). However, in more complex terms 
their role is actually to confine cAMP signalling to specific areas of the cell. In a singular cell, 
it is quite common that multiple cAMP ‘clouds’ exist in segregated compartments 
maintained by PDEs, resulting in distinct outcomes in different parts of the cell (Lefkimmiatis 
and Zaccolo, 2014). This occurrence is best exemplified in the heart, where various PDE 
isoforms operate in conjunction with AKAPs at different locations of the same cell can 
simultaneously regulate hypertrophy and excitation-contraction coupling mechanisms 
(Stangherlin and Zaccolo, 2012). So far 11 isoforms have been discovered, each categorised 
by their substrate specificities and their modes of regulation. In reality, each isoform 
consists of at least 2 splice variants with distinct properties and expression profiles, which 
diversifies the number of potentially different PDEs to well over 100 in mammals (Bender 
and Beavo, 2006).  
 
Physiologically, PDEs principally operate as dimers, with each monomer containing an N-
terminal regulatory region and the catalytic core in the C-terminal region (Francis et al., 
2011). Unsurprisingly the catalytic core is well conserved across all 11 families, whereas the 
regulatory region is very diverse (Bender and Beavo, 2006, Francis et al., 2011). A 
comprehensive expression profile of all PDE splice variants with their KO phenotypes in mice 
has already been discussed elsewhere (Bender and Beavo, 2006, Keravis and Lugnier, 2012, 
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Maurice et al., 2014); so in this account only a brief overview for each isoform will be 
provided. In general, despite the quantitative differences, all PDE isoforms display 
widespread expression profiles except for 6 (eye, lung and pineal gland), 10 (brain and 
testes) and 11 (male reproductive system, salivary and pituitary gland). 
  
PDE1 is a Ca2+ sensitive PDE, as the binding of two CaM molecules per monomer increases 
the Vmax by 10 fold (Kincaid et al., 1985), possibly by the removal of autoinhbition (Francis et 
al., 2011). Unlike other isoforms, functional PDE1 normally exist as hetereotetramers 
(Francis et al., 2011). Three splice variants exist – PDE1A, PDE1B and PDE1C, of which A and 
B prefer cGMP as the substrate and C has equal preference for both cGMP and cAMP 
(Goraya et al., 2008). They are the subject of PKA and CaMKII phosphorylation, which results 
in PDE1 inhibition (Hashimoto et al., 1989, Ang and Antoni, 2002). PDE1B may have a role in 
learning and memory in mice, whereas PDE1C may regulate smooth muscle proliferation 
and olfaction (Siuciak et al., 2007, Cygnar and Zhao, 2009). 
 
PDE2 is a dual specificity enzyme, consisting of splice variants PDE2A1-3. They contain two 
GAF domains on the N-terminal domain – termed GAF-A and GAF-B, which facilitate its 
dimerization and allosteric activation (Francis et al., 2011). The binding of cGMP to GAF-B 
results in a 30-fold increase in cAMP hydrolysis; making it a cGMP-activated enzyme and 
provides a node in which cGMP-cAMP crosstalk can take place (Keravis and Lugnier, 2012). 
Due to its broad expression profile, PDE2 has been reported to affect numerous processes 
throughout the body; the most characterised of which being the regulation of the L-type 
Ca2+ current in cardiomyocytes (Fischmeister et al., 2005). Moreover, PDE2A KO in mice is 
embryonically lethal (Maurice et al., 2014). 
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PDE3 is also a dual specific enzyme, with the active site containing higher affinity for cAMP 
than cGMP, typified by the 10x higher Vmax for cAMP. Therefore, cGMP acts as a competitive 
inhibitor of PDE3 (Francis et al., 2011). Two different splice variants are known – PDE3A and 
PDE3B. They can be found anchored to membranes due to the membrane-associated 
domain(s) on its N-terminus (Shakur et al., 2001). PKA, Akt and PKC can all phosphorylate 
PDE3, resulting the activation of the enzyme; and facilitates binding to 14-3-3 adaptor 
proteins (Okumura et al., 2003, Shakur et al., 2001, Perino et al., 2011). PDE3A is vital for 
platelet aggregation and oocyte maturation (Conti et al., 2002, Masciarelli et al., 2004); 
whereas PDE3B regulates cardiac and vascular smooth muscle contractility (Patrucco et al., 
2004, Maurice et al., 2003) as well as playing a large role in regulating energy homeostasis 
(Guirguis et al., 2013, Degerman et al., 2011).  
 
PDE4 is a cAMP specific enzyme and contains four splice variants – PDE4A-D, each 
originating from different promoters and playing non-redundant roles (Keravis and Lugnier, 
2012). PDE4 has the largest group of splice variants within the PDE family, with that number 
exceeding 25 (Bender and Beavo, 2006). In the general structure, the N-terminal regions 
contain two upstream conserved regions (UCR1 and UCR2) (Francis et al., 2011). UCR1 can 
be phosphorylated by PKA resulting in activation (Sette and Conti, 1996, Beard et al., 2000); 
whereas UCR2 plays an autoinhibitory role for the enzyme, either directly or by binding to 
anchoring proteins such as XAP2 and DISC2 (Francis et al., 2011). This large family is further 
branched into 3 categories: the long form, which is the only PDE4 subtype to dimerise; the 
short form, which contains only UCR1; and the super short form, which contain only half of 
UCR2 (Keravis and Lugnier, 2012, Francis et al., 2011). The C-terminal end of the catalytic 
region is also the subject of phosphorylation by ERK, which activates the short forms of 
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PDE4 but inhibits the long forms (Houslay and Adams, 2003, Baillie et al., 2000). PDE4D KO 
appeared to result in drastic phenotype changes in terms of disease, as PDE4D KO mice 
displayed stunted growth and impaired muscarinic cholinergic stimulation (Hansen et al., 
2000); whereas PDE4B plays a significant role in initiating the inflammatory response in 
monocytes (Jin and Conti, 2002). 
 
PDE5 is a cGMP-specific enzyme, allosterically activated by cGMP binding in a negative-
feedback mechanism (Francis et al., 2011). Three variants are known – PDE5A1-3. PDE5 
contains two GAF domains (GAF-A and GAF-B); cGMP binds only to GAF-A, while GAF-B 
serves as an autoinhibitory domain (Zoraghi et al., 2005); this, combined with its 
phosphorylation by PKG, a downstream effector of cGMP, increases the Vmax and cGMP 
affinity in the active site (Francis et al., 2011, Corbin et al., 2000, McAllister-Lucas et al., 
1995). Like PDE1-4, PDE5 also has a broad expression profile, with its most notable role the 
regulation of vascular smooth muscle contraction, especially in the lung and penis (Conti 
and Beavo, 2007).   
 
PDE6 is specialised enzyme that is specific for cGMP, with its expression exclusively limited 
to the eye, though trace amounts have also been found in the lung (Bender and Beavo, 
2006). Their tertiary structure consists of two large catalytic subunits (PDE6A, B, C or D) 
attached to two small inhibitory subunits (PDE6G or PDE6H)(Keravis and Lugnier, 2012). 
Each catalytic subunit contains two GAF domains, to which cGMP must bind for full 
activation. They are important for the signal transduction of rhodopsin to CNG in rod and 




PDE7 is a cAMP specific enzyme, consisting of splice variants PDE7A and PDE7B. Its Vmax is 
among the lowest of all PDE families (Bender and Beavo, 2006). The mode of regulation for 
PDE7 is still not clear, due to its N-terminus containing no recognisable domains. However, 
what is known of that region is that it can bind to, and inhibit, the catalytic subunit of PKA 
with high affinity (Keravis and Lugnier, 2012). This PDE isoform is mainly found in the striatal 
neurones, cardiac and skeletal muscle, and cells of the immune system, in particular in T 
lymphocytes, where they have been implicated to play a role in T-cell activation and in 
chronic lymphocytic leukaemia (CLL) (Lee et al., 2002, Zhang et al., 2008a, Bender and 
Beavo, 2006). 
 
PDE8 is also a cAMP specific enzyme, and has the highest affinity for cAMP out of all 
enzymes (Gamanuma et al., 2003, Fisher et al., 1998a). Two variants are known, A and B. 
Though the consequence of which is unknown, the N-terminal regulatory region contains a 
REC (analogous to bacterial receiver domains)(Galperin et al., 2001) and PAS (involved in the 
regulation of circadian rhythms in bacteria) domain (Gilles-Gonzalez and Gonzalez, 2004), 
but they do have proposed PKA and PKG phosphorylation sites between the PAS and 
catalytic domain(Keravis and Lugnier, 2012). Although differential amounts of expression 
have been found elsewhere in the body, their main location of expression is in the testis, 
where they have been shown to take part in cholesterol synthesis (Bender and Beavo, 2006, 
Tsai and Beavo, 2012).  
 
PDE9 has the highest affinity for cGMP of all PDE classes; and is predominantly expressed in 
the immune tissues and the brain; and consists of splice variants PDE9A1-20 (Conti and 
Beavo, 2007, Fisher et al., 1998b). KO studies in mice have shown it to be important in 
35 
 
regulating insulin-related metabolism, as PDE9-/- mice appeared to have improved insulin 
response and have less fat content (Deninno et al., 2009). 
 
PDE10 in many aspects is the exact opposite of PDE3, in that it has a higher affinity to cGMP 
than cAMP, and consequently inhibited by cAMP in the same manner as cGMP for PDE3 
(Francis et al., 2011, Bender and Beavo, 2006). Strangely, it contains two GAF domains in its 
N-terminus that only binds cAMP (Francis et al., 2011). PDE10 may be involved in long-term 
potentiation, and are mainly expressed in the testes and the brain,(Conti and Beavo, 2007). 
PDE10A-/- mice displayed altered behaviour, appearing more ‘lethargic’ and having a 
delayed acquisition of conditioned avoidance (Piccart et al., 2011).  
 
PDE11 is another GAF containing dual specificity enzyme. Four variants are known – 
PDE11A1-4, each segregated by the differences in the architecture of the GAF domain 
(Yuasa et al., 2000, Bender and Beavo, 2006, Conti and Beavo, 2007). The role of this GAF 
domain is unknown; in fact, not too much is known about PDE11. They are mainly expressed 
in the prostate, testes and the pituitary gland, where they may have a hand in regulating 
sperm viability and movement (Wayman et al., 2005). However, a recent report using 
PDE11A-/- mice showed that it is also expressed in the brain, where the lack of this PDE 
isoform leads to mild psychological disorders (Kelly et al., 2010). 
 
1.4.3. Downstream cAMP effectors 
1.4.3.1. Protein Kinase A (PKA) 
PKA is a serine/threonine kinase that belongs to the greater AGC family of kinases, which 
also includes PKG, PKC and Akt (Taylor et al., 2012). It catalyses the transfer of a phosphate 
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onto a target substrate with the consensus sequence of RRXS/T, RKXS/T, KRXS/T and KKXR/T 
(i.e. positive residues near the substrate site) in response to cAMP binding (Shabb, 2001).  
 
Structurally in its inactive form PKA consists of a homodimer of two regulatory subunits (R 
subunits) each bound with a catalytic subunit (C subunit) bound, forming a R2C2 
stoichiometry (Taylor et al., 2008). Four different isoforms are known for C subunits in 
mammals (Prkx, Cα, Cβ, and Cγ), which are well conserved among its family members 
(Skalhegg and Tasken, 2000). It consists of a small N lobe and a larger C lobe, flanked by cis-
regulatory N and C tails; with the active site situated in between the two lobes, where the 
ATP and the substrate bind (Taylor et al., 2012, Taylor et al., 2013). In physiological 
conditions, C subunits are already pre-phosphorylated and active at assembly, with the R 
subunit being its sole inhibitor (Taylor et al., 2005). The R subunit is more diverse, of which 
four isoforms are known (RIα and RIβ, also called type I PKA; and RIIα, and RIIβ, also known 
as type II PKA) (Taylor et al., 2008, Taylor et al., 2012). From the N-terminus towards the C-
terminus,  it contains a docking and dimerisation domain (D/D), followed by a disordered 
linker region which includes an inhibitor sequence (Taylor et al., 2005, Taylor et al., 2012); 
with two cyclic nucleotide binding domains (CNBD) in tandem, named CNBA and CNBB, at 
the C-terminus (Taylor et al., 2004). There is significant homology between the D/D domain 
and the CNB domains across the four R subunits, with the linker region being the most 
diverse (Vigil et al., 2004). The R subunits bind to and inhibit the kinase activity of C subunits 
by directly docking its inhibitor sequence onto the active site cleft, effectively acting as a 
pseudosubstrate (Taylor et al., 2012). On RII but not RI subunits, this inhibitory sequence 
can be autophosphorylated by the catalytic subunit (Taylor et al., 2012). In RI subunits, 
Mg2ATP is required for binding and hence inhibition of the C subunit, whereas this does not 
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apply for RII subunits (Taylor et al., 2008, Taylor et al., 2013). The D/D domain is where R 
subunits interact to form homodimers. PKA is activated in an allosteric manner; where 
cAMP initially binds to the CNBB, which causes a change in conformation that exposes the 
CNBA for the binding of the second cAMP molecule to induce a second change in 
conformation to weaken the R/C subunit interface (Taylor et al., 2008). Consequently, each 
PKA R2C2 complex requires 4 cAMP molecules for complete C subunit release, with RI having 
four times higher affinity for cAMP than RII; the activation constant being 50-100nM and 
200-400nM respectively (Dostmann and Taylor, 1991, Pidoux and Tasken, 2010, Gamm et 
al., 1996). 
 
Downstream of PKA, three well-known substrates of this kinase are the transcription factor 
cAMP reponse element binding protein (CREB), which mediates PKA-induced genomic 
effects; and PDEs 3 and 4, which destroy cAMP, providing a negative feedback loop of the 
cAMP pathway. In reality, however, such is the ubiquitous nature of PKA, that processes 
such as ion channel and cell receptor dynamics (Martin et al., 2004, Howe, 2004) cell 
migration (Howe, 2004), mitochondrial function (Lefkimmiatis et al., 2013, Di Benedetto et 
al., 2014) metabolism (Luu et al., 2013), with this list not being exhaustive, are regulated by 
PKA. In fact, most processes in a mammalian cell have at least one component that is 
reportedly modulated by PKA, no matter which organ it was derived from. 
 
One way of regulating PKA is via differential expression of RI and RII isoforms in tissues. 
Even when both are expressed in the same cell, they can play non-redundant roles; with 
AKAPs further segregating their downstream functions (Skalhegg and Tasken, 2000). RIα and 
RIα are expressed everywhere (Lee et al., 1983, Scott et al., 1987), as their importance 
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underlined in the finding that RIα KO is embryonically lethal (Amieux et al., 1997, Amieux 
and McKnight, 2002); whereas RIIα KO is actually beneficial in mice, as they displayed 
resistance to obesity and conveyed intolerance to glucose (London et al., 2014). RIβ is 
mainly present in brain (Cadd and McKnight, 1989) where a knock-out in mice results in 
impaired hippocampal function (Gronholm et al., 2003); and RIIβ is expressed in the 
endocrine and reproductive system (Jahnsen et al., 1986), dominating in adipose tissues 
(Amieux et al., 1997), and the visual cortex where RIIβ play a pivotal role in long-term 
depression (Fischer et al., 2004). Moreover, it has been known for more than 20 years that 
the RI/RII ratio is an indicator for directing cellular growth, or growth inhibition and 
differentiation; where RI favours growth and RII favours inhibition (Cho-Chung, 1990). As 
such, alteration of the RI/RII ratio has been observed to affect a number of processes, most 
notably in carcinogenesis. Breast, prostate, colon and ovarian cancers, all have been 
documented to display elevated RI expression (Nesterova et al., 2000).  
 
Another additional level of PKA regulation can be achieved by sequestering it to defined 
microdomains to restrict their activity area (Lefkimmiatis and Zaccolo, 2014, Gold et al., 
2013, Stangherlin and Zaccolo, 2012, Jarnaess and Tasken, 2007). Curiously, RI has a 
generally diffused localisation in the cytosol, whereas RII is usually found anchored to the 
plasma membrane or other cellular structures (Colledge and Scott, 1999, Di Benedetto et 
al., 2008). PKA can be anchored to a specific cellular locations via interaction with A-kinase 
adaptor proteins (AKAPs), which is a scaffolding protein that bind to the D/D domain of the 
R subunit dimer (Taylor et al., 2004, Taylor et al., 2008). More than 50 types of AKAPs have 
now been discovered, each having their unique designated cellular locations and different 
affinities to RI and RII subunits (Tasken and Aandahl, 2004, Jarnaess and Tasken, 2007). Not 
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surprisingly, all of them are known to bind to type II PKA; although AKAPs that anchor type I 
PKA and those with dual specificity have also been documented (Huang et al., 1997, 
Colledge and Scott, 1999). In addition to regulating the location of PKA signalling, AKAPs also 
serve to accelerate the relay of signalling by tethering this kinase to other proteins such as 
PKA activators, substrates and antagonists (i.e. ACs, PDEs and phosphatases); bringing them 
in proximity with each other in macromolecular complexes to minimise the limiting factor of 
diffusion (Willoughby and Cooper, 2007). As a result, AKAP tethered PKAs can give rise to 
highly efficient, functionally distinct, spatially restricted signals (Stangherlin and Zaccolo, 
2012, Pidoux and Tasken, 2010). This phenomenon is widely accepted to play crucial roles in 
most systems, especially in cardiac (Taglieri et al., 2014, Soni et al., 2014) and neuronal 
signalling (Hoshi et al., 2010, Murphy et al., 2014, Dittmer et al., 2014) where a rapid relay 
of signalling is required.  
 
1.4.3.2. Exchange protein activated by cAMP (EPAC) 
EPAC is the most recently discovered of the downstream effectors of cAMP signalling. It is a 
cAMP-activated guanine nucleotide exchange factor (GEF) that activates Rap, which belongs 
to the Ras family of small G-proteins, by exchanging the bound GDP for GTP (Gloerich and 
Bos, 2010). There are two main isoforms of Epac discovered thus far - Epac1 and Epac2; with 
Epac2 having three splice variants (Epac2A, Epac2B and Epac2C) (Ueno et al., 2001, Niimura 
et al., 2009). Epac1 and Epac2 generally have broad but specific expression profiles; with 
Epac1 expression dominating all immune and blood cells as well as the kidney, the vascular 
system, heart, adipose tissue, and the female reproductive system (Grandoch et al., 2010, 
Schmidt et al., 2013); whereas Epac2 is mainly present in the pancreas and adrenal gland 
(Kawasaki et al., 1998). Epac2C is a specialised isoform that is only present in the liver (Fu et 
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al., 2011). The central nervous system is an exception in that it expresses both Epac1 and 
Epac2. 
In terms of its structure, both isoforms of Epac exist as monomers, with various domains 
that define their function. At the N-terminus of Epac1, there is a dishevelled-egl-10-
pleckstrin (DEP) domain linked to a CNB domain (cAMP-B) not dissimilar to that of PKA, 
which forms the regulatory region (de Rooij et al., 2000); after which comes the catalytic 
region, which contains a Ras-exchange motif (REM) connected to CDC25-homology domain 
(CDC25HD) at the C-terminus via a RA domain (Bos, 2006). Epac2 is largely identical to Epac1 
but contains a second CNB domain (cAMP-A) at the N-terminus before the DEP domain; 
Epac2C is truncated even further, lacking the DEP and the extra CNBC (Rehmann, 2013). 
REM binds to and stabilises CDC25HD to form a minicomplex, which carries out the GDP  
GTP exchange. Elsewhere, the DEP domain, as well as the extra CNBD on Epac2, is important 
in directing Epac to appropriate compartments of the cell (Ponsioen et al., 2009, Li et al., 
2011); while the common CNBD provides an autoinhibitory function on the active site 
(Rehmann et al., 2006). Inhibition is by the N-terminal common CNBD (cAMP-B) ‘latching’ 
onto the C-terminal catalytic region via an ionic bridge, obscuring CDC25HD from its targets 
(Rehmann et al., 2007); on binding of cAMP onto the CNBD, a conformational change takes 
place, breaking this ionic interaction and exposing the active site (Das et al., 2008).  
Compared to PKA, although the cAMP affinity is approximately the same for both proteins in 
vitro, physiologically Epac requires 30 times higher concentration of cAMP for activation due 
to a lack of allosteric cooperation between domains (Dao et al., 2006).  
 
Much like PKA, Epac is also spatiotemporally regulated via interactions with other cellular 
modules via AKAP binding. In fact, it is actually quite common for PKA and Epac to be in the 
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same AKAP complex, with a good example being the mAKAP signalosome in 
cardiomyocytes. There, this mAKAP complex containing PKA, PDE4D3 and Epac1 inhibits 
ERK5-mediated cardiac hypertrophy (Dodge-Kafka et al., 2005). However, localisation of 
Epac can also be modulated independently of AKAPs thanks to the DEP domain (Schmidt et 
al., 2013). The DEP domain allows the anchoring of Epac onto phosphatidic acid (PA) and 
ezrin-moesin-radixin (ERM) proteins on the plasma membrane to relay signals from cell-
surface receptors such as β1-adrenergic receptors (Consonni et al., 2012). Interestingly, 
Epac1 has been found at the nuclear pore complex, where it interacts with RanBP and Ran-
GTP via its RA domain to regulate the export of nuclear proteins such as histone deacetylase 
4/5 (HDAC4/5) and DNA damage responsive DNA kinases (Huston et al., 2008, Liu et al., 
2010, Metrich et al., 2010). There, its GTP exchange activity towards Rap is inhibited by 
RanBP, but is accelerated by binding to microtubules of the nucleoskeleton (Gupta and 
Yarwood, 2005).  
 
The most well-known downstream effector of Epac signalling is Rap1 and Rap2 (Gloerich 
and Bos, 2010). When this pathway was first discovered, their central function was the 
maintenance of cell polarity, cell-cell interactions and cytoskeletal turnover (Raaijmakers 
and Bos, 2009, Pannekoek et al., 2009). This is done via interactions of Rap with other 
scaffolding proteins. For example, binding to AF-6 stabilises adherens junctions by 
preventing E-cadherin internalisation (Hoshino et al., 2005), whereas Rap binding to Riam 
and RapL facilitates focal adhesion formation in T cells (Lafuente et al., 2004, Katagiri et al., 
2006). Moreover, Rap interactions with Krit1 tightens endothelial cell-cell junctions (Glading 
et al., 2007), interactions with RacGEFs vav2 and Tiam1 delivers Rac signalling to cell-cell 
contacts (Arthur et al., 2004), and actin dynamics can be regulated by Rap1-IQGAP1 
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complexes (Jeong et al., 2007). However, the understanding of the roles of Rap proteins has 
diversified since these findings; in particular, the Rap-PLCε-PKCε/CaMKII axis seems to be a 
common Epac-induced pathway in various cell-types (Schmidt et al., 2013). In pancreatic β 
cells, Epac2-Rap-PLCε is known to modulate KATP channel activity as well as potentiating the 
release of insulin via Ca2+ modulation (Hashiguchi et al., 2006, Ozaki et al., 2000, Eliasson et 
al., 2003). In cardiomyocytes, a similar signalling axis is known to control excitation-
contraction coupling via phosphorylation of myofilament proteins (Oestreich et al., 2009), 
and the inhibition of ERK5 mediated hypertrophy (Dodge-Kafka et al., 2005). 
 
1.4.3.3. Cyclic nucleotide-regulated ion channels 
Cyclic nucleotide-regulated ion channels belong to the same superfamily as the voltage 
gated K+ channel superfamily (Podda and Grassi, 2014). There are two types of ion channels 
that are directly regulated by cAMP – hyperpolarisation-activated cyclic nucleotide channel 
(HCN) and cyclic nucleotide gated channel (CNG) (Schunke and Stoldt, 2013). cAMP can 
directly bind to and activate both HCN and CNG without any intermediaries due to their 
structural setup, but with different activation profiles (Schunke and Stoldt, 2013).  
  
Structurally, each channel exists as tetramer, with each monomer containing a cytosolic N-
terminal region, the central transmembrane region, and the C-terminus (Long et al., 2005, 
Craven and Zagotta, 2006, Biel et al., 2009). The central transmembrane region consists of 6 
helices (S1-S6) that traverses the membrane, with each subunit contributing two helices (S5-
S6) to the tetramer to form the channel, with the positively charged S4 acting as the voltage 
sensor (Biel et al., 2009, Flynn et al., 2001, Craven and Zagotta, 2006). S5 and S6 are 
connected by a pore loop, which acts as a selectivity filter (Craven and Zagotta, 2006, Podda 
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and Grassi, 2014, Biel et al., 2009). The C-terminal domain on each monomer contains a 
cyclic nucleotide binding domain (CNBD), which acts as an autoinhibitory domain (Craven 
and Zagotta, 2006, Podda and Grassi, 2014, Benarroch, 2013). cAMP and/or cGMP activates 
the channel by binding to the CNBD, relaying a conformational change to the pore via a C-
terminal linker connecting the CNBD to S6 (Craven and Zagotta, 2006, Biel et al., 2009).  
 
HCN channels are mainly distributed in the nervous system and the heart, where they 
directly relay information mainly from cAMP, to control resting potentials and membrane 
resistance (Benarroch, 2013). Thus far, four isoforms are known (HCN1-4), each with slightly 
different properties and activation kinetics (Roubille and Tardif, 2013, Benarroch, 2013); 
however, the common characteristics between all 4 isoforms is that they are constitutively 
active at resting potentials, permeable to both Na+ and K+ ions conducting a cation Ih current 
(Biel et al., 2009, Kase and Imoto, 2012). The binding of cAMP results in the activation 
conditions shifted to more positive potentials; thus modulating the parameters of action 
potential generation (Biel et al., 2009, Benarroch, 2013). One example of HCN function is 
that in the heart sinoatrial node (SA), where Ih from HCN2 and HCN4 is known as the 
pacemaker current important in Ca2+ channel activation after repolarisation in diastole 
(Wahl-Schott and Biel, 2009, Postea and Biel, 2011, Roubille and Tardif, 2013). Moreover, 
HCN have also been shown to take part in learning, memory and motor coordination in the 
hippocampus and the cerebellum (Nolan et al., 2003, Nolan et al., 2004), and regulation of 
oscillations in thalamocortical neurones (Santoro and Baram, 2003); as mice missing certain 
types of HCN have been reported to cause symptoms of absence epilepsy and sinus 
dysrhythmia (Ludwig et al., 2003).  
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CNG channels consists of two types of subunits– A and B, of which four different isoforms of 
A (CNGA1-4) and 2 different isoforms of B (CNGB1 and CNGB3) are known in mammals 
(Bradley et al., 2001). The CNGA family are considered pore forming, while the CNGB family 
are modulatory as they cannot form pores when expressed on their own (Hofmann et al., 
2005). Unlike HCN channels however, CNG is voltage-independent; as they will only conduct 
Na+ and Ca2+ ions as a result of ligand binding, and tend to use cGMP more than cAMP as 
ligand; although in olfactory neurones CNG reacts to both cGMP and cAMP (Kaupp and 
Seifert, 2002). Much like HCN, they are prominently present in the nervous system, and are 
indispensable for sensory transduction in olfactory neurones and the eye (Podda and Grassi, 
2014). In olfactory neurones, the cAMP generated by odour activated Gαolf - ACIII binds to 
CNG, causing an influx of Ca2+ ions to subsequently activate Ca2+ activated CI- channels, 
leading to depolarisation and the amplication of the signal (Antunes et al., 2014, Breer et al., 
1990, Kleene, 2008). They are also reported to play a role in CNS development, synaptic 
plasticity and glial cell function (Podda and Grassi, 2014).   
 
1.5. Cell migration 
Cell migration is a physiologically important process that involves the translocation of a cell 
from its origin to another location to carry out its functions. It can take place over short 
distances, such as in wound healing and morphogenesis; or long distances such as in cancer 
metastasis and immune responses (Huttenlocher and Horwitz, 2011, Hoshino et al., 2013). 
Under normal circumstances this process takes place on the extracellular matrix (ECM), 
which is a mesh of structural proteins that serves as a supportive structure for its 
surrounding cells (Frantz et al., 2010). There are three general modes of cell migration - 
mesenchymal, amoeboid, and collective migration (Nurnberg et al., 2011). Amoeboid 
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migration is powered by hydrostatic pressure, which produces dynamic, non-apoptotic and 
intrusive blebs in areas of low cortical actin concentration; these ‘bleb intrusions’ are then 
consolidated by cortical actin polymerisation. This process is still poorly understood, but it is 
proposed to be downstream of Ezrin-radixin-moesin (ERM) and formin proteins (Nurnberg 
et al., 2011). Mesenchymal migration is perhaps the most studied and the best 
characterised form of cell migration, and involves the locomotion, or ‘crawling’, of a cell on 
a reasonably flat surface (Nurnberg et al., 2011). This is a highly coordinated process 
powered by the manipulation of intracellular actin cytoskeleton and the turnover of focal 
adhesions (Parsons et al., 2010). Lastly, collective migration is the plural form of 
mesenchymal migration, and is the movement of a cluster or sheet of cells that retain their 
cell-cell contacts on its substratum (Nurnberg et al., 2011). It is important to note that these 
three modes of cell migration are not mutually exclusive, and are instead rather part of a 
continuum. For example, a dendritic cell is capable of using a combination of amoeboid and 
mesenchymal type of migration to reach their destination, and non-mesenchymal cells can 
use mesenchymal migration for movement (Huttenlocher and Horwitz, 2011).    
 
1.5.1.  Actin – properties  
 
Despite the differences in mechanism, what is beyond doubt is that the actin cytoskeleton is 
the central linchpin of all types of cell migration. Supporting this, both the inhibition of F-
actin disassembly by jasplakinolide, and of G-actin polymerisation by cytochalasin D or 
latrunculin resulted in the obliteration of cell migration (Yarrow et al., 2004, Sayed et al., 
2008, Zhang et al., 2012). Therefore, in order to understand this physiological process, it is 
important to consider the intrinsic properties of actin.  
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Actin is a ubiquitous, globular 42kDa protein that has the ability to bind and hydrolyse ATP. 
When bound with ATP, actin monomers (G-actin) can quickly associate with each other and 
polymerise into double helical filaments (F-actin, used interchangeably with actin filaments) 
(Nurnberg et al., 2011). Once incorporated into the filament, ATPase activity of each actin 
monomer increases; and the hydrolysis of ATP to ADP destabilises the actin filament, 
promoting depolymerisation (Nurnberg et al., 2011). Actin polymerisation normally consists 
of three phases - nucleation, elongation and steady state. Nucleation is the spontaneous 
formation of an ATP-actin trimer, also called the nucleus; this is the rate-limiting step of the 
process, due to the instability of this nucleus (Nurnberg et al., 2011, Krause and Gautreau, 
2014). If the nucleus perseveres, then the elongation phase would take place rapidly, where 
ATP-actin monomers are added onto either side of the nucleus at an asymmetrical rate. 
During elongation, polymerisation occurs much more rapidly on one end (the ‘+’, or the 
‘barbed’ end) than the other (the ‘-‘ end) (Nurnberg et al., 2011). Lastly, the stabilisation 
phase is reached when equilibrium is reached between the addition of ATP-actin subunits at 
the barbed end and ATP hydrolysis-induced dissociation at the – end; such that the total 
length of the actin filament is not changed (Nurnberg et al., 2011). F-actin is a highly 
dynamic structure, constantly undergoing cycles of polymerisation and depolymerisation. 
Upon stabilisation, the actin filament has a tendency to ‘move forward’ in the direction of 
the barbed end whilst maintaining the same length as it polymerises at the barbed end 
while losing G-subunits at the – end; this is a process known as ‘treadmilling’. It is this 
treadmilling property of F-actin that provides cells the necessary force to drive migration 





1.5.1.1. Accessory proteins of actin  
 
Under physiological conditions, spontaneous polymerisation and breakdown of actin 
filaments is far too slow to support the throughput required for migration; so a horde of 
proteins was developed by cells to make this process much more efficient. Profilin and β-
thymosins act as buffers for G-actin monomers, where profilin ‘prime’ them again for 
polymerisation by catalysing the exchange of ADP for ATP and deliver them to the barbed 
ends of existing filaments; in contrast, the exact function of β-thymosins is still ambiguous, 
although it is thought to negatively regulate the amount of free actin monomers available 
for polymerisation, actin monomers can be readily exchanged between β-thymosin and 
profilin (Goldstein et al., 2005, Xue and Robinson, 2013). It is interesting to note that in 
migrating cells the concentration of free G-actin-ATP is maintained by profilin in such a way 
that F-actin formation is favoured under physiological conditions (Bravo-Cordero et al., 
2013). This means that as soon as any short actin filaments become available, they are more 
likely to spontaneously elongate, skipping nucleation phase altogether. The major supplier 
of these short filaments in question is the F-actin-severing protein cofilin. Indeed, cofilin 
does technically take part in the disassembly of the actin cytoskeleton by breaking them up 
into fragments; however, in doing so this also creates ready-made nuclei for another round 
of assembly almost immediately (Bravo-Cordero et al., 2013). Nucleation can also be 
achieved de novo via Junction-mediating and regulatory protein (JMY), which bring actin 
monomers together in proximity to promote and stabilise oligomerisation; and SPIN90 
proteins, which mimick the F-actin barbed end to ‘lure’ actin monomers into elongating 
against it (Krause and Gautreau, 2014, Nurnberg et al., 2011). Owing to the intracellular 
conditions, elongation can take place rapidly without assistance; however, to maximise this 
rate even further the barbed end of the filament, where actin polymerisation is occurring 
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the fastest, can be manipulated. For example, capping proteins (CPs) bind to the barbed end 
of the filament, preventing any further assembly of actin monomers and shifts the dynamics 
towards ATPase-mediated filament disassembly (Edwards et al., 2014). Counteracting this, 
the formin family of proteins, CARMIL proteins (capping protein, arp2/3 and myosin I linker) 
and ENA/VASP proteins compete with CPs for the barbed ends while recruiting competent 
profilin-G-actin complexes to encourage further filament assembly (Edwards et al., 2014, 
Krause and Gautreau, 2014). At the end of the actin cycle, cofilin makes its return, this time 
serving to remove any older actin filaments that are no longer contributing to force 
generation (e.g. at the back of the lamellipodia), with the resultant actin monomers or 
oligomers are turned back over to a location where they can be reused (Bravo-Cordero et 
al., 2013). Cooperating with cofilin, gelsolin is another severing protein that cuts actin 
filaments but remains attached to the barbed end of its product after cleavage as a capping 
protein, preventing it from becoming a nucleus for elongation (Sun et al., 1999). In reality 
however, in in vivo situations cofilin and gelsolin carry similar functions - to facilitate F-actin 
disassembly by severing actin filaments, while providing new polymerisation-competent 
oligomers to ensure the turnover of actin cytoskeleton.  
 
1.5.2. Manipulation of actin in cell migration 
 
During mesenchymal migration, cells are often flat and extended while exhibiting broad, 
protrusive and ruffling cell membranes that are densely packed with actin, called the 
lamellipodia, biased onto one side of the cell (called the leading edge) (Krause and 
Gautreau, 2014, Bravo-Cordero et al., 2013). Additionally, the area behind the lamellipodia 
protrusion of the cell is called the lamella, while the boundary between the lamellipodia and 
lamella is the ‘transition zone’ (Parsons et al., 2010, Nurnberg et al., 2011). This is the most 
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common morphology that competent cells employ for 2-dimensional movement; although 
other types of structural polarity exist. For example, filopodia are short, finger-like 
protrusions on the leading edge that are ‘sharper’ in appearance; but only support slower 
modes of migration (Howe, 2004). Occasionally, cells can migrate downwards into the ECM 
by degrading its structural framework in a specialised process known as invasion, using 
invadopodia and podosomes (Hoshino et al., 2013). This ability is prominent in cancer cells 
and immune cells such as leukocytes, where they can penetrate through the ECM and 
basement membranes to enter the bloodstream where they can travel long distances to 
enter other tissues (Hoshino et al., 2013). It is important to note here that these structures 
are highly dynamic and transient in nature; such that lamellipodia and filopodia are 
interchangeable, and can be rapidly created or disassembled when instructed by 
extracellular cues. 
 
After an actin filament is made, the next level of complexity lies in the manipulation of the 
actin filaments so that they can be morphed into different tertiary structures. The 
lamellipodium, which takes part in mesenchymal migration, utilises a network of actin 
branches to generate a broad ‘protrusive front’ via the polymerisation of the barbed end 
tips pushing against the leading edge membrane (Nurnberg et al., 2011, Krause and 
Gautreau, 2014, Bravo-Cordero et al., 2013). This branching effect is thanks to the actin 
related protein 2 and 3 complex (Arp2/3), a protein that binds to an existing actin filament 
and facilitates the nucleation and elongation of another that branches off from the original; 
while this newly formed branch can also serve as the template from which another branch 
can be created by the virtue of another arp2/3 protein (Nurnberg et al., 2011, Krause and 
Gautreau, 2014). Cumulatively, these Arp2/3-F-actin branches significantly increases the 
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density of the lamellipodial actin network, and gives this structure its broad, spread-out 
appearance which maximises the surface area in which new focal adhesions can be formed 
for the next step. However, it must be emphasized here that these structures are highly 
dynamic and are constantly undergoing cycles of creation and destruction (Krause and 
Gautreau, 2014). Indeed, a balance is maintained between activities of proteins that make 
F-actin longer (JMY, SPIN90, profilin, CARMIL, formins and ENA/VASP) and of those that 
shorten or disassemble actin filaments (β-thymosins, capping proteins, cofilin, gelsolin and 
its own endogenous ATPase activity) within this compartment (Edwards et al., 2014, Krause 
and Gautreau, 2014, Nurnberg et al., 2011, Bravo-Cordero et al., 2013). This is done so that 
the actin branch network is constantly being turned over rapidly in order to maintain the 
force of protrusion against the leading edge while not overcrowding the lamellipodia with 
unproductive filaments (Krause and Gautreau, 2014, Bravo-Cordero et al., 2013). Supporting 
this, the density of actin branches correlates positively to the stability of the lamellipodia, 
but is inversely proportional to the speed of migration (Krause and Gautreau, 2014). This 
means that the more concentrated the branch network (more branches), the longer the 
lamellipodia will persist but in exchange of the slower migration; whereas less branches 
would mean faster cell migration but the lamellipodia becomes more prone to breakdown 
(Krause and Gautreau, 2014).  
     
To enter the next stage of migration the leading edge protrusions must persist for long 
enough and provide enough mechanical force so that the lamellipodium can come into 
contact with part of the ECM that was previously in front of the cell (Bravo-Cordero et al., 
2013). If successful, the contacts are then consolidated by integrin, forming a nascent focal 
adhesion. Integrins are heterodimeric transmembrane receptors that function to link the 
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ECM to the cytoskeleton while also relaying signalling to the cell (Bridgewater et al., 2012). 
Indeed, numerous isoforms of integrins are known, each with different binding affinities to 
ECM components, intracellular signalling and the phenotype they convey onto the cell 
(Bridgewater et al., 2012). While still in vesicles inside the cell, integrins are ‘activated’ by 
kindlin and talin binding, which serve to link the actin cytoskeleton to integrin, before being 
translocated to the PM (inside-out integrin signalling) (Bridgewater et al., 2012). At this 
stage, two outcomes are possible; either the intracellular integrin signalling complex fails to 
adequately make a connection with the actin cytoskeleton and disassemble, or it connects 
fully with the actin network and mature into a full focal adhesion as more integrin-ECM 
complexes accumulate in this concentrated area to stabilise this actin-integrin-ECM 
connection (Parsons et al., 2010, Huttenlocher and Horwitz, 2011). Integrin binding to the 
ECM then activates a wide range of signalling pathways that is translated into the rest of the 
cell (outside-in signalling) (Bridgewater et al., 2012).  
 
In a polarised, migrating cell, behind the lamellipodia sits the lamella, which is rich in 
maturing, larger focal adhesions that anchor the cell to the ECM (Huttenlocher and Horwitz, 
2011, Parsons et al., 2010). Here the actin filaments are not branched, but are instead 
arranged into a series of parallel bundles (called stress fibres) by myosin II and α-actinin into 
an extensive network of actomysosin bridges. In the transition zone (i.e. the lamellipodia-
lamella border), actin filaments are either disassembled with the remnants transported back 
to the front of the lamellipodia or are remodelled into bundles (Parsons et al., 2010, 
Huttenlocher and Horwitz, 2011); while nascent adhesions undergo maturation into focal 
complexes, as components of the integrin signalling complex start to arrive (Shen et al., 
2012, Huttenlocher and Horwitz, 2011). Outside-in integrin signalling activates a series of 
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actin-binding proteins – talin, vinculin and α-actinin, further promoting the bundling of the 
actin filaments while stabilising the focal adhesion (Parsons et al., 2010, Huttenlocher and 
Horwitz, 2011). To relay physiological effects downstream, the integrin signalosome also 
contains tyrosine kinases Src and focal adhesion kinase (FAK), and the adaptor protein 
paxillin to communicate the downstream effects of focal adhesion establishment (Shen et 
al., 2012, Huttenlocher and Horwitz, 2011). One of the most prominent effects is the 
activation of myosin II, resulting in the movement of antiparallel actin bundles past each 
other and cellular contraction (Shen et al., 2012, Huttenlocher and Horwitz, 2011, Parsons et 
al., 2010). During cell movement the force of lamellipodial protrusions is opposed by the 
resistance from the PM. Therefore, newly formed focal adhesions provide traction for the 
cell, from which the protrusions can be translated into forward movement whilst utilising 
actomyosin contraction to propel the rest of the cell forward in the direction of the 
lamellopodia to consolidate this event (Shen et al., 2012, Huttenlocher and Horwitz, 2011, 
Parsons et al., 2010). Moreover, this type of contraction also produces a force tension that is 
important for the full maturation and effective signalling of focal adhesions (Parsons et al., 
2010). 
 
It is thought that components of the integrin signalling machinery are constantly recycled 
around the central ‘core’ of the adhesion (Bravo-Cordero et al., 2013). In order for the cell 
to make a forward movement, it must release most of its focal adhesions at the rear of the 
cell. Actomysosin contraction provides tensional force that facilitates its detachment from 
the ECM (Parsons et al., 2010). However this is still not a completely understood process, 
though myosin IIA-mediated pulling of the integrin-linked actin bundles, the microtubule 
cytoskeleton and the protease activity of calpain to cleave protein components of the 
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integrin signalosome (talin, FAK and paxillin) are proposed to contribute to this process 
(Parsons et al., 2010). 
 
1.5.3. Regulation of signalling in cell migration 
 
Cell migration is a spatiotemporally regulated process that is carefully coordinated; during 
which the cell is constantly under the influence of a variety extracellular cues such as 
chemokines and ligands (chemotaxis), ECM density (haplotaxis), electric fields (electrotaxis), 
and the rigidity of the substratum (durotaxis) (Petrie et al., 2009). These cues are conveyed 
by surface receptors (RTKs and GPCRs) or ‘sensors’ and ion channels on the PM which are 
then relayed onto the regulators of actin dynamics by a complicated web of signalling 
pathways. Despite the differences in mechanisms of migration activation, Phosphoinositide -
3-kinase (PI3K) signalling and subsequently the Rho family of GTPases, namely Rho, Rac and 
CDC42, appear to lie at the centre of this signalling hub (Parsons et al., 2010, Krause and 
Gautreau, 2014, Bravo-Cordero et al., 2013). Although there are notable exceptions (Shen et 
al., 2012), active Rac and CDC42 mainly populate the leading edge, where they facilitate the 
formation and maintenance of lamellipodia (Rac) and filopodia (CDC42) respectively (Howe, 
2004); whereas the Rho family (including RhoA, RhoB and RhoC) predominantly operate 
from the lamella backwards where they mainly mediate actomyosin contraction and focal 
adhesion detachment (Ridley, 2013, Howe, 2004). Indeed, PtdIns(3,4)P2 (PIP2), a substrate of 
both PI3K and phospholipase C (PLC), is an important module for both the activity of cofilin 
and Rho GTPases (Bravo-Cordero et al., 2013, Krause and Gautreau, 2014). Rho GTPases act 
as molecular switches that are active when bound with GTP, but are inactivated when GDP-
bound. Their regulation is by GTPase activating proteins (GAPs), which promote their 
endogenous GTPase activities to hydrolyse GTP to GDP to switch the protein off; and 
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guanine nucleotide exchange factors (GEFs), which activate the protein by exchanging the 
bound GDP with GTP (Shen et al., 2012). To enforce the protein in the inactive state, Rho 
guanine-nucleotide dissociation inhibitors (Rho-GDI) bind to RhoGDP to prevent GEF-
mediated GTP exchange (Shen et al., 2012).  
 
During the first protrusion step, the formation of lamellipodia requires Rac-GTP activity 
which, in collaboration with the Ras  ERK and Src Abl kinase pathways, activates the 
SCAR/WAVE family verrolin-homologous protein (WAVE), a giant heteropentameric complex 
(400kDa) which acts as a signalling hub for direct effectors of actin dynamics (Chen et al., 
2014a, Krause and Gautreau, 2014); and lamellipodin, which is important in defining the 
location and the speed of protrusion by modulating lamellipodial size and stability (Law et 
al., 2013), in a series of phosphorylations (Krause and Gautreau, 2014). Once activated, 
phosphorylated WAVE and lamellipodin translocate to the PM where they interact with the 
components that are regulated by PI3K and SH2 domain-containing inositol 5’-phosphatase 
2 (SHIP2), namely PIP3 and PIP2 (Krause and Gautreau, 2014). Interestingly, WAVE also 
requires PIP3 binding on liposomes before recruitment to the PM in addition to RacGTP for 
full activation (Krause and Gautreau, 2014). While at the PM, activated WAVE and 
lamellipodin form a complex with each other and recruits arp2/3, an actin filament 
branching protein crucial in the creation lamellipodial protrusions; and ENA/VASP, an 
elongation factor important in the generation of forces behind the protrusions, to initiate 
the cell migration cycle. However, Rac also has inhibitory effects on actin dynamics by 
activating arpin, which switches off the arp2/3 at the edge of the lamellipodia (Dang et al., 
2013). In reality, the leading edge usually consists of both lamellipodial and filopodial 
intrusions, as activities of Rac and cdc42 are oscillating between cycles of protrusion and 
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retraction as the cell is continuously probing the ECM (Krause and Gautreau, 2014). The 
movements of the leading edge requires careful spatial coordination between the activities 
of GEFs and GAPs to sculpt the architecture and the direction of the protrusion (Bos et al., 
2007). Indeed, GEFs such as β-PIX (downstream of coronin1A), TRIO (downstream of 
CARMIL1), Tiam1 and Vav2; and GAPS such as SH3BP1 (downstream of exocyst) and SLIT-
ROBO (SrGAP, as a potential negative feedback loop from lamellipodin and WAVE) have all 
been reported to provide positive and negative feedbacks for Rac in this compartment 
(Krause and Gautreau, 2014).  
 
Cofilin, which is one of the central mediators of actin turnover, is also under the control of a 
range of signalling cascades, reviewed in detail previously (Bravo-Cordero et al., 2013). It is 
inactivated when bound to PIP2 on the PM, and hence are activated by PLC, which releases 
cofilin into the cytoplasm. Once there, however, cofilin is also the subject of cytoplasmic 
control by phosphorylation such that when phosphorylated, cofilin activity is inhibited, and 
it translocates to the cytosol away from the leading edge. Therefore, the combined effects 
of PLC mediated PIP2 cleavage and phosphatases are required for the full activation of 
cofilin. This process is also dependent on Rho-GTPases. For example, RAC2 activates the 
phosphatase CIN to activate cofilin, whereas phosphorylation by LIM kinase is considered 
inhibitory for the enzyme. It is interesting to note that Ca2+ signalling, which regulates 
gelsolin in actin disassembly, also plays a prominent role in cofilin activity, by regulating 
phosphatase slingshot1 (SSH) which, like CIN, serves to activate cofilin by 
dephosphorylation. SSH activity is inhibited when it is phosphorylated by CaMKII, which is 
opposed by calcineurin; meaning that cofilin is activated when calcineurin is dominating 
over CaMKII.   
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Nascent focal adhesions that were first formed in the lamellipodia gradually mature (i.e. 
more ECM-integrin-actin complexes are formed) as its cytosolic environment ‘above’ makes 
the transition from lamellipodia to lamella, and eventually to the trailing edge (Parsons et 
al., 2010). As such, the integrin signalosome undergoes constant remodelling at different 
stages of the migration cycle. Firstly, under the lamellipodia, integrin in nascent adhesions 
potentiates Rac activity by activating its specific GEFs DOCK180, hence feeding further into 
the generation of branched protrusions (Avraamides et al., 2008, Cote and Vuori, 2007). 
However, as some of the actin filaments coordinate with integrin there, they are also 
committed to the conversion from actin branches into bundles. Rac also appears to 
contribute to this by activating p21-activated kinase (PAK) to regulate myosin II-mediated 
contraction at the back-end of the lamellipodia and in the transition zone (lamellipodia-
lamella interface) (Parsons et al., 2010, Brzeska et al., 2004, Riento and Ridley, 2003). Rho 
activity is generally suppressed in the lamellipodia by the activation of RhoGAPs (e.g. 
p190RhoGAP) as well as the inhibition of RhoGEFs (e.g. p115RhoGAP) in a concerted effort 
by Gα13, Src kinases, FAK-paxillin and Rac (Shen et al., 2012, Parsons et al., 2010). As the 
lamellipodia moves on, the signalling begins to change as the nascent adhesion matures into 
a focal complex and then into a full focal adhesion when the lamella arrives. From the 
transition zone backwards the balance begins to shift from Rac to Rho as RhoGEFs such as 
leukaemia-associated Rho-GEF (LARG) and GEF-H1 are activated, resulting in the activation 
of Rho-associated kinase (ROCK) to inhibit myosin light chain phosphatase (MLCP) (Kimura 
et al., 1996). This keeps MLC in an activated, phosphorylated state and maintains the 
tension produced by actomyosin bridges, hence aiding in the maturation of the focal 
adhesion and its signalling. This tension has also been proposed to switch off Rac by 
activating its GAP ARHGAP22, which provides one potential way that Rho can negate Rac 
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behind the leading edge (Sanz-Moreno et al., 2008). Activated Rho also couples to the 
formin mDia, which facilitates in the polymerisation of actin in the production of stress 
fibres (Huttenlocher and Horwitz, 2011, Parsons et al., 2010). Moreover, as mDia also 
interact with microtubules, it cannot be ruled out that this part of the cytoskeleton may also 
take part in the detachment of focal adhesions (Huttenlocher and Horwitz, 2011, Parsons et 
al., 2010). The reciprocal regulation of Rho and Rac activity during the cell motility cycle in a 
polarised cell is still poorly understood, as this role appears to be carried out by integrins 
and mediated by the similar upstream elements (i.e. FAK/paxillin/Src tyrosine kinases) (Shen 
et al., 2012). Therefore, it is likely that it is the spatiotemporal regulation of specific GEFs 
and GAP localisation around the core integrin signalosome that determines whether the 
signal they relay results in lamellipodial protrusion, cell contraction or tail retraction 
(Parsons et al., 2010, Shen et al., 2012).     
 
1.5.4. Podosomes and invadopodia 
 
Podosomes and invadopodia are actin-rich, integrin based complexes which have the ability 
to break down the ECM in order to migrate into it (Nurnberg et al., 2011). Compared to 
focal adhesions, which consists of ECM-integrin-actin bundles, actin molecules in 
podosomes and invadopodias are not arranged into bundles. Instead, the actin dynamics 
here is similar to that in the leading edge, where actin branches are formed by arp2/3 
complexes allowing it to protrude into the ECM (Hoshino et al., 2013).  
Podosomes are transient structures that are important for matrix remodelling, and are used 
by non-cancerous cells like dendritic cells, endothelial cells and osteoclasts (Huttenlocher 
and Horwitz, 2011, Hoshino et al., 2013). Their formation often start with the formation of 
actin protrusions, which is then enclosed by a ring of integrin complexes and the exocytosis 
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of metalloproteinase (MMP)-containing vesicles to enable degradation of the ECM (Weaver, 
2006, Albiges-Rizo et al., 2009). On a cell, podosomes are able to arrange themselves into 
two rows at the cell periphery, called podosome belts, or into rings of podosome rosettes 
(Luxenburg et al., 2007). Invadopodia are similar in appearance to podosomes, but are 
generally more aggressive in terms of matrix degradation and protrude further into the 
ECM, as well as being more stable (Hoshino et al., 2013, Huttenlocher and Horwitz, 2011). 
Moreover, invadopodia don’t often form higher order structures like podosomes unless in 
special circumstances. For example, in Src-transformed cells, belts and rosettes of 
invadopodia (termed ‘invadosomes’) are readily formed (Brabek et al., 2004).  
 
Much like the formation of lamellipodia and filopodia, which involves the PI3K/SHP2  
Rac/cdc42  WAVE pathway, the formation of invadopodia involves a similar mode of 
signalling. During the initiation phase of invadopodia formation, powered by the activation 
of growth factor receptors (e.g. EGF), PI3K signalling again coordinates with another Rho 
GTPase, CDC42, downstream to activate N-WASP (hence in an analogous PI3K/SHP2  
cdc42  N-WASP pathway) (Nurnberg et al., 2011, Hoshino et al., 2013), which serves as 
the central signalling axis for the activation of actin nucleators such as arp2/3 and cortactin 
to mediate actin polymerisation and downward protrusion (Nurnberg et al., 2011). The next 
stage of invadopodia formation involves the enclosement of the actin rich regions by a ring 
of integrin-ECM complexes, which facilitates the degradation of the ECM beneath (Branch et 
al., 2012). Although components of the integrin signalosome mentioned earlier (i.e. paxillin, 
FAK, Cas/Crk, calpain and RhoA) have all been reported to contribute to invadopodial 
physiology, it is Src kinases and integrin-linked kinases (ILK) that appeared to play the least 
ambiguous roles (Huttenlocher and Horwitz, 2011, Hoshino et al., 2013). ILK, in association 
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with IQGAP1, the formin mDia and the exocyst complex, has been proposed to recruit the 
vesicle-bound MT-MMP1 to the PM to bring about ECM degradation (Sakurai-Yageta et al., 
2008, Liu et al., 2009, Lizarraga et al., 2009). The activity of MT-MMP1 outside the cell has 
been shown to activate a range of signalling pathways such as TGFβ and VEGF (Hoshino et 
al., 2013).  
 
1.6. Aims of this study 
cAMP signalling has been reported to be important in the regulation of PDAC, especially that 
of cell migration (Burdyga et al., 2013, Zimmerman et al., 2013). However, the exact cAMP 
toolkit is poorly characterised in this cell type. Therefore, the first aim of this study is to 
characterise the cAMP handling machinery in PDAC cells, using PANC-1 cells as the model 
cell-line. Specifically two main questions will be addressed: Which extracellular agonist 
can stimulate cAMP production? Which PDE isoform is predominantly active in PANC-1 
cells?  
 
In light of the fact that Ca2+ signalling can influence cAMP signalling in many cell types, the 
second aim of this study is to investigate the signalling crosstalk between Ca2+ and cAMP 





























Chapter 2 – Materials and methods 
 
2.1. Drugs and chemicals 
Thapsigargin (TG) and rapamycin were obtained from Calbiochem (Nottingham, UK). PDE 
inhibitors i.e. 8-methoymethyl-IBMX (8-mm-IBMX), EHNA, T0156, rolipram, BRL-50487, 
BC11-38 and cilostazol, as well as forskolin, secretin, VIP, Iloprost, Isoproterenol, and H89 
were purchased from Tocris biosciences (Abingdon, UK). IBMX, papaverine and neurotensin 
were purchased from Sigma-Aldrich (Gillingham, UK).  
 
2.2. Plasmids and constructs 
Lifeact-RFP construct was purchased from Ibidi (Martinsreid, Germany). TK-YFP-STIM1 and 
both constructs of the rapamycin-inducible linkers (PM-FKBP-mRFP and ER-FRB-CFP, (Varnai 
et al., 2007) were kind gifts from Dr. Tamas Balla (NIH, Maryland, USA). Genetically encoded 
probe for PKA activity, A-kinase activity reporter 4 (AKAR4), was a kind gift from Dr Jin Zhang 
(John Hopkins laboratory, USA) (Depry et al., 2011). Genetically encoded probe for cAMP 
concentration, mTurq2Del-EPAC(dDEPCD)Q270E-cp173Venus(d)-Venus(d) (H134), was a 
kind gift from Dr Kees Jalink (The Netherlands Cancer Institute, 
http://research.nki.nl/jalinklab/Constructs.htm) (Klarenbeek et al., 2011). On receiving the 
plasmids they were amplified using Qiagen Plasmid Maxi Prep HiSpeed kit (Manchester, UK) 






2.3. Cell Culture  
Dulbecco’s Eagle Medium (DMEM), Heat inactivated Foetal Bovine Serum (FBS), Penicillin-
Streptomycin-Glutamine (PSG) and 0.05% trypsin-EDTA solution were all obtained from Life 
technologies (Paisley, UK). The incubator for cell culture (model Galaxy S) was purchased 
from Wolf Laboratories (York, UK). Cell culture flasks were purchased from Corning 
(Buckinghamshire, UK). Pre-made sterile phosphate-buffered saline was purchased from 
Lonza (Nottingham, UK). PANC-1 cells were obtained from ATCC and were constantly 
maintained at 5% CO2 and 37
oC in sterile and humidified incubator, in DMEM supplemented 
with 10% FBS and 1% PSG. At each passage, cells at 90-110% confluency were quickly rinsed 
twice with sterile, phosphate buffered saline (PBS) solution before being treated with 800µl 
0.05% trypsin-EDTA solution for approximately two minutes to detach the cells. Afterwards 
5ml of fully supplemented DMEM was added to the cells suspension, which was 
subsequently centrifuged at 500rpm for 2 minutes. Finally the supernatant was removed 
and the pellet was suspended in 10ml of fully supplemented media; the cells were then 
diluted further in media so that 90% confluency could be attained again in 4 days.    
  
2.4. Cell transfection 
At the end of each passage, 2ml of cell containing solution was placed into 35mm MatTek 
glass-bottomed dishes (MatTek, USA) or regular plastic 35mm dishes (Corning, UK) with a 
small 18mm circular glass coverslip (VWR international, UK) for live cell imaging and 
immunofluorescence experiments respectively. Cell density was adjusted so that they would 
reach their corresponding confluence at the time of experiment (after 3 or 4 days): in 
studies examining fixed cells, the confluence would be 40%; whereas for live cell FRET 
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measurements it was closer to 80%. 24 hours prior to each experiment, plasmids were 
mixed with Promofectin reagent (Promokine, UK) with the ratio of 1.5µl promofectin per 
1µg of plasmid per dish, which is made up in 50µl DMEM (not supplemented). This plasmid-
promofectin mixture in DMEM was then left in sterile conditions at room temperature for 
20 minutes for equilibration. 1ml media was removed from each dish before the addition of 
the plasmid-containing solution into the cells to attain the maximum possible transfection 
efficiency. Therefore, at the end of transfection each 35mm dish of cells should contain: 1ml 
of fully supplemented media, plus a transfection mixture containing 1.5µl promofectin + 1µg 
of plasmid made up in 50µl of unsupplemented DMEM. Note that in the case of co-
transfections i.e. transfection of 2 plasmids simultaneously into the same dish of cells, 1µg 
of each plasmid (so that there are now 2µg of plasmid) was then mixed with 3µl of 
promofectin (so the concentration was correspondingly doubled) and made up in 50µl 
unsupplemented DMEM.  
          
2.5. Cytosolic Ca2+ measurements in live cells 
The ratiometric fluorescent Ca2+ dye Fura-2 was purchased from Life Technologies (Paisley, 
UK). On the day of the experiment the supplemented DMEM solution bathing the PANC-1 
cells was removed and rinsed twice with a custom-made Na+-HEPES based solution 
(composed of 140mM NaCl, 4.7mM KCl, 1.13mM MgCl2, 10mM HEPES, 10mM Glucose, 
1.8mM CaCl2, all purchased from Sigma Aldrich, adjusted to pH 7.4; will be referred to as 
just HEPES solution hereafter) before being incubated in 5µM Fura-2 dissolved in HEPES 
solution for 1 hour at room temperature. After incubation the Fura-2 dye was removed by 
rinsing the cells twice with HEPES-based solution, before being placed into the perfusion 
chamber for live cell imaging. During each experiment cells were perfused with HEPES-
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based solutions containing either 1.8mM Ca2+ or ‘no Ca2+’ (nominally Ca2+ free solution), and 
various drugs defined in the description of specific experiments. DMSO, the vehicle used to 
dissolve most of the drugs in this study, was added to control solutions in experiments 
where concentrations of 0.1% or more were used.  
 
2.6. FRET measurements in live cells  
Before each experiment transfected cells were rinsed twice with HEPES-based solution to 
remove the DMEM media. All test solutions, including controls, were made using their 
corresponding HEPES-based solutions. After initial rinsing the dish containing the cells was 
attached to a custom-made metal insert, into which approximately 2mls of the baseline 
solution (HEPES-based solution, with or without added Ca2+) was added. This insert was then 
placed in an enclosed chamber with the temperature set at 32oC where the microscope 
resides. Once inside, the insert containing the cells was connected to a gravity-fed perfusion 
system, which accommodated an adaptor for a 6-way manifold on one side for solution 
entry and a vacuum line with a fluid trap for solution removal on the opposite side. The 
solutions were held in syringes, which were placed above the microscope stage. The nozzles 
of the syringes were equipped with two-way taps connected via silicone tubing to the 
manifold. This setup allows the cells to be under 2mls of solutions at all times with a 
perfusion rate of about 1ml/minute. To ensure that the solutions arriving in the chamber 
can reach the cells at the bottom as quickly as possible the entry point is situated at the 
bottom of the insert, whereas the vacuum suction is at the top of the insert. As with 
cytosolic Ca2+ measurements, DMSO was added to control solutions in experiments where 
concentrations of 0.1% or more were used . 
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The cell-containing chamber was mounted on the stage of an Olympus IX71 based inverted 
imaging system (Till Photonics GmbH, Germany). Excitation of fluorescence was provided by 
a 150W xenon high stability lamp and a polychrome V monochromator wavelength control 
(Till Photonics GmbH, Germany). Emission light was collected using band or high pass filters 
and sent to an iXon DV885 cooled EM CCD camera (Andor technology, UK). Camera binning 
was set to 2 both horizontally and vertically which provided a 502x502 pixel points per 
image. TillVision software (Till Photonics, Germany) was used to control the parameters of 
image acquisition and post-analysis, and allowed for the measurement of fluorescence 
while the experiment was in progress. 
For Fura-2 experiments cells were sequentially excited by 340nm and 380nm light. Emission 
light was collected using a 510nm high pass filter. PANC-1 cells transfected with either 
AKAR4 or H134 were excited at 405nm, which is close to the excitation maximum of the 
donor, CFP. Emissions of both CFP and YFP fluorescence were measured simultaneously 
using specialised filters (Optical Insights Dual-View Filter cube with D480 + 30m and D535 + 
40m Filter Sets, BioVision Technologies, USA) only allowing wavelengths of 480nm and 
535nm to reach the camera. For both Ca2+ and FRET measurements, only spread out, 








Figure 2.1. H134 – structure and function. 
A simplified schematic of cAMP induced changes in the H134 FRET signals. H134 
(mTurqoise-EPAC-Q270E-VV) was made using Epac1-Q270E as backbone, with the 
GlnGlu mutation induced to increase its binding affinity to cAMP. The Epac was flanked 
on its N-terminus by a CFP variant and YFP variants on its C-terminus. At resting levels the 
CFP and YFP are in close proximity, therefore FRET would be at its maximum; the binding 
of cAMP to its EPAC backbone leads to a conformational change that takes CFP away from 
YFP, dissipating FRET. An increase in cAMP concentration inside the cell increases the 
amount of cAMP-bound H134, resulting in a decreased overall FYFP/FCFP ratio or increased 
FCFP/FYFP ratio. It is via this mechanism that one can correlate relative cAMP concentration 



















Figure 2.2. AKAR4 – structure and function. 
A simplified schematic of the AKAR4 response to increased PKA activity. AKAR4 (A-Kinase 
activity reporter 4) is a biologically engineered probe flanked by CFP variant on the N-
terminus and an YFP variant on the C-terminus. Between the two fluorescent proteins it 
contains a fork-head association domain followed by a consensus PKA substrate 
sequence. When PKA activity is increased inside the cell, PKA phosphorylates the 
threonine residue on the consensus sequence, creating a binding site for its neighbouring 
FHA1 domain. The binding of FHA1 to phospho-threonine brings CFP in proximity to YFP, 
increasing FRET. Hence, via this mechanism one can correlate increased PKA activity to 
increased FYFP/FCFP ratio (Depry et al., 2011).  
 



















FYFP/FCFP ratio ∝ PKA activity  
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Anti-rabbit Phospho-PKA antibody was purchased from Cell Signalling technologies (Hitchin, 
UK). All secondary antibodies (mouse anti-rabbit Alexa488 and Alexa647), and Prolong Gold 
anti-fade medium were purchased from Life Technologies. All chemical components used to 
make up PBS (137mM NaCl, 2.7mM KCl, 10mM Na2PO4 and 1.8mM KH2PO4, adjusted to pH 
7.4), as well as goat serum and bovine serum albumin (BSA) were all purchased from Sigma 
Aldrich. Paraformaldehyde (PFA) was purchased from Agar Scientific (Essex, UK). 
In all immunofluorescence experiments the first step was always to remove existing media, 
which was done by rinsing the cells twice, and then replacing the cell maintenance solution 
with the HEPES solution supplemented with 1% FBS and 1.8mM Ca2+. The cells were then 
incubated at 37oC and 5% CO2 for 30 minutes for acclimatisation.  
In experiments concerning cells transfected with the PM-FKBP-mRFP and ER-FRB-CFP 
linkers, following acclimatisation the cells were treated with 100nM rapamycin dissolved in 
HEPES based solution for no more than 3 minutes. At the end of this treatment, cells were 
quickly rinsed twice with phosphate-buffered saline (PBS) before being fixed with 4% 
paraformaldehyde (PFA, made by diluting 16% PFA in PBS) for 30 minutes. All solutions 
hereafter were made up using PBS as base. Afterwards the PFA was removed by washing 
the cells three times for 5 minutes each with PBS on the rocker before the coverslips were 
then carefully dried and placed faced down onto a droplet of 20µl Prolong gold anti-fade 
medium on a microscopic slide (Fisher Scientific, UK). The fixed cells on the coverslip were 
kept at 4oC in darkness for at least 24 hours to allow Prolong gold to harden.  
In experiments involving cells transfected with Lifeact-RFP, following acclimatisation in 
HEPES-based solution supplemented with 1.8mM Ca2+ and 1% FBS at 37oC and 5% CO2 for 
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30-35 minutes; the cells were then rinsed twice with PBS before 30 minutes of fixation with 
4% PFA at room temperature. Following the fixation procedure, the PFA was removed by 
rinsing the cells three times for 5 minutes on the rocker. The fixed cells were then treated 
with 0.2% Triton x-100 for 5 minutes. The three-time PBS rinse on the rocker was carried out 
again for the removal of Triton, before PBS supplemented with 10% Goat serum and 1% BSA 
were added to the fixed cells for 1 hour at room temperature to block any non-specific sites. 
After that the coverslip containing the cells was removed from the dish and placed face 
down onto a 100µl droplet containing the antibody against phospho-PKA substrate, diluted 
by a factor of 1/500 in PBS (supplemented with 5% Goat Serum and 0.1% BSA). The antibody 
containing solution and the coverslip were usually placed on the underside of the 35mm 
dish lid. The coverslips were then incubated like this for approximately 18 hours on the 
rocker at 4oC. After this incubation the coverslips were rinsed 3 times with PBS for 5 minutes 
to remove excess primary antibody. The rabbit anti-mouse alexa488 secondary antibody 
diluted at 1:1000 in non-supplemented PBS, was then added to the cells via the same 
‘inverted coverslip onto a 100µl droplet’ method and incubated for 30 minutes on the bench 
at room temperature. This was followed by another three-time 5-minute rinse with PBS on 
the rocker to remove excess secondary antibody. The coverslips were then carefully dried 
and placed faced down onto a droplet of 20µl Prolong gold solution on a microscopic slide. 
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Figure 2.3. FKBP-FRB heterodimerisation system – structure and function. 
PM targeted PM-FRB-CFP and the ER targeted ER-FKPB-mRFP. These two proteins were 
modelled on an mTOR backbone. When Rapamycin is added, a FKBP-FRB bridge is formed 
in areas where the distance between PM and ER is less than 14nm, resulting in the 
colocalisation of CFP and mRFP. By this mechanism, any close contacts between the PM 
and ER will be ‘cross-linked’ and the fluorescence of CFP and mRFP will be colocalised; 















2.8. Confocal microscopy 
All immunofluorescence coverslips were imaged using Leica TCS SP2 inverted laser scanning 
confocal microscopes (LSCM) fitted with an Acousto-Optical Beam Splitter (AOBS). All 
images were taken on a 63x oil immersion (NA=1.4) objective, using Leica confocal software 
for image acquisition. The XYZ mode of imaging with the airy unit set to 1 was used, which 
Z-scanned the focal plane from the bottom of the coverslip towards the top of the cell. A 
512 x 512 pixel resolution was used in combination of 8 line averages to ensure that high 
quality of images with a high signal to noise ratio were taken.  
During acquisition of images, Alexa488 was excited using the 488nm laser line with emission 
collected at 500-540nm, CFP was excited by the 405nm laser line and its emission was 
collected at 450-490nm; and mRFP was excited by the 594nm laser line with its emissions 
collected at 605-690nm.  
In experiments involving linker constructs, CFP and mRFP were excited simultaneously for 
each confocal slice. However, imaging of cell samples transfected with the Lifeact-RFP 
constructs and Alexa488 were carried out sequentially (i.e. Lifeact-RFP was excited first, 
quickly followed by Alexa488) for each confocal slice to avoid spectral bleed through.  
  
2.8.1. Analysis of confocal images 
All colocalisation analyses were carried out using the ImageJ software (Schneider et al., 
2012). For linker experiments i.e. where 2 fluorophores were imaged at once, 
colocalisationRGB plugin (developed by Sergio Caballero Jr, University of Florida, script can 
be found via http://rsb.info.nih.gov/ij/plugins/download/misc/ColocalizeRGB_.java) was 
used to first assess the localisation of mRFP and CFP via threshold analysis, with a map 
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showing spots in the cell where the two linkers colocalised (i.e. where mRFP and CFP 
localised at a particular pixel and passed a set fluorescence threshold) was obtained while 
‘masking’ everything else. 
Colocalisation of Lifeact-RFP and Alexa488 fluorescence (representing phosphor-PKA 
substrates) was performed using the Leica LAS AF Lite software.  
  
2.9. Boyden chamber assays 
The 24-well Fluoroblok chambers and their accompanying 24-well plates were purchased 
from BD biosciences (UK). 100% Methanol and RNase A were purchased from Sigma Aldrich. 
Propidium iodide was purchased from Life Technologies.  
Random cell migration was assessed using 24-well Fluoroblok Boyden chambers with 8µm 
pore size. At the start of each experiment DMEM supplemented with 1% FBS and 1% PSG 
was added into the top and bottom well of the Boyden chamber. This solution would serve 
as the control to which test compounds would be added to in other conditions in the 
experiment. For measuring directional, chemotactic migration, the bottom well was 
supplemented with 5% FBS while the top well where the cells would be seeded was kept 
serum free so that at the time of seeding, cells were suspended in DMEM containing only 
1% PSG but no serum. At the time of cell seeding, the bottom part contained 750µl of 
solution while the top section contained 350µl of solution in each chamber/well. Each 
chamber containing appropriate solutions in the top and bottom sections of the well was 
kept in the incubator at 37oC and 5% CO2 for 1 hr before the cells were seeded onto the top 
section. The seeding procedure is identical to the passaging protocol described in 2.3 until 
the pellet stage. Here the supernatant was removed, and the pellet was resuspended in 2ml 
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of DMEM containing 1% FBS in the case of random migration, and in serum-free DMEM in 
the case of chemotactic migration. 100µl of the solutions containing the resuspended cells 
were then seeded into the top section of each chamber before the chambers were returned 
into the incubator to commence the experiment. Each condition was carried out in 
duplicates and each experiment was repeated in at least 4 separate cell preparations. 
After seeding, cells were allowed to migrate through the porous membrane during a 6-hour 
incubation period. Afterwards they were rapidly rinsed twice with PBS before being fixed 
with 100% methanol for 10 minutes at room temperature. The non-migrated cells were 
then removed from the top surface of the Boyden chamber membrane using a common 
cotton swab. The chambers were then incubated for 10 minutes in PBS to remove excess 
methanol, before being treated with PBS supplemented with 10µg/ml RNase A for 30 
minutes to degrade RNA and facilitate the imaging process later. Finally, the chambers were 
incubated in PBS supplemented with 100µg/ml Prodium Iodide for 10 minutes at room 
temperature to stain the cells migrated to the bottom face. Between each step the wells 
were quickly rinsed with PBS to remove solutions from the previous step. For preservation 
and future imaging the chambers were then placed into 24-well plates containing 1ml PBS 
per well. This method of fixing and staining migrated pancreatic cells for imaging was 
described in a recent study (Burdyga et al., 2013).  
 
2.9.1. Imaging and processing Boyden chambers  
The chambers were imaged using a 10x dry objective (NA = 0.3) on the Leica AOBS TCS SP2 
microscope, with a maximally open pinhole and no digital zoom. Propidium iodide was 
excited by the 514nm laser line with the emission collected at 570-690nm. The resulting 
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images were taken with 2 line averaging. Cell profiler software (Carpenter et al., 2006) was 
used to identify and count the number of migrated cells, stained with propidium iodide, on 
the bottom surface of the chamber membrane in each condition. The number of migrated 
cells in each condition was expressed as a % of their respective controls (i.e. conditions in 
which no test compounds were added). The results were analysed using unpaired, student’s 
t-test; P ≤ 0.05 was considered statistically significant. The error bars shown in the figures 













Chapter 3 – Characterisation of physiological cAMP agonists 
and PDE isoforms in PANC-1 cells 
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Chapter 3 – Characterisation of PDE isoforms in PANC-1 cells  
Overview 
cAMP signalling has only been discovered to play a role in PDAC physiology recently. In 2003 
a report was published (Farrow et al., 2003) detailing the dominant expression of the PKA 
RIα subunit in PANC-1 cells; the inhibition of which by both H89 and by RNAi inhibited cell 
growth and promoted apoptosis. However, in the same study a notable expression of RII 
subunits was also observed in MiaPaCa-2 and SUIT-2 cells, the other two pancreatic cancer 
cell lines tested; which were less sensitive to H89 than PANC-1 cells but are still susceptible 
to its growth inhibiting effects. In another study, the activation of PKA had little effects on 
proliferation but appeared to provide protection against apoptosis (Boucher et al., 2001). In 
terms of Epac, MiaPaCa and PANC-1 cell line, as well as in pancreatic cancer tissues, have 
been reported to overexpress the Epac1 isoform; where both forskolin treatment (to 
increase global cAMP concentrations) and the preferential activation of Epac1 by 8-pCPT-2’-
O-Me-cAMP inhibited cellular growth in a PKA independent manner (Lorenz et al., 2008). 
These reports imply that Epac1 activation stunts PDAC cell growth; whereas PKA appears to 
have exactly the opposite effects and protect PDAC cells from apoptosis.  
Intriguingly, when cAMP signalling was tested against another important caveat of PDAC 
physiology- cell migration and invasion, Epac activation appeared to potentiate cell 
migration, whereas PKA activation potently inhibited cell migration (Burdyga et al., 2013, 
Zimmerman et al., 2013).  
Previous data from our lab has shown that increasing cAMP concentrations by activating 
adenylyl cyclases using forskolin and inhibiting most PDEs using IBMX additively and 
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significantly inhibited cell migration and invasion in 5 different PDAC cell lines tested. 
Collectively, these results point towards the cAMP signalling cascade being important 
regulators of PDAC physiology; the manipulation of which can provide avenues for 
developing therapeutic interventions, especially that of metastasis, which is main cause of 
death in PDAC patients. Although the studies mentioned above have provided valuable 
insights into the downstream effects of cAMP signalling, the mechanism by which the levels 
of this second messenger is regulated remains poorly characterised (Zimmerman et al., 
2013). 
In this chapter we attempt to address this issue by characterising the cAMP signalling toolkit 
in PDAC cells, using PANC-1 cells as model cell line. To do this, we adopted a 
pharmacological, live cell imaging approach, in which we used a genetically encoded FRET-
based probe to measure changes in cellular cAMP levels as various agents were added. The 
main focus of this study is two-fold: to find out how cAMP is produced physiologically; and 
to deduce which family of PDE isoforms is dominant in PANC-1 cells.   
3.1. Characterisation of PDE isoforms  
3.1.1. Preliminary experiment 
Using H134, an Epac-based construct that senses cAMP concentration by measuring the 
FCFP/FYFP ratio, we measured cAMP concentration in PANC-1 cells whilst manipulating the 
cAMP machinery. In our preliminary experiments we found that adding IBMX (500µM) to 
unstimulated cells produced small and inconsistent increases in cAMP (data not shown). 
Therefore, simply treating PANC-1 cells with isoform-specific PDE inhibitors in baseline 
conditions is not likely to yield decisive results; prompting another strategy. To this end, as 
shown in figure 3.1.1, the addition of a sub-maximal concentration of forskolin (500nM) 
79 
 
effectively increased cAMP levels; as an elevated plateau was reached within 5 minutes in 
PANC-1 cells. Moreover, subsequent addition of IBMX (250µM) while maintaining the 
presence of forskolin treatment drastically increased cAMP levels as revealed by a further 
increase of the FCFP/FYFP ratio. These observations suggest that the inconsistent results from 
IBMX treatment alone is due to low endogenous background AC stimulation in these cells. 
This is because in the presence of adequate cAMP stimulation, with forskolin in this case, 
the incomplete inhibition of PDEs was already sufficient to saturate the probe, whereas the 
signal wasn’t as strong when stimulation was absent. Doubling the IBMX concentration from 
250µM to 500µM only produced a small increase in the FCFP/FYFP ratio and plateaued; 
suggesting that 500µM IBMX was enough to maximise the cAMP concentration in PANC-1 
cells at 500nM forskolin stimulation. Increasing the concentration of forskolin to 20µM in 
the presence of IBMX increased the FCFP/FYFP ratio further; suggesting that AC activity was 
not saturated at 500nM of forskolin.  
Therefore, for the protocol to characterise PDE isoforms, it was decided that PANC-1 cells 
would undergo 15 minutes of background cAMP stimulation by forskolin (500nM) to allow 
plateau formation and stabilisation before isoform-specific PDE inhibitors were added for 10 
minutes without the removal of forskolin. The rationale is that if a particular PDE isoform 
was active, then inhibiting it would potentiate the forskolin-mediated cAMP response. To 
this end, 500µM IBMX was added at the end of each experiment as positive control for 
general PDE activity. During analysis, traces that did not produce stable forskolin-induced 
plateaus were omitted.   
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Figure 3.1.1 Effects of forskolin and IBMX on cAMP concentration in PANC-1 cells. 
PANC-1 cells transfected with H134 were first subjected to forskolin (500nM) treatment 
before IBMX (250µM) was added without the removal of forskolin. The concentration of 
IBMX was doubled (500µM) before the additive increase of forskolin concentration 
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3.1.2. Cilostazol significantly increases cAMP concentration in PANC-1 cells 
PDE3 and PDE4 were chosen to be the starting point as it was previously mentioned that 
both of these isoforms perform the bulk of cAMP destruction in most cells (Bender and 
Beavo, 2006). Firstly, to reveal PDE activity, we treated PANC-1 cells with the PDE3 inhibitor 
Cilostazol (CLZ) (Schror, 2002) in the presence of forskolin and recorded the FCFP/FYFP ratio. 
The addition of 5µM CLZ after the formation of the forkolin-induced cAMP plateau 
produced additive effects, as reported by the increase in the FCFP/FYFP ratio during CLZ 












Figure 3.1.2. Cilostazol, an inhibitor of PDE3, significantly increases cAMP concentration in 
PANC-1 cells. 
PANC-1 cells expressing H134 were first treated with forskolin (500nM) for 15 minutes 
before cilostazol (5µM) was additively applied for 10 minutes. IBMX (500µM) was added 
at the end of the experiment (n=6 experiments, n=29 cells).  
  






















































3.1.3. Testing high doses of cilostazol in PANC-1 cells. 
Cilostazol has been successfully used for PDE3 inhibition in various systems, with the 
concentration required depending on the cell type tested. For example, less than 5μM was 
required in primary human platelets and (Liu et al., 2004), and both concentrations of 1μM 
and 10μM had been used successfully on human endothelial cells (Kim et al., 2014, Kim et 
al., 2002, Omi et al., 2004). 10μM was optimal for melanoma cells and chondrocytes (Wei et 
al., 2014, Wang et al., 2014), whereas higher concentrations of 50μM and 100μM was used 
for colon cancer cells and human monocytic leukaemia cell lines, respectively (Chuang et al., 
2011, Murata et al., 1999).   
Therefore, to determine the maximal inhibitory effect of this compound for PDE3, we tested 
three different concentrations of cilostazol (5μM, 10μM and 50μM) on PANC-1 cells against 
the background forskolin-induced cAMP response. It seems that 5µM, the smallest 
concentration tested, appeared to be enough to fully inhibit PDE3 activity in PANC-1 cells 
and in so doing increasing cAMP production; as higher concentrations of cilostazol (10 and 
50µM) did not increase cAMP levels any further, as reported by the F(CFP/YFP) ratio (fig 3.1.3). 




Figure 3.1.3. The effect of increasing concentrations of cilostazol on cAMP levels in PANC-1 
cells. 
PANC-1 cells expressing H134 were first treated with forskolin (500nM) for 15 minutes 
before increasing concentrations of cilostazol (5, 10 and then 50µM) were applied 
additively for 10 minutes. IBMX (500µM) was added at the end of the experiment (n=4 

































































3.1.4. Testing for PDE4 activity in PANC-1 cells 
To test for potential PDE4 activity in PANC-1 cells, we used rolipram, a well-known PDE4 
inhibitor (Teixeira et al., 1997). After pre-treatment of H134-transfected cells with forskolin, 
rolipram was added to see if a similar response to cilostazol could be observed. The 
concentration was set at 10μM, which has been demonstrated to effectively inhibit PDE4 in 
other human cell types, including some cancers (Moon et al., 2012, Santamaria et al., 1999, 
Henderson et al., 2014, McEwan et al., 2007, Tsunoda et al., 2012, Marquette et al., 2011).   
As shown in figure 3.3, PDE4 appeared to be active in PANC-1 cells, as the addition of 
rolipram after 15 minutes of forskolin pre-treatment caused a resolvable increase in the 
FCFP/FYFP ratio (figure 3.1.4). These observations suggest that PDE4 is also active in PANC-1 














Figure 3.1.4. The effect of rolipram, an inhibitor of PDE4, on cAMP concentration in PANC-
1 cells. 
PANC-1 cells expressing H134 were first treated with forskolin (500nM) for 15 minutes 
before they were treated with rolipram (10µM) additively for 10 minutes. IBMX (500µM) 






























































3.1.5. Testing for PDE1 activity in PANC-1 cells  
8-methoxymethyl-IBMX (8-mm-IBMX), was used at 100μM, a concentration previously 
reported to inhibit PDE1 activity in pancreatic β-cells and human arterial smooth muscle 
cells (Tian et al., 2012, Rybalkin et al., 2002). It was used to test for PDE1 activity in PANC-1 
cells in the continuous presence of forskolin.  
Interestingly, 8-mm-IBMX produced a small but noticeable increase from the forskolin 
plateau, but the increase returned to pre-treatment levels within 10 minutes (figure 3.1.5). 
While this does suggests that this Ca2+-sensitive PDE is present and active in PANC-1 cells, 

















Figure 3.1.5. The effect of 8-mm-IBMX, an inhibitor of PDE1, on cAMP concentration in 
PANC-1 cells. 
PANC-1 cells expressing H134 were first treated with forskolin (500nM) for 15 minutes 
before 8-methoxymethyl-IBMX (100µM) was applied additively for 10 minutes. IBMX 






























































3.1.6. Testing for PDE2 activity in PANC-1 cells 
To probe for the presence of PDE2 in PANC-1 cells, EHNA, a well-known inhibitor for this 
isoform (Podzuweit et al., 1995), was used. Although some past studies with EHNA reported 
that <50μM was sufficient for effective PDE2 inhibition (Saito et al., 2010, Hashemi et al., 
2005, Burton et al., 2010, Adderley et al., 2009), in our study we decided to use 100μM, a 
concentration used to inhibit PDE2 in human melanoma cells (Morita et al., 2013, Hiramoto 
et al., 2014), in order to maximise the inhibition of this enzyme, if present.  
After 15 minutes of forskolin treatment, 100µM EHNA addition did not appeared to have 
















Figure 3.1.6. The effect of EHNA, a PDE2 inhibitor, on cAMP levels in PANC-1 cells. 
PANC-1 cells expressing H134 were first treated with forskolin (500nM) for 15 minutes 
before EHNA (100µM) was applied additively for 10 minutes. IBMX (500µM) was added at 
































































3.1.7. Testing for PDE5 activity in PANC-1 cells 
To test if preventing cGMP breakdown has any influence on cAMP levels in PANC-1 cells, we 
treated PANC-1 cells with a highly potent PDE5 inhibitor T-0156 (Mochida et al., 2002), after 
the induction of forskolin plateau. A concentration of 1μM, previously reported to 
effectively inhibit PDE5 (Santos et al., 2014, Santos-Silva et al., 2008, Liu et al., 2008), was 
chosen. As shown in figure 3.1.7, T-0156 in the presence of forskolin induced a slight 
decrease on the FCFP/FYFP ratio, but the effect was not significant. These results suggest that 
either endogenous cGMP production is too low to have any effects, or that cGMP 
accumulation as a result of PDE5 inhibition had no effects on cAMP levels in PANC-1 cells. 
However, taken together with the results from EHNA experiments shown in figure 3.1.6, the 
data here suggests that the cGMP-activated PDE2 and the cGMP specific PDE5 are unlikely 
to have a substantial influence of on cAMP signalling in PANC-1 cells, though the cGMP-














Figure 3.1.7. The effect of PDE5 inhibition on cAMP concentration in PANC-1 cells. 
PANC-1 cells expressing H134 were first treated with forskolin (500nM) for 15 minutes 
before T0156 (1µM) was applied additively for 10 minutes. IBMX (500µM) was added at 































































3.1.8. Testing for PDE7 activity in PANC-1 cells 
To test for PDE7 activity in PANC-1 cells, the compound BRL-50481 (BRL), previously 
reported to inhibit PDE7 selectively with maximum inhibition achieved at 30μM (Smith et 
al., 2004), was used here. Although previous studies have utilised a higher concentration to 
inhibit PDE7 activity in other systems (Zhang et al., 2008a, Pekkinen et al., 2008), the 
concentration chosen for this drug was 10μM for this study as a starting point.    
When applied after the induction of a forskolin plateau, 10µM BRL-50481 somehow caused 
a slight, paradoxical decrease in FCFP/FYFP ratio; which may be due to an off-target effect of 
this compound (fig 3.1.8). Nonetheless, this was not investigated further as no cell tested 
displayed any increases in cAMP concentration in response to this compound. This 
















Figure 3.1.8. The effect of BRL-50481, a PDE7 inhibitor, on cAMP levels in PANC-1 cells. 
PANC-1 cells expressing H134 were first treated with forskolin (500nM) for 15 minutes 
before BRL-50481 (10µM) was applied additively for 10 minutes. IBMX (500µM) was 






























































3.1.9. Testing for PDE11 activity in PANC-1 cells 
To test for PDE11 activity in PANC-1 cells we employed the use of the recently discovered 
inhibitor for this isoform, BC11-38, with an IC50 of 0.28µM (Ceyhan et al., 2012). Therefore, 
as a starting point we decided to use 10μM. After forskolin pre-treatment, BC11-38 did not 
seem to have any effects on the FCFP/FYFP ratio after the initial increase caused by forskolin 





















Figure 3.1.9. The effect of BC11-38, an inhibitor of PDE11, on cAMP concentration in PANC-
1 cells. 
PANC-1 cells expressing H134 were first pre-treated with forskolin (500nM) for 15 minutes 
before BC11-38 (10µM) was additively applied for 10 minutes. IBMX (500µM) was added 






























































3.1.10. A preliminary test for PDE10A activity in PANC-1 cells  
Next, the activity of PDE10A was tested, using papaverine, a well-known semi-specific 
inhibitor for this PDE isoform (Li et al., 2014, Siuciak et al., 2006), at a concentration of 
10µM, which was used to successfully inhibit PDE10A (Tian et al., 2011b, Nishi et al., 2008, 
Hsu et al., 2011). Due to concordant reports across various suppliers of this drug that 
papaverine also inhibits PDE3 at a nanomolar range, which we now know to be the 
dominant isoform in PANC-1 cells, cilostazol treatment was carried out 10 minutes before 
the addition of papaverine to ensure that any cAMP increases observed after papaverine 
treatment is more likely to be due PDE10A than PDE3. After the increase in the FCFP/FYFP 
ratio as a result of cilostazol addition, papaverine significantly increased cAMP 
concentrations further in PANC-1 cells in the presence of cilostazol (figure 3.1.10); 
suggesting that PDE10A is likely to be active in PANC-1 cells. However, due to the poor 














Figure 3.1.10. The effect of papaverine, a semi-specific inhibitor of PDE10A, on cAMP 
concentration in PANC-1 cells in the presence of cilostazol. 
PANC-1 cells expressing H134 were first treated with forskolin (500nM) for 15 minutes 
before cilostazol (5µM) was applied additively for 10 minutes. Papaverine (10µM) was 
added in the presence of cilostazol for a further 10 minutes before IBMX (500µM) was 




























































3.1.11. Testing combined PDE3 and PDE4 inhibition on cAMP signalling in PANC-1 cells 
Out of the 7 compounds that were tested alone in this study, cilostazol (CLZ), when applied 
after the establishment of forskolin plateaus, was the only agent that increased cAMP 
concentrations in almost all PANC-1 cells tested. Yet, compared with its corresponding 
positive control (IBMX treatment), only approximately half of the total inhibition at that 
level of stimulus is down to PDE3. This strongly suggests that although PDE3 is the major 
isoform in PANC-1 cells, other PDE isoforms were in operation to keep cAMP levels in check. 
This candidate appears to be PDE4 because while its inhibitor rolipram only increased cAMP 
concentrations mildly, it was still the second best compound in terms of strength and clarity 
of response. To test this possibility, a similar experiment to figure 3.1.10 was carried out, in 
which 5µM CLZ was first added after the induction of the forskolin-induced plateau as a pre-
treatment; then the cells were treated with rolipram in the presence of CLZ. As figure 3.1.11 
shows, CLZ treatment increased the FCFP/FYFP ratio in the presence of forskolin, and the 
subsequent addition of rolipram produced an additive increase to the ratio; an effect that 
brought the relative cAMP concentration close to the maximal response. These results 
support the hypothesis that PDE3 and PDE4 are both active in PANC-1 cells, and that they 








Figure 3.1.11. Effects of rolipram on PANC-1 cells in the presence of Cilostazol. 
PANC-1 cells expressing H134 were first treated with forskolin (500nM) for 15 minutes 
before being treated additively, first with cilostazol (5µM) and then rolipram (10µM), both 
for 10 minutes. IBMX (500µM) was added at the end of the experiment (n=7 experiments, 





























































3.2. Characterisation of cAMP agonists in PANC-1 cells 
Having established the role of individual PDEs in controlling cAMP responses research 
direction was then shifted to asking how cAMP signalling can be physiologically activated in 
PANC-1 cells. Four different well-known Gαs-GPCR agonists, Isoproterenol, Vasoactive 
Intestinal peptide (VIP), Secretin, and Ilosprost (stable analog of prostacyclin), were tested 
on H134-transfected cells to measure their cAMP levels.   
 
3.2.1. Effects of β-adrenergic agonists on PANC-1 cAMP levels 
Isoproterenol, a well-known β-adrenergic agonist (Roze et al., 1976) in the exocrine 
pancreas, was first tested for their ability to activate cAMP signalling in H134-transfected 
PANC-1 cells. As a preliminary measure to first qualitatively observe if this agent has any 
effects, cells were treated with just 1 concentration, 10nM, of Isoproterenol, for 20 minutes. 
As shown in figure 3.2.1, 10nM Isoproterenol increased cAMP levels in PANC-1 cells, with 
the FCFP/FYFP ratio increasing significantly within 5 minutes of treatment before starting to 
slowly decline after the highest point was reached. This observation confirms the presence 










Figure 3.2.1. Isoproterenol increases cAMP levels in PANC-1 cells. 
PANC-1 cells expressing H134 were treated with the β-adrenergic agonist isoproterenol 




























































3.2.2. Concentration – dependent response of Isoproterenol in PANC-1 cells 
Having found that β-adrenergic receptors are present in PANC-1 cells in figure 3.2.1, we 
then asked if the isoproterenol response is dependent on the concentration. Therefore, in a 
similar experiment, H134-transfected PANC-1 cells were treated with increasing 
concentrations of isoproterenol (1, 10 and then 100nM) as their cAMP levels were 
measured. Results in figure 3.2.2A have shown that the amount of this Gαs-cAMP 
stimulation is dependent on the drug concentration; as increasing concentrations of 
isoproterenol (1nM, 10nM and 100nM) cumulatively increased the FCFP/FYFP ratio.  
In a separate set of experiments cells underwent 20 minutes of 1nM isoproterenol 
treatment before the concentration was increased to 100nM to end the experiment; 
bypassing the 10nM treatment in 3.2.2A. Figure 3.2.2B appeared to show that 1nM 
isoproterenol mildly but notably increased the FCFP/FYFP ratio before holding that value at a 
plateau for 20 minutes, before the subsequent addition of 100nM isoproterenol which 
drastically increased this ratio further. These observations show that isoproterenol activates 































































































































Figure 3.2.2. Isoproterenol increases cAMP levels in PANC-1 cells in a dose-dependent 
manner. 
A, PANC-1 cells expressing H134 were treated with increasing concentrations (1nM, 10nM, 
and 100nM) of the β-adrenergic agonist isoproterenol for 10 minutes each (n=4 
experiments, n=27 cells). B, PANC-1 cells expressing H134 were treated with a small 
concentration of isoproterenol (1nM) for 20 minutes before the isoproterenol treatment 





















3.2.3. Effects of VIP and Secretin on cAMP signalling in PANC-1 cells 
Next, we decided to test the effects of VIP and secretin, two agonists well known to activate 
cAMP signalling in pancreatic acinar cells (Christophe et al., 1976), from which pancreatic 
cancers may derive from (Schmid, 2002). H134-transfected PANC-1 cells were treated with 
increasing concentrations of VIP or secretin (1nM, 10nM, and 100nM) before 100nM 
isoproterenol was added to show that the same cells can still be externally triggered to 
produce cAMP. From figure 3.2.3 it seemed that neither VIP (A) nor secretin (B) increased 
cAMP levels in PANC-1 cells unlike isoproterenol; suggesting that either the activity of VIP 
and secretin was masked by the high endogenous PDE activity, or that VIP or secretin 











































































































































Figure 3.2.3. VIP and secretin do not increase cAMP levels in PANC-1 cells. 
PANC-1 cells expressing H134 were treated with increasing concentrations (1nM, 10nM, 
and 100nM) of VIP for 10 minutes each (n=3 experiments, n=18 cells). B, PANC-1 cells 
expressing H134 were treated with increasing concentrations (1nM, 10nM, and 100nM) of 
secretin for 10 minutes each (n=2 experiments, n=10 cells). On both occasions 






















To ask if the lack of cAMP increase as a result of VIP and secretin treatment was due to the 
high PDE activity in PANC-1 cells, we have also conducted experiments similar to those 
described in 3.2.3 but utilised IBMX as the positive control. In these experiments we did not 
observe responses in cAMP concentrations to 100nM of VIP (A) or 100nM secretin (B) 
treatment as displayed in figure 3.2.4. Considering that Isoproterenol at just 10nM have the 
capacity to potently increase FCFP/FYFP ratio without the presence of IBMX (figure 3.2.1), this 
small increase at the end of the experiments is most likely due to IBMX-mediated PDE 
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Figure 3.2.4. VIP and secretin does not increase cAMP levels in PANC-1 cells in the presence 
of IBMX.  
A, PANC-1 cells expressing H134 were treated with increasing concentrations (1nM, 10nM, 
and 100nM) of VIP (n=4 experiments, n=27 cells). B, PANC-1 cells expressing H134 were 
treated with increasing concentrations (1nM, 10nM, and 100nM) of secretin (n=3 
experiments, n=17 cells). On both occasions 500µM IBMX was added in the presence of 





3.2.4. Effects of VIP and secretin on PANC-1 cells after IBMX pre-treatment 
In the next attempt to tease out any cAMP increases due to VIP and secretin, IBMX pre-
treatment were performed before increasing concentrations of VIP or secretin (10nM and 
100nM) were added cumulatively before 100nM isoproterenol was added again as a 
positive control. However, even in the presence of IBMX, which increased the FCFP/FYFP ratio 
slightly, neither of the two agonists increased cAMP levels in PANC-1 cells; instead 
producing a mild decrease in FCFP/FYFP ratios (figure 3.2.5). This finding, combined with those 
shown in figures 3.2.3 and 3.2.4, support the notion that VIP and secretin receptors are not 

























































































































Figure 3.2.5. VIP and secretin do not increase cAMP levels in PANC-1 cells in the presence 
of IBMX. 
A, PANC-1 cells expressing H134 were treated with increasing concentrations (10nM, and 
100nM) of VIP after 15 minutes of IBMX (500µM) pre-treatment (n=2 experiments, n=12 
cells). B, PANC-1 cells expressing H134 were treated with increasing concentrations 
(10nM, and 100nM) or secretin after 15 minutes of IBMX (500µM) pre-treatment (n=3 




















3.2.5. The effects of Iloprost on cAMP signalling in PANC-1 cells 
Next, we sorted to probe the functionality of another Gαs-coupling GPCR, Prostacyclin 
receptor in PANC-1 cells by using iloprost, a stable analog of prostacyclin. Interestingly, 
treating H134-transfected PANC-1 cells with 1μM iloprost, the concentration that was 
widely used in other systems (Hutchison and White, 2014, Tsai et al., 2014b, Whittle et al., 
2012, Smyth et al., 2000), mildly activated cAMP signalling (figure 3.2.6A); and the same 
experiment performed in the presence of IBMX producing similar results (figure 3.2.6B). 
Although the magnitude of this response is dwarfed by isoproterenol, these results suggest 

















































































































Figure 3.2.6. Effects of prostacyclin on cAMP levels in PANC-1 cells.  
A, PANC-1 cells expressing H134 were treated with a stable analog of prostacyclin, iloprost 
(1µM), for 10 minutes before isoproterenol (100nM) was added as positive control (n=9 
experiments, n=54 cells). B, Same experiment as A, but this time IBMX (500µM) was 






















3.2.6. Effects of PDE3 inhibition on Isoproterenol-stimulated PANC-1 cells 
Forskolin was used for background stimulation in cAMP during PDE characterisation 
experiments in chapter 3.1. Therefore, we wanted to test the activities of PDE3 and PDE4 
when isoproterenol was used instead as a source of cAMP stimulation.  
Cilostazol was first tested in a similar protocol to 3.1.2; with the only difference being 
500nM forskolin being replaced by 10nM isoproterenol. Figure 3.2.7 shows that 10nM 
Isoproterenol increased FCFP/FYFP ratio as expected, cilostazol significantly increased this 
ratio further; (figure 3.2.7), suggesting that PDE3 takes part in the regulation of cAMP 












Figure 3.2.7. Cilostazol potentiates isoproterenol-mediated cAMP increases in PANC-1 
cells.  
PANC-1 cells transfected with H134 were subjected to 15 minutes of isoproterenol (10nM) 
treatment before being treated additively with cilostazol (5µM) for 10 minutes. IBMX 
(500µM) was used as positive control for PDE activity (n=3 experiments, n=20 cells).  
  























































3.2.7. Effects of PDE4 inhibition on Isoproterenol-stimulated PANC-1 cells 
Next, rolipram was added after 10nM isoproterenol pre-treatment to see if PDE4 had any 
effects in limiting cAMP increases produced by β-adrenergic stimulation. Rolipram addition 
increased the FCFP/FYFP ratio further from the isoproterenol induced plateau; similar to 
cilostazol (figure 3.2.8); suggesting that PDE4 also regulates cAMP responses induced by 





Figure 3.2.8. Rolipram potentiates isoproterenol-mediated cAMP increases in PANC-1 cells.  
PANC-1 cells transfected with H134 were subjected to 15 minutes of isoproterenol (10nM) 
treatment before being treated with roilpram (10µM) for 10 minutes. IBMX (500µM) was 
































































3.2.8. Effect of combined PDE3 and PDE4 inhibition on Isoproterenol-stimulated PANC-1 
cells 
To test if there is cooperation between PDE3 and PDE4 in limiting cAMP produced by β-
adrenergic stimulation like that observed in forskolin-treated cells, we then decided to 
determine the effect of combined inhibition of both PDE3 and PDE4 on cAMP levels of 
isoproterenol stimulated PANC-1 cells. Isoproterenol addition induced an increase in 
FCFP/FYFP ratio before declining very slowly just before cilostazol treatment, which increased 
the ratio further. The subsequent introduction of rolipram accelerated cAMP production, 
increasing FCFP/FYFP close to that of the IBMX response (figure 3.2.9). However, this was less 
than the maximal inhibition produced by IBMX, suggesting that PDE isoforms other than 3 
and 4 were active, or that the concentration of rolipram or cilostazol used was not maximal. 
Nevertheless, this phenomenon was similar to that observed in experiments illustrated by 
figure 3.1.11; confirming that PDE3 and PDE4 are the main regulators of cAMP signalling in 





Figure 3.2.9. Cilostazol and rolipram together potentiate Isoproterenol-mediated cAMP 
increases in PANC-1 cells.  
PANC-1 cells transfected with H134 were subjected to 15 minutes of isoproterenol (10nM) 
treatment before being treated additively, first with cilostazol (5µM) and then rolipram 
(10µM), both for 10 minutes. IBMX (500µM) was added at the end as positive control for 































































3.3. cAMP and PANC-1 cell migration  
Next, armed with the knowledge that Isoproterenol is the principal physiological cAMP 
agonist and PDE3 and PDE4 to be the main regulators of cAMP signalling in PANC-1 cells, we 
then tried to extend the results from our previous study (Burdyga et al., 2013) and asked if 
these more specific methods of increasing cAMP levels can inhibit cell migration. To this 
end, we utilised fluorblok transwell assays, which measure PANC-1 cell migration through a 
porous membrane, to assess this.  
3.3.1. Effects of PDE inhibitors and cAMP agonists on PANC-1 cell migration  
Fresh from the results described in figures 3.2.7-9, we decided to test the effects cilostazol 
and rolipram have on random, non-directional PANC-1 cell migration in the presence of 
isoproterenol. Six different conditions were designated: Control, 10nM isoproterenol alone, 
10nM isoproterenol plus 5µM cilostazol, 10nM Isoproterenol plus 10µM rolipram, 10nM 
Isoproterenol plus 5µM cilostazol plus 10µM rolipram, and finally 10nM isoproterenol plus 
500µM IBMX as positive control; with all results normalised to the control conditions. 
Interestingly, isoproterenol alone did not inhibit cell migration, not even when cilostazol 
was included with it (fig 3.3.1); instead having a tendency to even increase migration (10% 
increase for isoproterenol alone, and 20% for isoproterenol plus cilostazol). Strangely, the 
inclusion of rolipram partly but significantly inhibited migration by 23%, implying that PDE4 
may play a bigger role in PANC-1 cell migration than PDE3 in the presence of Isoproterenol.  
The presence of both cilostazol and rolipram also significantly inhibited migration by 35%, 
which provided the strongest inhibition aside from IBMX, which was 60%. Combining with 
the results from figure 3.2.9, this strongly supports the notion that cAMP increase produced 
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by PDE4 inhibition, and not PDE3, under the influence of β-adrenergic stimulation inhibits 







Figure 3.3.1. The effect of isoproterenol and both PDE3 and PDE4 inhibition on random cell 
migration.  
PANC-1 cells were seeded into Boyden Chambers containing equal amounts of FBS (1%) on 
both the top and bottom wells with 6 different conditions. They were left to migrate 
through a porous membrane from (fluroblok membrane) for 6 hours and were then fixed 
and loaded with propidium iodide for imaging. All results were normalised to control. 
Each Boyden chamber contains duplicates for each condition per experiment, and each 
experiment was repeated 5 times (n=5 experiments, but n=10 for the number chambers 
used for each condition). [Key: Iso – Isoproterenol (10nM), C – Cilostazol (5µM), R – 
Rolipram (10µM), IBMX (500µM)]   
 

























3.3.2. Testing the effects of Isoproterenol on PANC-1 cell migration  
One observation from figure 3.2.10 was that Isoproterenol had no inhibitory effects on 
PANC-1 cells. Note that 100nM isoproterenol alone gave a significant increase in FCFP/FYFP 
ratio, similar to the extent in which PDE3 and PDE4 inhibition together did in the presence 
of sub-maximal amounts of forskolin and 10nM isoproterenol (fig 3.2.9). Moreover, higher 
concentrations of isoproterenol (100nM) consistently gave drastic increases in the FCFP/FYFP 
ratio when used in previous experiments. Therefore, to investigate whether the inhibition of 
migration brought on by PDE3 and PDE4 inhibition together with 10nM isoproterenol in fig 
3.3.1 was due to an increased absolute cAMP concentration, the effects of higher 
concentrations of isoproterenol on random PANC-1 cell migration was tested. Neither 
concentration (10nM and 100nM) of isoproterenol alone seemed to have any significant 
effects on cell migration. It was only when IBMX was included did a significant inhibition 
take place, again by about 60% (fig 3.3.2). This implies that the cAMP produced via the β-







Figure 3.3.2. The effect of isoproterenol on random cell migration. 
PANC-1 cells were seeded into Boyden Chambers containing equal amounts of FBS (1%) on 
both the top and bottom wells with 4 different conditions. They were left to migrate 
through a porous membrane (fluoroblok membrane) for 6 hours and were then fixed and 
loaded with propidium iodide. All results were normalised to control. (n=4 repeats, and 



























3.3.3. Testing the effects of PDE3 and PDE4 inhibition alone on PANC-1 cell migration 
After finding that high concentrations of isoproterenol did not have any effects on cell 
migration, cilostazol and rolipram were tested alone on PANC-1 cells to remove ambiguity 
caused by the presence of isoproterenol in fig 3.3.1. Six conditions were tested, Control, 
5µM cilostazol, 10µM rolipram, 5µM cilostazol plus 10µM rolipram, 500µM IBMX, and 
500µM IBMX plus 100nM isoproterenol. IBMX again inhibited migration by about 55% which 
was consistent with the previous two experiments; and the inclusion of isoproterenol 
(100nM) in the presence of IBMX also did not have any additional effects, as illustrated by 
fig 3.3.3. Interestingly, when applied alone, cilostazol seemed to exhibit inhibitory effects on 
cell migration like rolipram; significantly inhibiting migration by 30% and 20% respectively 
compared to control (fig 3.3.3). However, when applied together, the same magnitude of 
inhibition was achieved as for cilostazol alone (30%). These findings suggest that in the 
absence of cAMP stimulation, PDE3 is the major player in regulating spontaneous PANC-1 









Figure 3.3.3. The effect of PDE3 and PDE4 inhibition and isoproterenol on random cell 
migration. 
PANC-1 cells were seeded into Boyden Chambers containing equal amounts of FBS (1%) on 
both the top and bottom wells with 6 different conditions. They were left to migrate 
through a porous membrane for 6 hours and were then fixed and loaded with propidium 
iodide. All results were normalised to control. (n=4 for the number of repeats, n=8 for the 
number of chambers used per condition) [Key: C – Cilostazol (5µM), R – Rolipram (10µM), 




























3.3.4. Testing the effects of PDE3 and PDE4 alone on chemotactic PANC-1 cell migration 
We repeated the experiments from fig 3.3.3 in a chemotactic setting in which cells seeded in 
the absence of FBS were migrating towards 5% FBS; all in the same 6 conditions described 
above. This time cilostazol inhibited cell migration much more dramatically; the 40% 
inhibition was significant compared to control. Surprisingly, rolipram instead appeared to 
slightly potentiated cell migration by 20% but not by a statistically significant margin, 
whereas the combination of cilostazol and rolipram significantly inhibited cell migration by 
50%. Interestingly, the presence of 100nM isoproterenol with IBMX this time also 
significantly inhibited cell migration more than IBMX alone, by 80% (fig 3.3.4). Taken 
together, these results suggest that in a polarised setting, PDE3 is the dominant player in 
regulating PANC-1 cell migration mediated by chemoattractants in the form of FBS, and this 








Figure 3.3.4. The effect of PDE3 and PDE4 inhibition and isoproterenol on directional cell 
migration. 
PANC-1 cells were seeded into Boyden Chambers containing 0 FBS in the top wells and FBS 
(5%) in the bottom wells with 6 different conditions. They were left to migrate through a 
porous membrane for 6 hours and were then fixed and loaded with propidium iodide. All 
conditions were normalised to the control. (n=5 experimental repeats, n=10 chambers 
used per condition) [Key: C – Cilostazol (5µM), R – Rolipram (10µM), Iso – Isoproterenol 






























3.3.5. Testing the effects of isoproterenol on PKA activity in PANC-1 cells 
Given that isoproterenol effectively increased cAMP concentration in PANC-1 cells (fig 3.2.2) 
much like forskolin, it was perhaps surprising that it had only modest effects on cell 
migration (although results in fig 3.3.4 did suggest directional migration inhibition in the 
continuous presence of IBMX). We hence wanted to ask if this was because isoproterenol 
preferentially activates Epac, previously reported to potentiate PANC-1 cell migration 
instead of PKA, which inhibits cell migration (Burdyga et al., 2013). To this end, we treated 
PANC-1 cells transfected with the PKA sensor AKAR4 with increasing concentrations of 
isoproterenol, in an analogous experiment to that illustrated by fig.3.2.2. As shown in fig. 
3.3.5, isoproterenol clearly increased AKAR4 FRET ratio in a dose dependent manner; after 
1nM producing only a mild increase in PKA activity, the jump from 1 to 10nM notably 
increased the ratio. 100nM isoproterenol then caused another significant increase, just 
short of the maximum. Taken together, it appears that the cAMP increase induced by β-
adrenergic receptors on PANC-1 cells can activate PKA, and that the effects of isoproterenol 










Figure 3.3.5. Effects of increasing concentrations of isoproterenol on PKA activity in PANC-
1 cells.  
PANC-1 cells transfected with the PKA activity sensor AKAR4 was treated with increasing 
concentrations of isoproterenol (1, 10 and 100nM), each for 10 minutes, before forskolin 
























































Key summary of results in chapter 3 
Isoproterenol is the main physiological cAMP agonist in PANC-1 cells, whereas PDE3 and 
PDE4 are the primary cAMP signalling regulators in PANC-1 cells. However, PDE3 appears to 
play the bigger inhibitory role on regulating cell migration.  
Results from this chapter also suggest the presence of prostacyclin receptors in small 
amounts, as well as the activity of PDE1 and PDE10. The contribution of these mechanisms 
to cAMP regulation however was less clear or less substantial, and their effects on cell 







































ORAI-STIM punctas form when the ER Ca2+ stores are depleted to sustain medium-long term 
Ca2+ signals (Soboloff et al., 2012). The high efficiency and dynamic nature of puncta 
formation in PANC-1 cells strongly suggests that these cells have a highly competent and 
responsive Ca2+ signalling system (Dingsdale et al., 2013). Therefore, applying a similar 
pharmacological/live-cell imaging approach used in chapter 3, we aimed to characterise Ca2+ 
signalling in PANC-1 cells. In this chapter particular emphasis will be given to SOCE which 
was not extensively characterised in this cell type, but is likely to play important 











4.1 Characterisation of Ca2+ responses in PANC-1 cells 
4.1.1. Neurotensin induces Ca2+ responses in PANC-1 cells  
The intracellular cytosolic Ca2+ dye Fura-2 coupled with live cell imaging was used to 
investigate Ca2+ signalling in PANC-1 cells. Under Ca2+ free conditions, neurotensin (NT), a 
known Gαq GPCR agonist of PANC-1 cells (Wang et al., 2011), induced a single spike; 
indicative of Ca2+ release from the ER stores (fig 4.1.1). However, no further Ca2+ signals 
were seen after the initial signal until Ca2+ was introduced into the extracellular solution 10 
minutes later, when another spike was observed almost immediately after Ca2+ application, 
followed by a plateau. This is indicative of SOCE first being activated which allows Ca2+ entry 
into the cytosol, and the subsequent attainment of equilibrium between SOCE SERCA and 
PMCA as it removes Ca2+ from the cytosol into the ER and outside the cell respectively. 
Another 10 minutes later, the treatment of thapsigargin (TG), an inhibitor of SERCA, tipped 
that balance towards SOCE activation as the amplitude of Ca2+ signal increased substantially 
(fig.4.1.1).  
Taken together, these results confirm that upon NT application PANC-1 cells release Ca2+ 
from internal stores, which subsequently activate SOCE.   
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Figure 4.1.1.Ca2+ responses to neurotensin and thapsigargin in PANC-1 cells 
PANC-1 cells loaded with the Fura-2 dye were first treated with neurotensin (10nM) in a 
nominally free Ca2+-free solution for 10 minutes before Ca2+ (1.8mM) was added to the 
extracellular solution for another 10 minutes before the application of thapsigargain 





















































4.1.2. Store depletion and SOCE in PANC-1 cells 
The fast reaction and high amplitude in response to NT, extracellular Ca2+ and TG in fig.4.1.1 
suggests that PANC-1 cells have a highly adaptable SOCE process. Therefore, to confirm this 
phenomenon, a similar experiment to fig 4.1.1 was performed; this time using TG as the 
agent for depleting intracellular Ca2+ stores instead of the physiological agonist NT. Under 
nominally Ca2+ free conditions, the addition of TG also produced a small spike which 
returned back to the baseline after approximately 10 minutes; and the subsequent addition 
of Ca2+ into the extracellular solution quickly induced a slowly declining plateau (fig 4.1.2). 





Figure 4.1.2. Store depletion and SOCE in PANC-1 cells. 
PANC-1 cells loaded with the Ca2+ dye fura-2 were treated with thapigargin (2μM) for 15 
minutes to deplete intracellular Ca2+ stores before 1.8mM Ca2+ was applied to activate 
store operated Ca2+ entry for 15 minutes (n=2 experiments, n=47 cells).

















































4.2. Pharmacological characterisation of store operated Ca2+ entry (SOCE) in 
PANC-1 cells 
Observations from section 4.1 indicated that SOCE is an efficient and dynamic process in 
PANC-1 cells. In the next part of the study, we then decided to characterise the components 
of SOCE signalling in PANC-1 cells utilising reported pharmacological inhibitors. A near-
comprehensive list of well-known SOCE inhibitors were used in this study: the lanthanide 
gadolinium (Gd3+) (Dragoni et al., 2014), SKF-96365 (Chen et al., 2013a), Pyr3 (Schleifer et 
al., 2012), 2-APB (DeHaven et al., 2008), BTP2 (Jairaman and Prakriya, 2013) and the newly 
discovered ORAI1/3 inhibitor GSK7975A (Derler et al., 2013). 
4.2.1. Effects of Gd3+ on SOCE in PANC-1 cells 
We first tested the ability of Gd3+, which is one of the most effective and well-known 
inhibitors of SOCE. To prevent Gd3+ chelation by FBS, PANC-1 cells were first serum-starved 
for 3 hours before the start of the experiment for acclimatisation, before being loaded with 
Fura-2 in the absence of serum. The experiment itself was also carried out in the absence of 
serum, in which cells were first treated with TG for 10 minutes to pre-deplete the 
intracellular stores, before extracellular calcium was added to induce SOCE, and form an 
elevated, slowly declining plateau for 10 minutes (fig 4.2.1). Gd3+ was then added to induce 
inhibition. PANC-1 cell treatment with Gd3+ did cause a notable SOCE inhibition in two 
phases: the first phase comprising of an immediate decrease within 100 seconds of addition, 
with the second phase being a more ‘stabilised decrease’, in which [Ca2+]cyt appeared to 
decrease in a part linear fashion (fig 4.2.1). This suggests that Gd3+ is an effective inhibitor of 
SOCE, although it was still surprising to see that the inhibition was not absolute (i.e. near 
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Figure 4.2.1. Gd3+ inhibits SOCE in PANC-1 cells. 
PANC-1 cells loaded with the Fura-2 dye were first treated with thapsigargin (2µM) in 
Ca2+-free conditions for 10 minutes before Ca2+ (1.8mM) was added to the extracellular 
solution to induce SOCE. 10 minutes later Gadolinium3+ (5µM) was added to the 
extracellular solution. This experiment was carried out entirely in the absence of FBS (n=3 
experiments, n=83 cells, all data points here were normalised to the point just before Gd3+ 




























































4.2.2. The effect of BTP2 on SOCE in PANC-1 cells 
We next tested the effects of BTP2, well-known CRAC channel inhibitor extensively used to 
inhibit SOCE in non-excitable cells (Ohga et al., 2008, Tsai et al., 2014a, Derler et al., 2013). 
Fura-2 loaded cells were first treated with TG for 10 minutes to deplete intracellular stores, 
before 1.8mM Ca2+ was added to activate SOCE. 10 minutes after SOCE was activated, cells 
were treated with 10μM BTP2 and the effects were observed (Yarotskyy and Dirksen, 2012, 
He et al., 2005). BTP2 effectively inhibited SOCE in PANC-1 cells; the plateau started to 
decrease about 200 seconds after BTP2 addition, with the decline showing signs of 
stabilising 10 minutes into the BTP2 treatment (fig 4.2.2). This finding suggests that BTP2-
sensitive CRAC channels play a significant part in PANC-1 SOCE, but does not account for all 






Figure 4.2.2. BTP2 inhibits SOCE in PANC-1 cells. 
PANC-1 cells loaded with 5µM Fura-2 dye were first treated with thapsigargin (2µM) for 
10 minutes in Ca2+-free conditions before Ca2+ (1.8mM) was added to the extracellular 
solution to trigger SOCE. 10 minutes later BTP2 (10µM) was added to the extracellular 
solution (n=3 experiments, n=46 cells, all data points here were normalised to the point 

























































4.2.3. The effect of SKF-96365 in SOCE in PANC-1 cells  
As mentioned in the introduction, TRPC channels can also take part in SOCE in a number of 
cells (Cheng et al., 2013). Therefore, we decided to test this possibility in Fura-2 loaded 
PANC-1 cells. First, TG was added for 10 minutes to deplete intracellular stores, before 
1.8mM Ca2+ was added to induce a SOCE plateau much like figs 4.2.1-2. 10 minutes after the 
plateau was established, treatment with 10μM SKF-96365 (SKF), a well-known TRP channel 
antagonist (Flemming et al., 2003, Chen et al., 2013a), started and its effects on the SOCE 
were observed. Interestingly, although there is a hint of a slight inhibition about 5 minutes 
into SKF treatment, the magnitude of this effect was much smaller than for Gd3+ or BTP2 as 
the SKF trace ran extremely close to the control trace (fig 4.2.3). This observation put doubts 






Figure 4.2.3. SKF-96365 has little effects on SOCE in PANC-1 cells. 
PANC-1 cells loaded with 5µM Fura-2 dye were first treated with thapsigargin (2µM) in 
Ca2+-free conditions for 10 minutes before Ca2+ (1.8mM) was added to the extracellular 
solution. 10 minutes following SOCE activation SKF-96365 (10µM) was then added into the 
extracellular solution (n=3 experiments, n=72 cells, all data points here were normalised 



























































Differences in Ca2+signals as a result of TG-induced store depletion  
At this point, it is worth mentioning that the magnitude of signals provided by TG-mediated 
depletion differs greatly from cell to cell, resulting in significant differences in TG responses 
in figs 4.2.1-3. Moreover, occasionally some baselines displayed elevated basal [Ca2+]cyt 
(such as 4.2.2). The reason for this is that in some cells TG induces CICR. However, as this 
study mainly concerns with SOCE and not store depletion or CICR, we’ve decided to funnel 
the study down to SOCE only, and all the subsequent experiments were conducted on TG 
pre-treated cells. In these experiments, cells were already in contact with TG approximately 
10 minutes before the start of the experiment, the total time exposure to TG in Ca2+ free 
extracellular solution was about 20 minutes (10 minutes before the experiment, and 10 
minutes during the baseline period in the experiment).  
4.2.4. The effect of 2-APB on SOCE in PANC-1 cells 
Next, we tested another well-known SOCE inhibitor, 2-APB on SOCE in PANC-1 cells. After 20 
minutes of TG pre-treatment, SOCE induction was carried out by the addition of 1.8mM Ca2+ 
for 10 minutes before the addition of high concentrations of 2-APB (50µM), also for 10 
minutes. 2-APB appeared to be the most effective SOCE inhibitor in PANC-1 cells to date in 
our hands; as its application almost completely and immediately obliterated the SOCE 
response (fig 4.2.4). As 2-APB has so many reported targets including both ORAI and TRP 
channels as well as IP3 receptors (Peppiatt et al., 2003, Colton and Zhu, 2007), this does not 
conclusively put light on exactly what components are involved in SOCE in PANC-1 cells. 
However, this probably means that PANC-1 cells are unlikely to use ORAI3, which is 
activated by 2-APB, as a component of the CRAC channels; and does put 2-APB forward as 
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an effective SOCE inhibitor in PANC-1 cells in future studies, especially as positive control for 




Figure 4.2.4. 2-APB potently inhibits SOCE in PANC-1 cells. 
PANC-1 cells loaded with the Fura-2 dye were first pre-treated with thapsigargin (2µM) for 
approx. 20 minutes in Ca2+-free conditions before Ca2+ (1.8mM) was added to the 
extracellular solution to induce SOCE. 2-APB (50µM) was then added 10 minutes after 
SOCE activation. Note that thapsigargin (2µM) was present throughout the experiment 
(n=2 experiments, n=49 cells, all data points here were normalised to the point just before 


























































4.2.5. The effect of GSK-7975A on SOCE in PANC-1 cells 
We then sorted to test a GSK-7975A, novel compound reported to be selective inhibitors of 
ORAI1 and ORAI3, on SOCE in PANC-1 cells. In a similar protocol to that described in fig 
4.2.4, TG pre-treatment was carried out approximately 10 minutes before the 
commencement of the experiment. After SOCE was induced by 1.8mM Ca2+ addition, 
various concentrations (10µM and 30µM) of GSK-7975A was tested in separate experiments 
to determine the dose-dependent effects of this drug on SOCE, as they have not been tested 
previously in these cells. It seems that the GSK-7975A is also an effective inhibitor of SOCE in 
PANC-1 cells (Fig 4.2.5); though not as strong as 2-APB (Compare figs 4.2.4 and fig 4.2.5). 
Quantitatively, both concentrations appeared to have the same end-point effects after 10 
minutes, inhibiting the response by about 55-60%; with the higher concentration exerting 
the effects about 100 seconds quicker than the lower concentration (fig 4.2.5). These results 
confirm ORAI1 to play a dominant role in SOCE in PANC-1 cells, but other channels may still 




Figure 4.2.5. GSK-7975A inhibits SOCE in PANC-1 cells. 
PANC-1 cells loaded with 5µM Fura-2 dye were pre-treated with thapsigargin (2µM) for 
about 20 minutes in Ca2+-free conditions before Ca2+ (1.8mM) was added to the 
extracellular solution. In separate experiments GSK (10µM or 30µM) was then added after 
SOCE activation. No GSK was added in the control experiment. Note that thapsigargin 
(2µM) was continuously present from the start of the experiment (n=5 experiments and 
n=193 cells for control, n=5 experiments and n=162 cells for 10µM; n= 5 experiments and 
n=145 cells for 30μM. All data points here were normalised to the point just before GSK-
7975A was added, at 1200 seconds). 
 






















































4.2.6. Effect of nifedipine on SOCE in PANC-1 cells 
Pancreatic cancer cells often show a tendency towards invading the nervous system 
(Buchler et al., 2005). Moreover, in terms of this study, the ease of Ca2+ signalling activation 
in PANC-1 cells led us to test whether this high efficiency is due to the expression of voltage-
gated Ca2+ channels (VGCCs), which has one of the fastest activation times of all Ca2+ 
channels (more than 1 million fold faster than ORAI1)(Soboloff et al., 2012).  
Therefore, we used nifedipine, a well-known antagonist of the VGCC (Mamo et al., 2014, 
Itzhaki et al., 2011, Kirkman-Brown et al., 2003), to test for their role in SOCE. Here, Fura-2 
loaded PANC-1 cells were again pre-treated with TG for 20 minutes to deplete the stores, 
before the activation of SOCE via 1.8mM Ca2+ application to the extracellular HEPES. 10 
minutes after SOCE activation, nifedipine treatment ensued. As shown in figure 4.2.6, the 
application of nifedipine had no effect on [Ca2+]cyt. This result strongly suggests against the 








Figure 4.2.6. Nifedipine has no effects on SOCE in PANC-1 cells. 
PANC-1 cells loaded with 5µM Fura-2 dye were pre-treated with thapsigargin (2µM) for 
about 20 minutes in Ca2+-free conditions before Ca2+ (1.8mM) was added to the 
extracellular solution. 10 minutes after SOCE was activated, nifedipine (1µM) was then 
added to the extracellular solution. Note that thapsigargin (2µM) was continuously 
present from start of the experiment (n=2 experiments, n=51 cells. all data points here 

























































4.2.7. The effects of combined GSK-7975A and 2-APB treatment on SOCE in PANC-1 cells 
As the results from fig 4.2.5 showed that there was still approximately 40% of the SOCE 
response that was not inhibited by GSK-7975A, we then asked whether that remaining 
component can be diminished by 2-APB, which in experiments illustrated by fig 4.2.4 was 
shown to be the be best inhibitor of SOCE in PANC-1 cells. In an experiment aiming to test 
the combination of the two inhibitors, PANC-1 cells loaded with Fura-2 were treated with TG 
for 10 minutes to deplete the stores before 1.8mM Ca2+ was added to induce SOCE; after 10 
minutes, the GSK-7975A (30µM) was added for another 10 minutes before ending the 
experiment with 10 minutes of 2-APB treatment. As shown in figure 4.2.7, GSK-7975A again 
decreased the plateau by a similar extent as the results illustrated in fig 4.2.5. Subsequent 
addition of high concentrations of 2-APB almost completely diminished the amplitude of the 
plateau in the same cells in the continuous presence of GSK-7975A. This implies that the 
majority of SOCE can be attributed to the ORAI1/3 family, whereas the rest can be down to 
a component inhibited by 2-APB; and strongly indicates that other types of channels such as 









Figure 4.2.7. Combined GSK-7975A  and 2-APB treatment potently inhbited SOCE in PANC-
1 cells. 
PANC-1 cells loaded with the Fura-2 dye were first treated with thapsigargin (2µM) for 10 
minutes in Ca2+-free conditions before Ca2+ (1.8mM) was added to the extracellular 
solution to induce SOCE. 10 minutes after SOCE activation GSK (30µM) was added to the 
extracellular solution and finally 2-APB (50µM) in the continuous presence of GSK (n=3 






















































4.2.8. The effects of combined GSK-7975A and Pyr3 treatment on SOCE in PANC-1 cells 
To test the candidacy of TRPC3, one of 2-APB’s targets and proposed to be part of the CRAC 
channel machinery in pancreatic acinar cells (Cheng et al., 2013), we then used Pyr3, 
previously reported to be an efficient antagonist of this channel, (Zhou and Roper, 2014). 
Cells were first pre-treated with TG for about 20 minutes before the start of the experiment, 
then SOCE was activated by the addition of 1.8mM Ca2+ to the extracellular solution. 10 
minutes later 30µM GSK-7975A was added for another 10 minutes before the addition of 
Pyr3. GSK-7975A again inhibited the bulk of the SOCE response, which was slightly higher 
than that recorded in figure 4.2.5 (fig 4.2.8); but Pyr3 application in the presence of GSK-
7975A failed to produce further inhibition, unlike 2-APB. This suggests that TRPC3 is not 














Figure 4.2.8. Pyr3 has no effects on GSK7975A-resistant component of SOCE in PANC-1 
cells. 
PANC-1 cells loaded with the Fura-2 dye were pre-treated with thapsigargin (2µM) in Ca2+-
free conditions for about 20 minutes before Ca2+ (1.8mM) was added to the extracellular 
solution to induce SOCE. GSK-7975A (30µM) was then added for 10 minutes after SOCE 
activation for 10 minutes before Pyr3 (10µM) treatment commenced in the continuous 
presence of GSK-7975A. Note that thapsigargin (2µM) was continuously present from the 
beginning of the experiment (n=2, n=58).   
 
  














































* 2M Thapsigargin in constant presence
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Key results from chapter 4 
PANC-1 cells have an efficient Ca2+ signalling system, in which Store operated Ca2+ entry 
(SOCE) is particularly effective. ORAI1 channels appear to be the primary contributor to 
SOCE, but other channels that are sensitive to 2-APB-induced inhibition are likely to 















Chapter 5 – The effect of Ca2+ signalling on cAMP/PKA 
















Chapter 5 – The effect of Ca2+ signalling on cAMP/PKA 
signalling in PANC-1 cells 
Overview 
Some Ca2+ signalling processes, especially that of SOCE, can activate cAMP signalling in 
various cell types; as mentioned in chapter 1.3. Therefore, the aim of this chapter was to 
apply the results from chapter 4, to ask whether the Ca2+ to cAMP cross-talk exists in PANC-
1 cells. 
In particular, it has been known for a number of years thanks to the work of Cooper’s and 
Hofer’s labs that SOCE can directly activate cAMP signalling in a large number of cell types 
(Willoughby and Cooper, 2007, Lefkimmiatis et al., 2009). Therefore, utilising a similar 
approach to chapter 3, we decided to measure PKA activity and cAMP levels in PANC-1 cells 
when Ca2+ signalling is manipulated. In this part of the study H134, which was already used 
in the characterisation of PDEs in chapter 3, measured changes in the relative cAMP 
concentration; whereas AKAR4 was used to measure downstream PKA activity in PANC-1 
cells.   
5.1. Effects of Neurotensin treatment on PKA activity in PANC-1 cells 
First, to see if the activation of the Ca2+ signalling pathway can activate cAMP signalling in 
PANC-1 cells, in the presence of 1.8mM extracellular Ca2+, we treated AKAR4-transfected 
cells with NT. As shown in fig 4.3.1A, the addition of 10nM NT transiently increased PKA 
activity, using the FYFP/FCFP ratio of AKAR4 as readout; giving strong indications that 





Figure  5.1. Neurotensin transiently increases PKA activity in PANC-1 cells.                                          
A, PANC-1 cells transfected with AKAR4 was treated with neurotensin (10nM) for 10 
minutes before forskolin (2μM) and IBMX (500μM) were added as positive control (n=2 


















































5.2. Effects of store depletion and SOCE on cAMP signalling in PANC-1 cells.  
Ca2+ signalling in non-excitable cells usually involve two core processes– Ca2+ release from 
intracellular stores induced by agonists, and SOCE to replenish stores to sustain signalling. 
Preliminary experiments described in fig 5.1 illustrated that NT, an  effective activator of 
Ca2+ signalling, activates the cAMP signalling pathway. Coupling this with the knowledge 
that both of these processes can activate cAMP signalling (Lefkimmiatis et al., 2009, 
Willoughby and Cooper, 2007), we next decided to investigate the specific contributions of 
SOCE and the release of intracellular stores to cAMP signalling in PANC-1 cells.   
5.2.1. Effect of store depletion and SOCE on cAMP levels in PANC-1 cells 
PANC-1 cells transfected with H134 underwent 15 minutes of store depletion by TG in 
nominally Ca2+ free HEPES. This was followed by 15 minutes of SOCE induced by the addition 
of Ca2+ to the extracellular solution before 2µM forskolin and 500µM IBMX was used as 
positive control. Compared to the positive control, both treatments caused very mild effects 
(5.2.1A); on closer look, store depletion appeared to cause a very small decrease from the 
baseline whereas subsequent SOCE activation caused a mild transient increase of cAMP 




Figure 5.2.1. The effects of store depletion and SOCE on cAMP levels in PANC-1 cells.                                                                                                                                                    
A, PANC-1 cells transfected with H134 were treated with thapsigargin (2µM) for 15 
minutes before Ca2+ (1.8mM) was added to induce SOCE for another 15 minutes. Forskolin 
(2µM) was used at the end of each experiment as positive control. B, Enlarged figure of A 
at the lower end of the scale (n=6 experiments, n=47 cells).  







































































































































5.2.2. Effects of SOCE and store depletion on cAMP levels in PANC-1 cells in the presence 
of IBMX 
Although effects shown in figure 5.2.1 were very small as compared to the positive control, 
SOCE activation did give a very mild increase in FCFP/FYFP ratio. To test whether the mild 
effects in response to store depletion and SOCE activation was due to the high PDE activity 
in PANC-1 cells, the same protocol as in as 5.2.1 was carried out; but this time in the 
presence of IBMX, which was added 15 minutes before TG application and present 
thereafter. In these experiments the addition of IBMX caused a slow increase from the 
baseline, making it difficult to analyse the difference between the baseline and effects 
caused by TG (figure 5.2.2A). However, on inspection, the addition of TG into Ca2+ free 
solution seemed to slow down the rise of the FCFP/FYFP ratio induced by IBMX. In the 
presence of IBMX, SOCE activation seemed to cause a small, stable increase in the FCFP/FYFP 
ratio (figure 5.2.2B). Taken together, these data do point at the existence of a Ca2+ to cAMP 


















































* 500M IBMX in constant presence





























































































Figure 5.2.2. The effect of SOCE on cAMP levels in PANC-1 cells in the presence of IBMX. 
A, PANC-1 cells transfected with H134 were treated with thapsigargin (2µM) for 15 
minutes before Ca2+ (1.8mM) was added to induce SOCE. IBMX (500µM) was added 15 
minutes before thapsigargin treatment and was present thereafter. Forskolin (2µM) was 
used at the end of each experiment as positive control. B, Fragment of A on an expanded 
scale (n= 6 experiments, n=30 cells. All data points here were normalised to the point just 





















5.2.3. The effect of store depletion and SOCE on PKA activity in PANC-1 cells 
Next, we opted to examine the impact of store depletion and SOCE have on PKA, one of the 
main downstream targets of cAMP. By transfecting PANC-1 cells with AKAR4, one can 
measure relative cellular PKA activity by correlating it to the increase in FYFP/FCFP ratio 
(opposite to H134). In this study, the protocols used in 5.2.1 and 5.2.2 were repeated, but 
carried out using PANC-1 cells transfected with AKAR4. Interestingly, SOCE induction caused 
a notable and significant increase in FYFP/FCFP ratio (figure 5.2.3A). In the presence of IBMX 
pre-treatment, SOCE also caused an increase in PKA activity (figure 5.2.3B). Interestingly, 
AKAR4 also seemed to be sensitive enough to detect a mild increase in the FYFP/FCFP ratio as 
a result of TG treatment, the effect of which appearing to be slightly higher and more stable 
when IBMX was present (comparing the same component in figures 5.2.3A and 5.2.3B). In 
conclusion, these data suggest that the mild cAMP increase in response to SOCE detected by 
H134 (fig 5.2.1-2) may be translated to more significant increases in PKA activity 
downstream (fig 5.2.3); as a secondary observation, it appeared that store-depletion can 



































































































Figure 5.2.3. SOCE increases PKA activity in PANC-1 cells. 
 A, PANC-1 cells transfected with AKAR4 were treated with thapsigargin (2µM) for 15 
minutes before Ca2+ (1.8mM) was added to induce SOCE for 15 minutes. Forskolin (2µM) 
and IBMX (500µM) was added at the end of each experiment as positive control (n=6 
experiments, n=41 cells). B, The same experiment as in A, but IBMX (500µM) was added 
15 minutes before thapsigargin treatment and was present thereafter. Forskolin (2µM) 




5.2.4. The effect of IBMX on store depletion or SOCE 
In this part of the project we decided to test if PDE inhibition modifies Ca2+ responses in 
PANC-1 cells as Ca2+ measurements were carried out in Fura-2 loaded PANC-1 cells. In 
nominally Ca2+ free conditions, the cells were first treated with IBMX for 15 minutes, before 
the application of TG for 15 minutes and finally the addition of 1.8mM Ca2+ into the 
extracellular solution. Figure 5.2.4 shows that both store depletion and SOCE still took place 
unhindered; confirming that PDE inhibition does not suppress either of the two Ca2+ 









Figure 5.2.4. Store operated Ca2+ entry (SOCE) in PANC-1 cells recorded in the presence of 
IBMX. 
PANC-1 cells loaded with Fura-2 were first pre-treated with IBMX (500µM) for 15 minutes 
before thapsigargin (2µM) was added to induce store depletion for 15 minutes. Ca2+ 




















































5.3. Testing the dependency of SOCE-mediated PKA activity on Ca2+ in PANC-1 
cells 
After discovering that SOCE can activate PKA activity in PANC-1 cells, we then carried out a 
series of experiments in an attempt to characterise this phenomenon. For this study we 
applied the methodology described in chapter 5.2.3 to answer this question. Here, we 
decided to focus upon increases in PKA activity as a result of SOCE even though small 
increases were also observed as a result of store depletion.  
5.3.1. SOCE-induced increase in PKA activity in PANC-1 cells is suppressed by removal of 
extracellular Ca2+ 
Removing extracellular Ca2+ is one effective way of inhibiting SOCE. Therefore, in this 
experiment we decided to test if this procedure will suppress SOCE-activated PKA responses 
in PANC-1 cells. To do this, PANC-1 cells transfected with AKAR4 was first simultaneously 
treated with 500µM IBMX and 2µM TG for 15 minutes in nominally Ca2+ free conditions, 
1.8mM Ca2+ was then introduced into the extracellular solution to initiate SOCE. Figure 5.3.1 
shows that SOCE did indeed induce an increase in the FYFP/FCFP ratio, but afterwards the 
removal of Ca2+ from the extracellular solution resulted in a significant decline in the PKA 






Figure 5.3.1. PKA activity in PANC-1 cells is dependent on Ca2+ entry via SOCE. 
PANC-1 cells transfected with AKAR4 were treated with thapsigargin (2µM) and IBMX 
(500µM) simultaneously for 15 minutes before Ca2+ (1.8mM) was added for a further 15 
minutes to induce SOCE. Extracellular Ca2+ was then removed by the re-introduction of 
Ca2+-free solution for 15 minutes; whereas in the control, Ca2+ was not removed. Forskolin 
(2µM) was applied at the end of each experiment as positive control (n=5 experiments, 
and n=25 cells for 0 Ca2+; n=3 experiments and n=20 cells for control. All data points here 
were normalised to the point just before Ca2+ was removed at 1500 seconds).   
 
 


























































5.3.2. Testing the dependency of SOCE-mediated PKA activity on ORAI channels in PANC-1 
cells 
One of the major conclusions from section 4.2 was that ORAI1 is the main contributor to 
SOCE in PANC-1 cells. Therefore, we next went one step upstream of Ca2+ entry and asked 
whether this SOCE-mediated PKA activation is dependent on ORAI activity. In these 
experiments, we measured PKA activity utilising the protocol similar to that illustrated in 
figure 5.3.1. Fifteen minutes after SOCE was activated in AKAR4 transfected cells pre-treated 
with both IBMX and TG, 30µM GSK-7975A, a selective inhibitor of ORAI channels, was added 
to inhibit SOCE (see in fig 4.2.6 for the effect of GSK-7975A on SOCE). Compared to control, 
GSK-7975A application significantly inhibited SOCE-dependent PKA activity (fig 5.3.2); 
reducing the increase almost to pre-SOCE levels. Altogether, results described in 5.3.1 and 













Figure 5.3.2. The Ca2+-induced increase in PKA activity in PANC-1 cells is ORAI dependent. 
PANC-1 cells transfected with AKAR4 were treated with thapsigargin (2µM) and IBMX 
(500µM) simultaneously for 15 minutes before 1.8mM Ca2+ was added to induce SOCE. 15 
minutes after SOCE induction GSK-7975A (30µM) was added whereas in the control no 
drug was added. Forskolin (2µM) was applied at the end of each experiment as positive 
control (n=6 experiments and n=39 cells for GSK-7975A; n=5 experiments and n=25 cells 
for control. All data points here were normalised to the point just before GSK-7975A was 





























































5.3.3. Testing the dependency of SOCE-induced AKAR4 responses on H89 in PANC-1 cells  
Experiments in this section aimed to verify that SOCE-induced AKAR4 responses can indeed 
be attributed to PKA. In these experiments PANC-1 cells transfected with AKAR4 were pre-
treated with IBMX and TG for 15 minutes before SOCE was activated via external Ca2+ 
application. Following SOCE activation, which increases the AKAR4 FRET response, 10µM 
H89, a PKA inhibitor that had been used successfully in our hands previously (Burdyga et al., 
2013), was added before forskolin was used as positive control. Notably, H89 application; 
completely obliterated the increase in FYFP/FCFP ratio back to pre-SOCE activation levels as 
compared to the control (fig 5.3.3). Furthermore, even after wash off, some degree of 
inhibition still remained as the positive control in H89-treated cells was also reduced as 
compared to control. This observation strongly supports the notion that SOCE-induced 











Figure 5.3.3. The Ca2+-induced increase in the AKAR4 FYFP/FCFP ratio in PANC-1 cells is H89 
dependent. 
PANC-1 cells transfected with AKAR4 were treated with thapsigargin (2µM) and IBMX 
(500µM) together for 15 minutes before Ca2+ (1.8mM) was added for a further 15 minutes 
to induce SOCE. Cells were then treated with the PKA inhibitor H89 (10µM); whereas in 
the control no drug was added. Forskolin (2µM) was applied at the end of each 
experiment as positive control (n=4 experiments and n=13 cells for H89; n=4 experiments 
and n=12 cells for control. All data points here were normalised to the point just before 
H89 was added, at 1500 seconds).   
 


























































5.4. Correlation of ER-PM junctions and areas of high PKA activity in PANC-1 
cells 
This and other studies revealed cAMP/PKA-dependent regulation of PANC-1 cell migration. 
We therefore decided to characterise the distribution of PKA activity in PANC-1 cells with 
particular emphases on PKA activity in the proximity of the leading edge, where the 
essential component of the migratory machinery are localised. To characterise the 
distribution of PKA activity we utilised commercially available antibodies against 
phosphorylated PKA substrates (Marcinkiewicz et al., 2006). Considering the observed 
SOCE-dependent activation of PKA responses (see fig 5.2.3) we also decided to investigate 
the localisation of ER-PM junctions, which serve as platforms for SOCE (Lewis, 2011). 
In our laboratory we possess the necessary tools for the visualisation of ER-PM junctions 
which serves as platforms for SOCE - the PM-FRB-mRFP + ER-FKBP-CFP rapamycin-induced 
dimerization system (Varnai et al., 2007) and high resolution confocal microscopy. In this 
part of the study we also used commercially available antibodies against PKA substrate to 
visualise the distribution of PKA activity.   
5.4.1. Mapping the localisation of endogenous ER-PM junctions in PANC-1 cells 
It has been known for some time that SOCE is activated in ER-PM junctions in most non-
excitable cells. More specifically, in PANC-1 cells these ER-PM junctions tend to be situated 
in the cell periphery adjacent to the leading edges, according to previous published data in 
our laboratory (Dingsdale et al., 2013). Therefore, to confirm this finding in this particular 
study we utilised the hetereodimerisation system involving two proteins modelled from an 
mTOR backbone – PM-FRB-mRFP and ER-FKBP-CFP. When rapamycin is added, if these two 
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constructs are within 10-14nm of each other, they will be cross-linked, inducing the 
colocalisation of mRFP and CFP fluorescence (Varnai et al., 2007). This technique is used to 
visualise ER-PM junctions already pre-formed under basal conditions, and random contacts 
where the ER and PM are in close proximity by chance. PANC-1 cells transfected with these 
two constructs were treated with 100nM rapamycin for 3 minutes before being fixed and 
imaged.  
PM-ER punctas, as made visible by this method, seem to localise in the cell periphery; and 
appeared to congregate in the area behind the leading edge (fig 5.1). Although it is too early 
to extrapolate at this stage, this observation suggests that the machinery contained in ER-
PM junctions regulate cell migration from just behind the leading edge, possibly in the 























Figure 5.4.1. Mapping the localisation of endogenous ER-PM junctions in PANC-1 cells. 
PANC-1 cells co-transfected with the PM-FRB-mRFP (red panel) and ER-FKBP-CFP (blue 
panel) constructs were first incubated in Na+-HEPES-based solution supplemented with 
1.8mM Ca2+ and 1% FBS for approximately 30 minutes at 37oC and 5% CO2 before being 
treated with Rapamycin (100nM). The cells were then fixed using 4% PFA and imaged with 
a confocal microscope. CFP and mRFP fluorescence emissions were recorded 
simultaneously. The bottom confocal optical slice of the cell (i.e. slice closest to the 
coverslip) was taken for processing. The resulting images were then analysed using the 
colocaliseRGB plugin on the ImageJ software, which performed a pixel analysis on the 
images; and then produce a map to show where in the cell CFP and mRFP fluorescence 
overlapped by the greatest amount, which is assumed to be the locations of the ER-PM 
junctions (displayed by white spots). PM-mRFP + ER-CFP panels show where the ER-PM 
junctions are located with respect to the plasma membrane as reported by PM-mRFP 










5.4.2. Mapping out the location of PKA activity in PANC-1 cells 
In an effort to elucidate the distribution of PKA activity in PANC-1 cells, we then decided to 
use the immunofluorescence approach using the antibody specific for phosphorylated PKA 
substrate. Unstimulated PANC-1 cells maintained in 1% FBS and 1.8mM Ca2+ for 30 minutes 
were fixed and stained for phospho-PKA substrate using Alexa 488 as the secondary 
antibody. Interestingly, there seems to be heavy staining for PKA substrates in the leading 
edges of migrating cells and in the nucleus (fig 5.4.2). There was also staining in the cytosol, 
with a generally dispersed intensity gradually decreasing towards the cell periphery before 
almost disappearing in the region just behind the leading edge. These observations strongly 














Figure 5.4.2. PKA substrates accumulate in the nucleus and leading edges of migrating 
PANC-1 cells. 
Unstimulated PANC-1 cells maintained in Na+-HEPES based solution plus 1% FBS and 
1.8mM Ca2+ for 30 minutes were immuno-stained for phospho-PKA substrates and were 
then imaged via confocal microscopy, with Alexa488 conjugated to the secondary 
antibody for readout. Two different confocal slices of two different cells are shown: A1 
and B1, confocal section closest to the coverslip; A2 and B2, sections positioned a few μm 



















5.4.3. Mapping the location of PKA substrates and actin in PANC-1 cells  
Such a significant presence of phosphorylated PKA substrates in the leading edges of PANC-
1 cells implies that PKA is likely to have a role in the regulation of cell migration, and would 
co-localise with polymerised actin. In an attempt to verify this statement the same PKA 
staining experiments as described in 5.4.2 was done here, but in PANC-1 cells transfected 
with Lifeact-RFP. Figure 5.4.3 shows that in 4 different migrating PANC-1 cells imaged, the 
leading edge actin displayed notable colocalisation with phospho-PKA substrates. These 
observations confirm the spatial proximity of PKA substrates and polymerised actin in the 
leading edge. Such spatial proximity could be important for cAMP/PKA-dependent 


















Lifeact-RFP Phospho-PKA substrate Merge 
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189 
 
Figure 5.4.3. Phospho-PKA substrate partially co-localise with leading edge actin ruffles in 
PANC-1 cells. 
PANC-1 cells transfected with Lifeact-RFP maintained in Na+-HEPES based solution plus 1% 
FBS and 1.8mM Ca2+ for 30 minutes were immunostained with phospho-PKA substrate 
antibody (using alexa488 as the secondary antibody) before being imaged using a confocal 
microscope. All images were recorded from the ventral parts of the cell closest to the 
coverslip and processed using the ImageJ software. Lifeact-RFP is in green, phospho-PKA 
substrates are in magenta; and the areas of co-localisation are in white. Scale bars in all 

















Key summary from chapter 5 
Store operated Ca2+ entry can effectively increase PKA activity in PANC-1 cells, in a process 
that is sensitive to the inhibition of ORAI1.   
ER-PM junctions, which are platforms for SOCE, are concentrated behind the leading edge. 
On the other hand, high densities of phosphorylated PKA substrates were observed in the 
leading edge, where phospho-PKA substrates co-localise with actin. High density of 































Chapter 6 – Discussion  
The main aim of chapter 3 was to see if more specific ways of increasing cAMP levels in 
pancreatic cancer cells than forskolin and IBMX can be found after finding that increasing 
global cellular cAMP concentration significantly inhibited migration and invasion in 
pancreatic cancer cell lines. The results from the first part of the study suggests that under 
basal conditions, the cAMP signalling pathway is unlikely to be endogenously active in 
PANC-1 cells because in the sole presence of PDE inhibition by IBMX, increases in cAMP 
levels was slow and low in magnitude; whereas in the presence of stimulation like forskolin 
and isoproterenol IBMX rapidly saturated the probe within minutes. This implicates that like 
other cancers, PDAC has high endogenous PDE activity to keep basal cytosolic cAMP levels 
as low as possible (Savai et al., 2010).  
 
6.1. PDE3 and PDE4 are the main regulators of cAMP in PANC-1 cells 
One notable observation from chapter 3.1 was that PDE3 seemed to be the main cAMP 
regulator in PANC-1 cells, whereas PDE4 also appeared to be active, albeit at a lower 
magnitude. However, rolipram dramatically increased cAMP levels in nearly every cell 
tested when PDE3 was inhibited previously. This observed hierarchical nature of PDE3 and 
PDE4 activity in PANC-1 cells suggests that PDE3 may act as the ‘sentinel’ of cAMP signalling, 
serving as the first point of regulation to prevent the overstimulation of the pathway in the 
cytosol. As a result, PDE3 (i.e. A and/or B isoforms) and PDE4 could play non-redundant 
roles in this cell type by the virtue of different cellular locations; where PDE3 is located near 
ACs where cAMP is made, and PDE4 is located deeper in the cell. Indeed, PM-specific PDE3 
activity was seen previously in pheochromocytoma cells, where it regulates EGF and NGF-
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mediated nuclear ERK activity (Herbst et al., 2011). Also, the apparent PDE3-PDE4 synergy 
observed in this study is not uncommon, as it was also observed in the pancreatic β-cell line 
MIN6 cells (Tian et al., 2012), brown adipose tissue (Kraynik et al., 2013), vascular smooth 
muscle cells (VSMC); and in airway smooth muscle, where the application of both PDE3 and 
PDE4 inhibitors together had a more potent relaxant effect than when either was added 
alone (Shakur et al., 2001).      
In terms of cancer, PDE3 expression and activity has been reported in only a few studies. 
Notable examples include human squamous cell carcinomas (Shimizu et al., 2002) and 
neoplastic submandibular gland intercalated duct (Murata et al., 2001), where cilostamide 
has growth inhibitory effects; and melanomas, where the treatment of the cell line B16-F10 
with cilostazol promoted melanin production in a PKA/CREB dependent manner (Wei et al., 
2014). PDE3 is also found to be expressed in three different hepatoma cell lines, where their 
exact functions remains elusive (Murata et al., 1996); moreover, PDE3B expression has been 
found in trace levels in human chronic lymphocytic leukaemia (C-LL) cells when PDE4 was 
inhibited as a compensatory mechanism (Moon et al., 2002).  
In non-cancerous tissues, PDE3A is expressed in the heart, vascular smooth muscle, oocytes 
and platelets; whereas PDE3B is found predominantly in adipose tissues, hepatocytes and 
pancreatic islets (Shakur et al., 2001). The activation of PDE3 is predominantly via 
phosphorylation by PKA and protein kinase B (PKB, also known as Akt kinase), which is 
counteracted by the phosphatase PP2A (Shakur et al., 2001, Bender and Beavo, 2006). 
Interestingly, when PDE3 was first discovered in adipocytes, the insulin signalling pathway 
was one of the first discovered mechanisms that activate this isozyme (Shakur et al., 2001). 
In this case, the activation of the insulin receptor results in the activation of PI3K, leading to 
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the activation of PKB, which then in turn phosphorylates PDE3, activating the enzyme to 
destroy cAMP (Shakur et al., 2001). In cells that take part in metabolism, this PKB-PDE3 
pathway serves to counteract and modulate catecholamine-induced lipolysis (Shakur et al., 
2001). In the context of this study, insulin and insulin-like growth factor (IGF) receptors have 
been found expressed on a various PDAC cell lines (Fisher et al., 1996), including PANC-1 
cells, where it appeared to potentiate cell proliferation as well as GPCR-mediated Ca2+ 
signalling in a PI3K dependent manner (Young and Rozengurt, 2010). Given the proximity of 
PDAC (exocrine pancreas) to the endocrine pancreas, it is not unreasonable to hypothesise 
that PDAC may be in a microenvironment where local insulin levels is high (Nakagawa et al., 
1993, Bertelli et al., 2001); and chronic insulin stimulation can hold PDE3 at a constitutively 
active state to keep cAMP levels down. Supporting this interpretation, destruction of β-cells, 
which produces insulin, inhibited pancreatic tumour development, whereas agents that help 
β-cells to proliferate also promoted carcinogenesis in a BOP-induced PDAC model in 
hamsters (Hennig et al., 2004). Keeping this in mind, it would be useful to use antagonists of 
insulin receptors (Schaffer et al., 2008) and inhibitors of PKB/Akt to test this hypothesis.   
In contrast to PDE3, the link between PDE4 and cancer is better established. PDE4A and 
PDE4D is highly expressed and active in a variety of lung cancer cell lines in response to 
hypoxia (Pullamsetti et al., 2013) and TGFβ activation (Kolosionek et al., 2009); where the 
downstream activation of NF-κB, Nrf2, p38, ERK and increases of ROS levels have all been 
reported as a result of PDE4-mediated cAMP suppression (Yeo et al., 2014, He et al., 2014, 
Wagner et al., 2002, Kolosionek et al., 2009). In brain tumours, PDE4A (especially the super-
short PDE4A1 isoform) is reported to play a significant role in facilitating tumour and 
xenograft growth downstream of Ca2+ and phospholipase D (PLD) signalling by sculpting the 
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intracellular cAMP gradient (Sengupta et al., 2011, Warrington et al., 2010, Goldhoff et al., 
2008, Gallagher et al., 2004, Chen et al., 2002, Schmidt et al., 2010). Colorectal cancer cells 
overexpress PDE4B (PDE4B2) as a result of oncogenic KRAS signalling, which suppressed 
apoptosis, possibly via the PI3K-Akt pathway, and potentiated the disassembly of epithelial 
tight junctions (Tsunoda et al., 2014, Tsunoda et al., 2012, McEwan et al., 2007). This PDE4B-
Akt relationship is also reported to be excessively active in B-cell lymphomas to mediate 
glucocorticoid resistance (Kim et al., 2011, Smith et al., 2005). In prostate cancer, PDE4D 
appears to play a central role in proliferation and tumourigenesis (Rahrmann et al., 2009), 
where the PDE4D7 isoform appears to regulate cAMP levels in the sub-plasmalemmal 
compartments of androgen sensitive prostate cancer cells (Henderson et al., 2014). 
Moreover, PDE4 activity has been reported in melanoma cells downstream of ERK signalling 
to confer glucocorticoid resistance (Marquette et al., 2011, Kowalczyk et al., 2009, Narita et 
al., 2007). Elsewhere, the presence of PDE4 in other cancers is also observed in B-cell 
lineage chronic lymphocytic leukaemia cells (B-CLL) (Dong et al., 2010, Meyers et al., 2009, 
Meyers et al., 2007, Tiwari et al., 2005, Moon and Lerner, 2003), osteosarcoma cells 
(Ahlstrom et al., 2005, Narita et al., 2003), retinoblastoma cells (White et al., 2004) and 
pheochromocytoma cells (Chang et al., 1997). Interestingly, in nearly all of the cases 
mentioned above, the inhibition of PDE4 by rolipram or removal by RNAi resulted in growth 
inhibition, cell cycle arrest, decreased tumour size and increased apoptosis; implicating 
PDE4 to be a potentially important target for the development of cancer treatment.  
In the context of this study, it remains unclear how PDE4 is regulated in PANC-1 cells; 
therefore it would be interesting to measure cAMP levels in the presence of PKA and ERK 
(both reported activators of PDE4) activators and inhibitors. This is to test whether a cAMP-
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PKA feedback exists in this cell type and, to see if ERK, which is a downstream component of 
oncogenic Kras, activates PDE4. Moreover, due to half of the KRAS expressed in PANC-1 cells 
being constitutively active (Deer et al., 2010), it would also be useful to measure ERK activity 
in PANC-1 cells using cellular probes for ERK activity developed recently (Harvey et al., 2008) 
to test if basal ERK activity is indeed elevated in PANC-1 cells.  
This study also points towards the activity of PDE1 and PDE10A in PANC-1 cells. 8-mm-IBMX 
was chosen on the basis that it inhibited PDE1 in pancreatic β- cells (Tian et al., 2012).  
However, one must be cautious when confirming this because 8-mm-IBMX does not inhibit 
PDE1 fully at lower concentrations but displays inhibition of PDE4 at high concentrations 
(Dunkern and Hatzelmann, 2007). Therefore, the small, transient increase of cAMP reported 
here could be due to an off-target inhibition of PDE4 or a genuine effect on PDE1. Secondly, 
regarding the inhibition of PDE10A, papaverine is a semi-specific inhibitor for this isoform, 
as it has has been used to study PDE10A in various organs including the lung and the striatal 
neurones, where this isozyme is predominantly expressed (Xie et al., 2006, Tian et al., 
2011b, Siuciak et al., 2006). In this study, papaverine dramatically increased cAMP levels in 
PANC-1 cells when PDE3 was also inhibited. This can be interpreted as a genuine inhibition 
on PDE10A, or it can be due to an off-target inhibition of other PDEs. This is because 
papaverine has also been described as a non-specific PDE inhibitor, as it also displayed IC50 
at low micromolar ranges for PDE3 and PDE4 (Siuciak et al., 2006). Indeed, the increase in 
cAMP levels caused by 10µM papaverine appeared quite similar to that produced by 
rolipram; implying that PDE4 activity was also inhibited by papaverine treatment. On the 
other hand, PDE10A has also been recently reported to be expressed in human colon 
tumour cell lines, where 10µM papaverine treatment as well as PDE10 knockdown inhibited 
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cell growth by 60% but in a cGMP dependent manner (Li et al., 2014). Therefore, a 
comprehensive biochemical analysis of PDE1C and PDE10A is required to investigate the 
presence of PDE1 and PDE10 in PANC-1 cells.  
The last set of results from chapter 3.1 was that the potent PDE5 inhibitor T0156 did not 
have any effects on cAMP levels induced by forskolin. The direct conclusion from this 
experiment was that T0156 did not have any effects on cAMP-hydrolysing PDEs in PANC-1 
cells. In terms of cGMP signalling, however, this experiment was carried out in conditions 
where the stimulation of intracellular cGMP pathway has not been validated; so the 
inhibition of cGMP breakdown here may mean a slow accumulation of cGMP much like the 
cAMP in the presence of IBMX alone, where cGMP levels in the cell after 10 minutes of PDE5 
inhibition could be too low to affect cAMP levels in the cell. Indeed, PDE5A1 and PKG1 
activity has been reported in multiple PDAC cell lines including PANC-1 cells, the blockade of 
which resulted in reduced migration and proliferation and induced cytotoxicity 
(Karakhanova et al., 2014). Moreover, nitric oxide, (NO), a well-known activator of 
cGMP/PKG signalling, has recently been observed to potentiate migration and invasion in 
carbon ion irradiated PANC-1 cells; with the PI3K-Akt and RhoA signalling pathways being 
the possible downstream effectors (Fujita et al., 2014). Therefore, as well as biochemical 
analyses, it would be useful to repeat this experiment in the presence of guanylyl cyclase 
activators and PDE5 inhibitors to probe the potential cAMP-cGMP cross-talk further in 
PANC-1 cells. Indeed, much like cAMP, genetically encoded FRET-based cGMP/PKG  sensors 
have also been recently created (Niino et al., 2010, Sprenger and Nikolaev, 2013) which, 
given the relative success rate of PANC-1 cell transfection and cAMP measurement, would 
also be useful in answering these questions.      
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Therefore, the next part of this study would be to go deeper into the mechanism, starting 
with asking which of the 2 isoforms of PDE3 and which of the 4 isoforms of PDE4 are present 
in PANC-1 cells, either via RT-PCR or western blotting; before deducing the localisation of 
PDE3 and PDE4 in relation to each other by immunofluorescence. Note that PDE8, which is a 
cAMP-specific isoform that is insensitive to IBMX-mediated inhibition, was not tested 
pharmacologically as the inhibitor, PF-04957325 (Shimizu-Albergine et al., 2012), is not yet 
commercially available. However, with the reported synergy between PDE8 and PDE4 in 
mind (Demirbas et al., 2013) it would be interesting to biochemically probe for its presence 
in PANC-1 cells.   
 
6.2. β-adrenergic agonists are the principal physiological cAMP agonist in 
PANC-1 cells 
The results of chapter 3 also suggests that β-adrenergic receptors (β-ARs) maybe the 
dominant Gαs-coupling GPCR to mediate cAMP signalling, as isoproterenol increased cAMP 
levels in PANC-1 cells in a dose-dependent manner. β-ARs are physiologically receptors for 
catecholamines adrenaline and noradrenaline, which are neurotransmitters produced 
during stress responses. There are generally two types of β-ARs, β1 and β2, to which 
noradrenaline is the physiological agonist of β1-AR and adrenaline is the agonist of β2-AR 
(Schuller and Al-Wadei, 2010); whereas isoproterenol, the agent used in this study, can 
activate both types. The finding that isoproterenol readily increased cAMP concentrations in 
PANC-1 cells is not too surprising, as pancreatic cancer cells have been reported to express 
both types (β1 and β2) of ARs in a number of studies, with β2 being the dominant isoform 
(Lin et al., 2012). Indeed, β-ARs have been prominently reported to affect the physiology of 
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a wide range of cancers, where they can modulate proliferation/growth, cell 
migration/invasion and apoptosis (Tang et al., 2013). The purpose of this study was to 
confirm that the β-ARs expressed on PANC-1 cells can increase cellular cAMP levels when 
activated, which was achieved with isoproterenol. The next step of this study would be to 
use β1 and β2-selective agonists to specifically investigate if the two β-AR subtypes have 
differential effects on cAMP signalling in this cell type. This is in light of reports in the past 
that β1 and β2 expressed on the same cell can mediate different downstream effects 
(Communal et al., 1999, Richter et al., 2008). Immediately downstream, we have also found 
that both PDE4 and PDE3 regulates cAMP produced by β-ARs; with the same observations 
made of the cAMP levels being the highest when PDE4 and PDE3 inhibitors were present 
together than either was present alone. Therefore, it would also be interesting to couple 
β1/ β2-selective agonists with isoform-specific PDE inhibitors in cAMP measurements to 
probe if the two receptors are coupled with distinct macromolecular complexes containing 
different PDE isoforms. Furthermore, although we have yet to test this possibility at this 
stage, it would be intriguing to use pertussis toxin to test if the Gαi subunit opposes the 
isoproterenol-mediated cAMP activation and, if either of the β-AR subtypes can couple to 
this AC-inhibitory subunit when activated.  
Data from chapter 3 also showed that VIP and secretin, prominent cAMP agonists in the 
pancreas and other organs of the digestive system, did not appear to increase cAMP levels 
in PANC-1 cells as compared to isoproterenol at increasing concentrations (1, 10 and 
100nM); even when PDE activity was inhibited. In the normal exocrine pancreas VIP, 
secreted by vagal parasympathetic nerve terminals, binds to VIP-1 and VIP-2 receptors (also 
known as VPAC1 and VPAC2 respectively) to modulate the  secretion of digestive enzymes in 
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acinar cells and fluid/electrolyte secretion in ductal cells (Sabbatini et al., 2013, Lee et al., 
2012). Our current observations supports previous reports that PANC-1 cells only weakly 
express the VIP-1 receptor but do not couple ligand binding to cAMP production (Jiang et 
al., 1997, Igarashi et al., 2002, al-Nakkash et al., 1996, Ding et al., 2002). However, looking at 
the literature, it seemed that PANC-1 and MiaPaCa-2 cell lines represent the minority in 
terms of VIP signalling; as it was found that intact human PDAC tumours express both VIP-1 
and VIP-2 receptors and, apart from MiaPaCa-2 and PANC-1 cells, most other PDAC cell lines 
actually express VIP-1 (but not VIP-2) receptors (Jiang et al., 1997, Ding et al., 2002). 
Moreover, activation of VIP-1 receptor in PDAC cells that express them by nanomolar 
concentrations of VIP increased intracellular cAMP levels in a dose-dependent manner. 
When tested in one of the PDAC cell lines (Capan-2) that endogenously express VIP-1 
receptors and in a non-cancerous cell line (Chinese hamster ovary, CHO cells) ectopically 
expressing VIP-1 receptors, VIP actually promoted cell proliferation (Jiang et al., 1997, Ding 
et al., 2002); supporting similar studies carried out nearly 30 years ago (Ruellan et al., 1986, 
Estival et al., 1983). Therefore, it would be inappropriate at this stage to extrapolate the 
conclusions of this part of the study to all PDAC cell types; but it would be interesting to 
study the mechanism in which VIP-mediated cAMP production mediates cell 
growth/migration in responsive cells such as Capan-2 cells. 
In the healthy normal pancreas, secretin, produced by intestinal S cells, is the principal 
inducer of bicarbonate and fluid secretion in the pancreatic duct; via its group B family of 
Gαs-coupling GPCRs (Lee et al., 2012). Secretin receptors are expressed extensively in ductal 
epithelial cells and acinar cells (Chey and Chang, 2003, Korner et al., 2005). However, during 
neoplastic transformation the expression of secretin receptors seem to significantly 
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decrease and become more heterogenous (Korner et al., 2005). Moreover, although 
multiple pancreatic cancer cell lines were found to express secretin receptors; their ability 
to stimulate cAMP production was impaired in response to secretin, requiring very high 
concentrations of this ligand for activation (Ding et al., 2002). In that particular study, PANC-
1 cells, alongside MiaPaCa-2 cells, did not respond to secretin at all, even at micromolar 
concentrations (Ding et al., 2002). This was proposed to be due to their expression of a 
dominant-negative, soluble form of the secretin receptor, which is a splice variant form in 
which the third and fourth exon (expressing the N-terminal tail) was spliced out (Ding et al., 
2002, Hayes et al., 2007). Not only do they not respond to secretin, the splice variants 
disrupted the normal functions of wild-type secretin receptors. Therefore, in this study it 
was not a surprise to see that PANC-1 cells failed to respond to secretin. Interestingly, 
ectopic expression of functional secretin receptors in Chinese hamster ovary (CHO) cells 
actually resulted in growth inhibition, suggesting that the intracellular pathway generated 
by secretin-generated cAMP signalling is growth-inhibitory (Ding et al., 2002). Therefore, 
unlike VIP, results from our current study that PANC-1 cells have defective secretin signalling 
correlated relatively well with other PDAC cell types.  
As an extension of this study, apart from VIP and secretin, it would also be useful to test 
other agents reported to modulate cAMP in the pancreas and PDAC cells like somatostatin 
(Li et al., 2004), Pituitary adendylyl-cyclase activating peptide (PACAP) (Hollande et al., 
1995), peptide YY and neuropeptide Y (Liu et al., 1995, Vona-Davis and McFadden, 2007, 
Schwetz et al., 2013), GABA (Takehara et al., 2007, Al-Wadei et al., 2012), acetylcholine 
(Ackerman et al., 1989) and cholecystokinin/gastrin (Smith et al., 1996, Thommesen et al., 
2001, Cayrol et al., 2006). 
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PDAC cells and samples have been reported to overexpress cyclooxygenase-2 (COX-2), 
which partly mediate the aggressive phenotype of this cancer (Hennig et al., 2002, Hennig et 
al., 2005, Ding et al., 2001, Tucker et al., 1999). COX-2 is an enzyme that catalyses the 
production of the prostaglandin family of signalling molecules from arachidonic acid 
(Hausmann et al., 2014). Among this family, the two best described prostaglandins are 
prostaglandin E2 (PGE2) and prostacyclin (also called prostaglandin I2); which mediate 
signalling by activating an equally diverse family of GPCRs (DP, EP1-4, FP, IP, and TP), the 
specificity of which depending on the cell type as reviewed previously (Hata and Breyer, 
2004, Coleman et al., 1994). In pancreatic cancer, PGE2 appeared to be the dominant 
downstream effector of the overexpressed COX-2 (Hasan et al., 2008); with increased 
expression of metalloproteinases and enhanced migration/invasion as one of its major 
documented effects (Ito et al., 2004, Eibl et al., 2003). Prostacyclin, on the other hand, has 
not been studied in PDAC. In other organs, prostacyclin mainly targets the vascular 
endothelium and erythrocytes to mediate anti-platelet and vasodilatory effects (Vane and 
Botting, 1995) via the IP receptor. As the IP receptor is a Gαs-coupling GPCR which 
stimulates cAMP signalling when activated, we decided to test the ability of prostacyclin to 
increase cAMP in PANC-1 cells.  
To do this, iloprost, a stable analog of prostacyclin, was used in this study. Our preliminary 
results showed that iloprost treatment resulted in a modest increase of cAMP levels, both 
when applied alone or in the presence of IBMX. However, the cAMP responses observed 
here was still less consistent and lower in amplitude as compared to that produced by 
isoproterenol. There could be two reasons for this - either trace amounts of IP receptors are 
expressed on PANC-1 cells, or the off-target activation of EP1 receptors (which couple to the 
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Gαq subunit to activate the PLC pathway) by iloprost may have influenced cAMP 
concentrations as a secondary effect (Abramovitz et al., 2000). The first hypothesis can be 
tested easily by using RT-PCR or western blotting for IP receptor presence, as well as to see 
if prostacyclin is made in PANC-1 cells like PGE2. Indeed, PANC-1 cells have an established 
PGE2 autocrine signalling loop, meaning that they can make and secrete their own PGE2 as 
well as respond to PGE2 at the cell surface (Ito et al., 2004). Therefore, it would be 
interesting to see if a parallel signalling loop exists for prostacyclin in the regulation of cAMP 
levels in PANC-1 cells. The second hypothesis can be tested by asking if EP1 receptor is 
expressed in PANC-1 cells, as well as by measuring cellular Ca2+ levels in response to 
iloprost. The results from these proposed experiments would still not confirm the 
hypothesis, but can at least invalidate it or confirm the existence of an EP1-Ca2+ pathway in 
PANC-1 cells; which would be interesting as a Ca2+ cAMP crosstalk exists in this cell type 
(chapter 5). Given that 5 out of 8 prostanoid receptors are linked to the activation of AC 
while the other 3 are linked to either Ca2+ mobilisation or the inhibition of ACs (Breyer et al., 
2001, Negishi et al., 1995); and PGE2 potentiates PANC-1 cell migration/invasion while an 
increase in cAMP signalling had the opposite effects, it would be interesting to next see if 
PGE2 can directly regulate prostacyclin and/or cAMP signalling in PANC-1 and indeed PDAC 
cells and tumours. Furthermore, one can investigate if other agonists of the prostaglandin 
family such as thromboxane, prostaglandin D2 and F2α can mediate cAMP signalling.    
 
6.3. Isoproterenol has little effects on PANC-1 cell migration    
After finding that β-ARs are capable of physiological cAMP activation, whereas PDE3 and 
PDE4 are the dominant cAMP destroyers in PANC-1 cells, the second aim of chapter 3 was to 
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apply these findings to test if manipulating each of these cAMP signalling components can 
influence PANC-1 cell migration further downstream; as reported by Boyden chamber 
assays.   
Despite its ability to increase cAMP levels in PANC-1 cells, isoproterenol did not inhibit 
PANC-1 cell migration even at very high concentrations (100nM) whereas forskolin (Burdyga 
et al., 2013) and IBMX alone did. In comparison, despite having next to no effects on 
random migration, high concentrations of isoproterenol (100nM) inhibited directional 
migration in the presence of IBMX compared to just IBMX alone; suggesting that β-AR 
signalling may have a role to play in chemotactic PANC-1 cell migration. Given that β-AR 
signalling is generally associated with a potentiation, and not inhibition, of cell migration 
and invasion of a wide range of cancer cells (Tang et al., 2013), this observation from our 
study is not entirely surprising. There could be a few reasons why cAMP increases from β-AR 
signalling failed to inhibit cell migration; but it was unlikely to be due to the preferential 
activation of Epac, which potentiates PANC-1 cell migration (Burdyga et al., 2013), instead of 
PKA because isoproterenol can also ably activate PKA in a dose dependent manner. It is 
likely here that both arms of the pathway are active in response to isoproterenol; such that 
the downstream effects of PKA and Epac are mutually cancelled out upstream of cell 
migration. However, it is also possible that the activation of β-adrenergic receptors could 
mediate off-target effects via the Gβγ subunit (Kim et al., 2012, Kang et al., 2014), or by 
coupling to different Gα subsunits such as Gαi, to either directly counteract cAMP signalling, 
or activate a cAMP-independent pathway to stimulate migration (Kirui et al., 2010). As 
mentioned earlier, isoproterenol can activate both β1 and β2 receptors and can therefore 
potentially trigger both Gαs and Gαi signalling simultaneously. On this regard, noradrenaline 
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has already been tested with regards to the migration and invasion of pancreatic cancer 
cells, but yielded ambiguous results in which 2 studies reported increases whereas 1 study 
reported inhibition (Huang et al., 2012, Guo et al., 2009, Stock et al., 2013). On the other 
hand, in another study blockage of β-AR signalling by antagonists has also been reported to 
suppress pancreatic cancer cell migration and invasion, with β2 playing a larger role in this 
process than β1 by upregulating COX-2, MMP family and VEGF (Zhang et al., 2010). 
Therefore, with evidence that the two β-AR subtypes can produce different signalling 
outcomes, next it would be more appropriate to assess the role of β1 specific agonists such 
as denopamine and β2 specific agonists such as clenbuterol on PANC-1 cell migration 
(Baker, 2010), as well as the application of pertussis toxin to test the effects of Gαi 
(mentioned earlier). This study can also be coupled with immunofluorescence in 
colocalisation studies to deduce where the β-ARs are in relation to different Gα-subunits in 
migrating cells. It is interesting to note here that β-AR signalling has been reported to 
transactivate EGF receptors (EGFR) in immortalised pancreatic ductal cells (Askari et al., 
2005), and EGFR has been shown to mediate PDAC cell migration (Stock et al., 2014). 
Therefore, this transactivation mechanism provides another avenue in which cAMP-
dependent inhibition of cell migration could be neutralised. Alternatively, as the migration 
experiment was carried out in 6-hours, the second reason could be that chronic receptor 
stimulation caused the internalisation of the receptors into a compartment of the cell where 
the receptor cannot influence cell migration. This hypothesis can be tested via 
immunofluorescence of β-adrenergic receptor distribution in migrating PANC-1 cells before 
and after isoproterenol stimulation; as well as a measurement of cAMP concentrations of 
PANC-1 cells that had undergone 6 hours of constant isoproterenol treatment to see if the 
cells can still respond to β-AR activation.     
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6.4. PDE3 is the principal regulator of the cAMP signalling arm that 
modulates PANC-1 cell migration  
Aside from β-AR signalling, results from chapter 3 also implied that both PDE4 and PDE3 
activity regulates PANC-1 cell migration; as cilostazol and rolipram application effectively 
inhibited cell migration. Under basal conditions, both PDE3 and PDE4 share the workload in 
regulating cAMP pools that influence spontaneous cell migration; though PDE3 is more likely 
to carry a higher importance in this physiological process. Intriguingly, in the presence of 
isoproterenol, PDE4 seemed to have a larger role to play than PDE3 in PANC-1 cell 
migration, as rolipram inhibited cell migration but cilostazol had no effects; though PDE3 
cannot be ruled out in this case because cilostazol and rolipram produced additive inhibitory 
effects on cell migration. As we’ve found earlier both PDE3 and PDE4 can regulate cAMP 
levels derived from β-AR, these results suggest that the pool of cAMP generated by β-AR 
signalling that can regulate cell migration is likely to be influenced mainly by PDE4 activity, 
where the synergy between PDE3 and PDE4 observed in the corresponding cAMP 
measurements also appeared to translate into the regulation of cell migration downstream; 
in an effect similar to that reported previously on vascular smooth muscle cells (Palmer et 
al., 1998). Of course, until the specificities of the β-Adrenergic pathway are better 
understood in PANC-1 cells, it is not productive at this stage to extrapolate any further. This 
can however be probed further by immunostaining for PDE3, 4 and the different subtypes of 
β-ARs in migrating PANC-1 cells to look at their locations with respect to each other.  
When migrating up the chemoattractant (5% FBS in this case) gradient, the results profile 
was similar to that observed for random migration, but with a larger magnitude of effects. 
The synergy between PDE3 and PDE4 on cAMP levels also did not apply to directional 
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migration, with PDE3 carrying the bulk of regulation of this process; interestingly, PDE4 
inhibition did not reduce directional PANC-1 cell migration compared to control this time, 
instead showing a slight tendency to increase directional migration. These results implicate 
PDE3 as being more important than PDE4 in modulating directional chemotactic PANC-1 cell 
migration.  
Collectively, these observations strongly suggest that the cAMP pathway that modulates 
PANC-1 cell migration is regulated principally by PDE3; though other PDE isoforms may also 
play a role in this process. This supports the results from a previous study that cilostamide 
(at 100µM) inhibited random migration, invasion and TGFβ-induced migration (Zimmerman 
et al., 2013) of PANC-1 cells. On the other hand, the finding that PDE4 may regulate 
migration in the presence of β-AR stimulation supports the idea that in terms of this 
physiological process, cAMP signalling in PANC-1 cells is compartmentalised, where PDE3 
may have more influence on cAMP levels produced non-specifically (e.g. forskolin) or by the 
basal activity of the ACs; whereas PDE4 may regulate cAMP derived from more specific 
modes of GPCR signalling, such as that of β-ARs, though overlaps likely occur due to 
cilostazol also potentiating cAMP levels from isoproterenol treatment. Indeed, experiments 
in which we observed most prominent suppression of migration by PDE3 inhibition was in 
the absence of added cAMP agonists; moreover, cilostazol and rolipram produced additive 
effects on cAMP levels in PANC-1 cells, but this synergy did not translate into cell migration 
downstream unless isoproterenol was present. Therefore, one could test the effects of 
cliostazol and rolipram in the presence of sub-maximal concentrations of forskolin instead 
of isoproterenol on cell migration to examine this hypothesis. Furthermore, parallel studies 
would also need to be made once the comprehensive characterisation of effective cAMP 
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agonists is complete, as it appears that PANC-1 cell migration depends as much on the mode 
of cAMP production as on the PDEs that sculpt the signal. Lastly, the repeated observations 
that IBMX produced higher levels of migration inhibition than combined PDE3/4 inhibition in 
both ‘basal’ conditions and in the presence of isoproterenol suggests that either other PDE 
isoforms may be present in the regulation of PANC-1 cell migration, or that the 
concentrations of cilostazol and rolipram used was not high enough to produce full PDE 
inhibition. 
Thus far, apart from the Zimmerman study (Zimmerman et al., 2013), reports that PDE3 
inhibition directly suppressed cell migration in other cancers has only been reported once 
before, in colon cancer cells (Murata et al., 1999). The only other cell type in which PDE3 has 
also been observed to regulate cell migration is human vascular endothelial cells, 
(Netherton and Maurice, 2005, Palmer et al., 1998) with the formation of a signalosome 
consisting of PDE3, Epac1 and PI3Kγ presenting one possible mechanism with which to 
orquestrate cell adhesion, spreading and locomotion (Wilson et al., 2011). In comparison, 
PDE4 is better represented in terms of cancer cell migration. For example, in breast cancer 
cell lines, PDE4 inhibition has been documented to suppress integrin-induced formation of 
lamellopodia and downstream chemotactic migration and invasion (O'Connor et al., 1998), 
but strangely PKA inhibition also inhibited this process (O'Connor and Mercurio, 2001). In 
addition, in the same cells PDE4 inhibition decreased constitutive Ca2+ entry, another 
process important for the migration of this cell type, by activating PKA (Clarysse et al., 
2014). In melanoma cells PDE4 is also a prominent regulator of cAMP/PKA signalling, the 
inhibition of which also inhibited cell migration (Watanabe et al., 2012).  
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Now with the knowledge that PDE3 has the greatest influence on cAMP-mediated 
regulation of PANC-1 cell migration, this study could also be coupled with the examination 
of the localisation of PDE3, Epac and the PKA catalytic subunits in migrating PANC-1 cells in 
an attempt to visualise any potential signalosomes.   
 
6.5. PANC-1 cells have highly effective Ca2+ signalling systems 
After taking the first steps into characterising cAMP signalling in PANC-1 cells, the main 
objective of chapter 5 was to establish if a cross-talk exists between Ca2+ and cAMP 
signalling, namely whether Ca2+ can influence cAMP levels in this cell type. However, before 
that main study could take place, we had to ask what the main components of the Ca2+ 
signalling machinery are in the cell. The answers of this question would refine the tools (i.e. 
identify specific inhibitors) with which to study the influences of Ca2+ signalling on cAMP, 
which was the main focus of chapter 4.   
Despite the variations, Ca2+ signalling in non-excitable cells generally follow the same 
reaction scheme – agonist stimulation  2nd messenger production  Ca2+ release from 
intracellular stores  SOCE to refill the stores. Therefore, for our first experiment we tested 
this scheme by measuring cytosolic Ca2+ levels using neurotensin (NT) as the agonist. In 
nominally Ca2+ free conditions, NT induced a Ca2+ signal within seconds, underlining the high 
efficiency of Ca2+ signalling in this cell type. It is very likely that this is due to 
compartmentalised signalling of this ion, typified by the proximity of IP3 receptors to PM 
signalling complexes to minimise diffusion distance. As it was shown recently that ER-PM 
junctions are prominent in PANC-1 cells and that they turnover efficiently (Dingsdale et al., 
2013), it is not unreasonable to propose that the relay of cell signalling from PM surface 
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receptors to the ER takes place near such junctions. Therefore, it would be useful in the 
future to also examine the localisation of NTR and IP3Rs in PANC-1 cells to test this.  
In the same experiment, following the depletion of intracellular stores, the addition of 
extracellular Ca2+ induced a substantial signal almost immediately; confirming the rapid 
responsiveness and effectiveness of SOCE. The subsequent stabilisation of the Ca2+ signal 
roughly to the magnitude of the NT spike implies that SOCE was sustaining the NT signal 
that was counteracted by another mechanism. Of course, as NTR is also a GPCR, one cannot 
rule out the possibility that NTR was internalised within minutes of stimulation here (Savdie 
et al., 2006). Thapsigargin (TG) treatment in the presence of NT almost doubled the 
magnitude of Ca2+ signal, again within seconds, strongly suggesting that SERCA was the one 
of the main opposing mechanism in suppressing the Ca2+ signal. The effects of PMCA or NCX 
on the SOCE signal in this particular case was not tested in this thesis, so we cannot rule out 
the activity of these two pumps on the PM having an influence on Ca2+ homeostasis. It 
would be worth testing the role of SERCA, PMCA and NCX in PANC-1 cells to ask which 
exchanger/pump is the most important for the maintenance of low resting cytosolic Ca2+ 
levels in this cell type.   
Having confirmed the efficiency of Ca2+ signalling in PANC-1 cells, we decided to deplete 
intracellular stores passively by TG-induced SERCA inhibition under nominally Ca2+ free 
conditions, and then introduce extracellular Ca2+ to activate SOCE in the absence of NT. The 
inhibition of SERCA induced a robust signal; however, the signature of the signal, which is 
typified by a slight 100s delay after TG addition, followed by a rapid singular spike, suggests 
the existence of Ca2+ induced Ca2+ release (CICR) from the ER, which is a phenomenon in 
which the presence of Ca2+ in the vicinity activates ryanodine receptors (RyRs) on the ER, 
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which mediates a number of processes, with both cardiac and smooth muscle contraction 
being the best studied (Van Petegem, 2012). RyR expression has been found in breast 
cancer cells (Saldana et al., 2009), where a recent study correlated RyR expression levels 
positively with breast cancer cell growth and tumour grade (Abdul et al., 2008). In 
nasopharyngeal carcinoma cells, the Ca2+ channel TRPM7 was proposed to induce RyR-
mediated CICR to promote cell migration (Chen et al., 2010). Secondly, this also suggests 
that the ER membrane in PANC-1 cells is leaky to Ca2+ i.e. this ion can spontaneously 
traverse the ER membrane, which may explain why these cells often display spontaneous 
Ca2+ activity in the presence of only 1% serum and extracellular Ca2+. Lastly, much like cAMP, 
NT is only one of potentially many Ca2+ agonists in PANC-1 cells, and the ability of this cell to 
generate spontaneous Ca2+ signals in serum make the characterisation of agonists difficult. 
Therefore, next it would be interesting to first characterise the expression and localisation 
of the Ca2+ signalling toolkit in PANC-1 cells immediately downstream of GPCR or RTK-
activated Ca2+ signalling, namely from PLCγ/PLCβ onwards to IP3Rs, SERCA, PMCA and 
possibly RyRs, in the modulation of PANC-1 cell physiology.  
The signal observed after the activation of SOCE in the presence of TG was much more 
stable and quantitatively larger as compared to NT, confirming the prominence of SERCA in 
the regulation of Ca2+ signalling in PANC-1 cells. This supports the past observations that the 
inhibition of this ER Ca2+ pump by either cyclopiazonic acid or TG induced the formation of 
STIM-ORAI puncta within seconds of addition (Dingsdale et al., 2013). Additionally, given 
that the Ca2+ buffering role of mitochondria is indispensable to the normal function of 
mouse pancreatic acinar cells (Voronina et al., 2014), one of the potential ancestors of 
PDAC, it would be intriguing to see what roles mitochondria play in the PANC-1 cell SOCE 
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process; especially that induced by NT as compared to SERCA inhibitors because 
mitochondrial Ca2+ buffering has been reported to be vital for SOCE in HUVEC cells and IP3-
dependent (but not TG-dependent) SOCE activation in HeLa cells (Deak et al., 2014, Naghdi 
et al., 2010).  
 
6.6. ORAI1 is the dominant SOCE channel in PANC-1 cells 
After describing the efficiency of Ca2+ signalling in PANC-1 cells the focus was shifted onto 
characterising the machinery involved in SOCE, a process pivotal for the long term stability 
of Ca2+ signalling in non-excitable cells; specifically on the PM channels involved in SOCE. 
The purpose of this study was to find the best possible inhibitor of SOCE for the Ca2+-cAMP 
cross-talk study. This investigation utilised the experimental scheme in which TG was used 
instead of NT due to the former being more effective at activating SOCE. The resulting data 
from this part of the study shows that ORAI1 appears to be the main constituent in the SOCE 
machinery, as its corresponding inhibitor GSK-7975A efficiently inhibited SOCE by well over 
50%. However, the observation that this magnitude of inhibition is not 90% or more 
suggests that it is more than likely that Ca2+ channels other than ORAI1 also contribute to 
SOCE in this cell type. However, ORAI3 is not likely to be one of the candidates because GSK-
7975A is also an inhibitor of ORAI3, and also because of the observation that this GSK-
7975A-resistant component of SOCE can also be inhibited by 2-APB; a well-known activator 
of ORAI3 (Schindl et al., 2008). This leaves ORAI2 in this family that remains to be tested. In 
an attempt to see what other channels mediate SOCE we also tested the possible role of 
VGCC in PANC-1 cells, The VGCC inhibitor nifedipine failed to elicit any changes in SOCE, 
indicating that VGCC are unlikely to be involved in this process. The ability of 2-APB to 
obliterate SOCE in PANC-1 cells prompted us to test the roles of the TRPC family of channels 
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in this process, as 2-APB has also been shown to inhibit TRPC channels (Jiang et al., 2013). 
TRPC3 is unlikely to take part in SOCE in PANC-1 cells, as its channel blocker Pyr3 did not 
affect the GSK-7975A-resistant component of SOCE. Furthermore, the addition of SKF-96365 
alone, considered as a wide-range inhibitor of multiple TRPC channels (Song et al., 2014), 
did not have any influences on the SOCE plateau either, suggesting that this family of Ca2+ 
channels are unlikely to take part in SOCE in PANC-1 cells. It is important to point out here 
though that in the past we have consistently observed that SKF-96365 significantly inhibited 
PANC-1 cell migration; meaning that TRPC channels may yet have a role in PANC-1 cells. 
More importantly, contribution of TRPC channels to SOCE is often ORAI-dependent (Cheng 
et al., 2013). As we did not test the role of SKF-96365 on the GSK-7975A-resistant 
component of SOCE in this study, the active role of this family of channels on SOCE in PANC-
1 cells cannot be ruled out. This is especially the case for TRPC1, which has the strongest 
claim to be a SOCE channel in the TRPC family (Cheng et al., 2013).  
Apart from the properties of other channels on the PM, the prospect of intracellular Ca2+ 
buffering during SOCE by organelles other than the ER, such as the mitochondria, also 
cannot be ruled out. Indeed, mitochondria can import Ca2+ via a uniporter MCU when the 
cytosolic Ca2+ concentration is high and extrude the ion via a specialised NCX (NCLX) in a 
mechanism that is not fully understood; essentially making this organelle a Ca2+ buffer 
(Voronina et al., 2014). As mitochondria can specifically take in Ca2+ derived from SOCE 
(Deak et al., 2014), it is not unreasonable to hypothesise that during the maximal plateau 
phase of SOCE mitochondria imports Ca2+ into its matrix in PANC-1 cells; such that when 
ORAI1 was blocked or when extracellular Ca2+ was removed, the Ca2+ stockpiled in the 
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mitochondria during SOCE could be released from the matrix and equilibrated with the 
cytosol.  
Overall, our results here indicate that ORAI1 is the principal SOCE channel of PANC-1 cells, 
supporting previous studies (Kondratska et al., 2014); though the expression of ORAI2 and 
TRPC1 needs to be tested. If these channels are expressed, one can look at the localisation 
of these channels in relation to ORAI1. It would also be advantageous to measure 
mitochondrial Ca2+ levels during SOCE activation and inhibition using specifically targeted 
genetically encoded Ca2+ sensors or mitochondria-localised fluorescent probes (Bonora et 
al., 2013), all in the continuous presence of GSK.   
 
6.7. SOCE activates PKA activity in PANC-1 cells  
After characterising the best tools for manipulating the Ca2+ signalling cascade in PANC-1 
cells, we decided to probe the existence of a Ca2+ cAMP crosstalk in PANC-1 cells (see 
chapter 5). First, the treatment of PANC-1 cells with NT both in the presence of extracellular 
Ca2+ and serum induced a small but notable increase in PKA activity, the effect of which 
appearing to be transient. This NT response provided the first indication that activation of 
the Ca2+ signalling cascade also activates cAMP signalling. As this increase in PKA activity is 
likely to be a compound effect of all 4 steps of Ca2+ activation (agonist stimulation, IP3 
production, Ca2+ release/depletion from stores, SOCE activation); we focused on the effects 
of the last two steps, because their stimulating effects on cAMP signalling have been 
reported in other cell types (Lefkimmiatis et al., 2009, Cooper and Tabbasum, 2014). 
Interestingly, TG-induced SOCE ably increased PKA activity, the effect of which appearing to 
be sustainable even in the absence of PDE inhibition. This effect appears to be dependent 
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on the properties of ORAI1 channels and the Ca2+ entry, because the application of GSK-
7975A or the removal of extracellular Ca2+, also successfully suppressed SOCE-induced PKA 
activity. On the other hand, the activation of the same Ca2+ signalling processes only 
modestly increased cAMP concentration; even in the presence of IBMX to inhibit PDE 
activity.  
The first hypothesis that can be derived from this observation is that SOCE only activated a 
small subset of AC isoforms, and the resultant cAMP that was produced was only enough to 
register a small increase on the H134 probe; however, this same modest increase in cAMP 
was already sufficient to activate PKA downstream to an extent that the AKAR4 probe can 
detect this. Supporting this, SOCE-activated PKA activity represented only a fraction of the 
maximal response, suggesting that not all AC isoforms were activated by this process. 
Moreover, this observation also suggests that SOCE preferentially activate PKA rather than 
Epac; this is because the H134 construct is modelled upon Epac and, despite the engineered 
Q270E mutation to drop its dissociation constant for cAMP, still only reported mild increases 
in FCFP/FYFP ratio in the presence of IBMX. This phenomenon has actually been reported 
before in the rat pancreatic acini, when cholecystokinin (CCK), a Ca2+ agonist in the normal 
pancreas, significantly increased PKA activity despite only mild increases being observed for 
the corresponding measurements of cAMP concentration (Marino et al., 1993). At this 
stage, given that the general signalling properties of all AC isoforms are known, an 
expression analysis of the different AC isoforms in PANC-1 cells would answer many 
remaining questions; the most important of which is whether AC1 and/or AC8 expression in 
these cells is the reason for this SOCE-activated PKA activity. Of course, one also cannot rule 
out the possibility that Ca2+-inhibited isoforms AC5 and/or AC6 are also present in PANC-1 
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cells, as a recent study showed that AC6 is expressed in the mouse pancreatic acini, the 
activity of which was enhanced by Ca2+ chelation; whereas AC1 or AC8 are absent  (Sabbatini 
et al., 2013). The combined occurrence of AC5/6 inhibition and AC1/8 activation could be 
one of the reasons why NT only induced a weak PKA response as compared to SOCE after 
pharmacological store depletion.  
This study measured the cAMP/PKA pathway at a whole cell level. Therefore, another 
reason why the measured of cAMP levels turned out to be small in response to SOCE could 
be due to the compartmentalised nature of this signalling pathway, where instead of a 
global increase, the cAMP increase could have occurred in a defined area of the cell where 
cAMP levels are tightly controlled, such that it is out of the scope of sensitivity for the H134 
probe. In a previous study, a cAMP probe Epac-camps was fused onto AC8 to successfully 
measure cAMP levels in the vicinity of the enzyme in pancreatic β-cells (Everett and Cooper, 
2013). Therefore, to test that hypothesis it would be useful to utilise specifically localised 
probes to measure cAMP/PKA signalling closer to the cell membrane where cAMP is first 
produced. Indeed, AC1 and AC8 signal predominantly in lipid rafts, where its sensitivity to 
SOCE is due its close proximity to ORAI1 channels; whereas AC2, which is not directly 
sensitive to Ca2+, are evenly distributed throughout the membrane (Willoughby et al., 
2012a, Willoughby et al., 2010b). This possibility could be tested via the use of AKAR4-Kras 
and Lyn-AKAR4, variants of the AKAR4 probes that are targeted to the lipid-raft and non-raft 
sections of the membrane respectively (Depry et al., 2011), these probes can be used to 
compare compartmentalised PKA activity at the membrane in response to SOCE. 
Additionally, cyclodextrin, which disrupts the lipid raft by extracting cholesterol from the 
PM, can be applied here to see if it can alter this form of PKA signalling (Zidovetzki and 
217 
 
Levitan, 2007). Due to the dependency of AC1 and AC8 activation on calmodulin, it would 
also be a good control to test calmodulin inhibitors on this SOCE-mediated PKA activity.  
If AC1 and AC8 are not expressed in PANC-1 cells, then the activation of PKA as a result of 
SOCE could also be due to cAMP independent effects. In particular, a novel cAMP-
independent PKA activation mechanism was reported recently in mouse acinar cells, where 
smad3/smad4 can directly interact with the regulatory subunit of PKA downstream of TGFβ 
signalling to activate CREB (Yang et al., 2008). In another study sphingosine has been shown 
to activate PKA type II independent of cAMP without the dissociation of C subsunits from 
the R subunits in COS cells (Ma et al., 2005). Given that sphingolipids can act as a second 
messengers in other cancers (human leukaemia and colonic carcinoma cell lines) (Sweeney 
et al., 1996), and that PDAC cells have an adept TGFβ/Smad3 signalling system themselves 
(Nicolas and Hill, 2003), these hypotheses cannot be ruled out. Secondly, this increase in 
FYFP/FCFP ratio by SOCE activation could also be a result of protein phosphatase (PP) 
inhibition. AKAR4 is a PKA substrate; therefore it is also a reporter for the phosphorylation 
status of PKA substrates. The reversibility of AKAR4 phosphorylation as a result of forskolin 
and IBMX removal (Burdyga et al., 2013) suggests that this negative feedback mechanism by 
PPs for this probe is just as effective in PANC-1 cells, but not well known. Therefore, prior to 
establishing if there is a link between SOCE and the inhibition of PPs, it would first be useful 
to characterise PKA opposing phosphatases in PANC-1 cells by using known inhibitors. On 
the other hand, it is also possible that this phenomenon is entirely independent of 
cAMP/PKA signalling; and is instead due to calmodulin-dependent protein kinase-2 (CaMKII) 
activity. This is because both PKA and CamKII have almost identical consensus substrate 
sequences (RRXS/T for PKA, RXXS/T for CamKII) (Ubersax and Ferrell, 2007), culminating in 
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the ability of CaMKII to phosphorylate substrates that were originally known to be targets of 
only PKA, such as CREB (Souza et al., 2012). In addition, in a recent study, SOCE has been 
found to directly activate the CaMKII/Raf/ERK signalling pathway in melanoma cells to 
potentiate migration and proliferation (Umemura et al., 2014). Linking this to our study, 
although the PKA inhibitor H89 potently inhibited SOCE-induced PKA activity in PANC-1 cells, 
H89 is also known to inhibit other kinases including CaMKII to a lesser extent. Therefore, as 
an additional control for PKA activity one should use CaMKII inhibitors like KN-62 to see if 
AKAR4 can also be phosphorylated by this kinase. 
         
6.8. PKA substrates accumulate in the leading edge and in the nucleus 
The purpose of the second part of chapter 5 was to investigate whether the SOCE PKA 
regulation of cell migration system exists in PANC-1 cells under basal conditions (1% serum, 
extracellular Ca2+ present). The localisation of PKA substrates was studied as readout for 
PKA activity using immunofluorescence. Results from this study clearly showed that the 
nucleus and the extreme leading edges are the locations where PKA activity appears to be 
the highest. In the nucleus, the prime candidate for the high phospho-PKA substrate 
fluorescence is p-CREB, which has been previously found to be basally active in PDAC cells 
(Zhang et al., 2010); and responsible for the activation of the transcription of the miRNA 
miR-373, and downregulates tumour suppressor proteins TP53INP1 and LATS2 to promote 
PDAC cell growth (Zhang et al., 2013). 
In another finding, the colocalisation of phospho-PKA substrate with actin in the leading 
edge suggests that PKA regulates PANC-1 cell migration via the modulation of actin in the 
lamellipodia. To accurately confirm that this distribution of phosphorylated PKA substrates 
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is indeed due to the preferential activation of PKA activity in the leading edge it would be 
useful to correlate this to the localisation of endogenous type I and type II PKA regulatory 
and catalytic subunits, as well as the localisation of CaMKII to see if this kinase also 
contributed to the observed co-localisation. Alternatively, to confirm that phosphorylated 
PKA substrates are actually in close proximity with actin one can also use antibodies against 
actin to reveal the endogenous distribution of actin. Indeed, this characteristic of PKA 
activation in migrating cells is actually quite common , as PKA has an already large and still 
growing list of substrates involved in cell migration (Howe, 2011). For example, in migrating 
breast cancer and colon carcinoma cells, PKA activity is the highest in the leading edge, 
mediated by AKAP-Lbc anchoring (Paulucci-Holthauzen et al., 2009); furthermore, AKAP 
anchoring of PKA R subunits is also important to ensure that the leading edge has the 
highest PKA activity in migrating epithelial ovarian cancer cells, which is vital for cell 
migration and extracellular matrix invasion (McKenzie et al., 2011). This phenomenon also 
extends to non-cancerous cells like Chinese hamster ovary (CHO) cells, where PKA activity 
downstream of integrin signalling is important for the maintenance of cell polarity via a PIP3-
dependent mechanism (Lim et al., 2008). Given that global increase of PKA activity in PANC-
1 cells suppresses migration (Burdyga et al., 2013), this compartmentalised effect of PKA 
activity in the leading edge in wild-type conditions is very likely a result of PKA anchoring, 
possibly via AKAPs. On this subject, knowledge regarding the AKAPs in PDACs is severely 
lacking; therefore it would be beneficial to characterise the type of AKAPs expressed in 
PANC-1 cells and then define the signature of the signalosome formed by the AKAPs. In 
particular, AKAP13 (or AKAP-Lbc) would be intriguing due to its ability to act as a RhoGEF as 
well as an adaptor protein for PKA. As an adaptor it has been shown to increase the 
proficiency of the Raf-MEK-ERK1/2 signalling pathway by cooperating with another 
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scaffolding protein KSR-1 (kinase suppressor of RAS-1) to bring Raf in proximity to MEK and 
ERK1/2 while also recruiting PKA to the macromolecular complex; where PKA phosphorylate 
KSR-1 and ERK1/2 to enhance the signalling (Smith et al., 2010). Given that this pathway is 
downstream of both KRAS and EGF, prominent signalling pathways in PANC-1 cells (Collisson 
et al., 2012, Binker et al., 2009), this mechanism of producing signalling efficiency could 
mediate the pathophysiology of PDACs. Another fascinating prospect are previous findings 
that α4 integrin can itself act as an AKAP to trap PKA signalling at the leading edge of the cell 
to facilitate cell migration in CHO cells (Lim et al., 2007). Although PANC-1 cells mainly 
express α5 integrin (Yao et al., 2011, Niu et al., 2010), it remains a possibility that this cell 
type may utilise integrin to compartmentalise PKA signalling to regulate cell migration. In 
terms of its RhoGEF activity, AKAP-lbc has been reported to activate RhoA downstream of 
combined integrin and LPA-stimulated signalling; which is required for downstream Rac1 
activation, lamellae formation and cell motility in breast cancer cells (O'Connor et al., 2012). 
This GEF property may be significant if expressed in PANC-1 cells because PKA-mediated 
inhibition of cell migration appears to be partly via the suppression of RhoA and RhoC 
activity (Zimmerman et al., 2013), and PKA anchored by AKAP-lbc may provide an avenue in 
which RhoA and RhoC activity can be regulated. In addition to AKAPs, it would also be 
important to check the localisation of active RhoA and RhoC in migrating PANC-1 cells to see 
if they are part of the phospho-PKA substrate population in the lamellipodia detected here.    
6.9 ER-PM junctions reside in areas of low phospho-PKA concentration 
immediately bedhind the leading edge 
In most of the migrating cells imaged, the region immediately behind the PKA substrate-rich 
lamellipodia is relatively free of PKA substrates, suggesting that in the lamella, PKA activity is 
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the lowest in PANC-1 cells. Interestingly, this ‘PKA free’ area appears to be the compartment 
in which endogenous ER-PM junctions congregate in polarised cells, supporting previous 
descriptions that STIM-ORAI punctas in PANC-1 cells are just behind the actin-rich leading 
edge (Dingsdale et al., 2013). This suggests that components of ER-PM junctions may have 
negating effects on PKA signalling in the immediate vicinity. There, the negation of PKA 
activity by SOCE could be either by the activation of PDEs or PPs in a Ca2+-dependent 
manner, possibly via PDE1 (breaks down cAMP) or calcineurin (CaN, removes the phosphate 
group put there by PKA). Indeed, results from chapter 3 indicate that the activity of PDE1, 
which is activated by Ca2+ signalling (Goraya and Cooper, 2005), remains inconclusive in 
PANC-1 cells. It should also be noted that calcineurin (also known as PP2B) has been well 
documented to oppose PKA phosphorylation (Santana et al., 2002). These observations 
underline the need to biochemically characterise PPs and PDE isoforms and their localisation 
in PANC-1 cells. Alternatively, in light of the finding that SOCE actually increased global PKA 
activity in PANC-1 cells, ER-PM junctions also tended to form a ‘band’ of some sort in the 
lamella, in close proximity to the lamellipodia, suggesting that SOCE taking place in those 
junctions can feed forward into the leading edge to activate PKA.  
Like cAMP, Ca2+ signalling is also an effective regulator of cell migration in its own right (Tsai 
and Meyer, 2012, Monteith et al., 2012). For example, STIM1-activated SOCE plays a vital 
role for cervical cancer cell migration, where STIM1 served to increase the number of 
actomyosin complexes to enhance the force of contractility in migrating cervical cancer cells 
(Chen et al., 2013b); as well as facilitating focal adhesion turnover via the protease calpain 
and kinase Pyk2, both Ca2+-regulated enzymes (Yang et al., 2009, Chen et al., 2011). STIM1 is 
also indispensable for the migration of breast cancer cells, where SOCE is required for 
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metastasis (Yang et al., 2009). In addition, TRPC1, another SOCE channel candidate, is 
required in the lamellipodia of glioma cells to maintain cell polarity during EGF-stimulated 
chemotactic migration (Fabian et al., 2008, Bomben et al., 2011). Downstream, an elegant 
study performed on migrating HUVEC cells provided valuable insight into the mechanism in 
which components and messengers of the Ca2+ signalling toolkit are manoeuvred around 
the cell to regulate migration (Tsai and Meyer, 2012). There, the authors observed that RTK, 
PMCA and STIM punctas are preferentially accumulated at the leading edge, establishing a 
DAG gradient in which the ‘front’ of the cell contains the highest DAG concentration; while 
the cytosolic Ca2+ gradient was inversed, with the back of the cell containing the highest Ca2+ 
concentration. Intriguingly, in PANC-1 cells, the basal activity of PLCγ, a physiological 
activator of Ca2+ signalling, has been found to be elevated in the presence of serum (Stock et 
al., 2013), which, coupled with the highly efficient SOCE system in this cell type, may 
contribute to the ability of this cell line to spontaneously form membrane ruffles and 
migrate without any other interventions.  
Although a Ca2+-cAMP crosstalk has been known for some time, studies on the 
consequences downstream of SOCE activated cAMP signalling is still at an infancy. So far we 
have only found one study, in which Ca2+ activated cAMP/PKA signalling is important for the 
spontaneous activation of action potentials in cardiac pacemaker cells (Yaniv et al., 2011); 
that reported a physiological effect as a result of this mode of signalling. Therefore, the 
proximity of STIM1 punctas and endogenous ER-PM junctions to phosphorylated PKA 
substrates in migrating PANC-1 cells, coupled with the ability of SOCE to activate PKA as 
observed in the live cell experiments, implies that this mode of signalling occurs at the 
leading edge to regulate cell migration, which is promising. However, to reinforce this 
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statement the localisation of the AC isoforms expressed in PANC-1 cells would need to be 
checked in conjunction with ORAI1 (and possibly other SOCE-mediating channels) after the 
activation of SOCE. Additionally, the expression of AKAP79, reported on numerous occasions 
to bridge Ca2+ and cAMP signalling together near the cell membrane (Willoughby et al., 
2012b, Willoughby et al., 2010a, Shen and Cooper, 2013, Hinke et al., 2012), can be tested 
to see if this AKAP has a hand in facilitating this interaction in PANC-1 cells. Secondly, as this 
study did not concern STIM2, which is considered to play a housekeeping role in maintaining 
basal ER Ca2+ levels in cells under physiological conditions (Soboloff et al., 2012), it would 
also be useful to couple measurements of STIM2 distribution with the ER-PM linker protocol 
to see how they correlate in PANC-1 cells under basal, non-stimulated conditions. Further 
down the line, as the physiological consequence of SOCE activated PKA responses in PANC-1 
cells is still unknown, and PKA phosphorylates and subsequently inhibit RhoA and RhoC 
activity in PANC-1 cells, it would be interesting to address what, if any, effects SOCE 
activation can have on these two Rho GTPases. Lastly, it would be particularly intriguing to 
study this when PANC-1 cells are grown on a lawn of matrigel in order to see if these 
relationships between Ca2+ and cAMP signalling observed in study here can be applied by 
the cells to regulate invasion and 3-dimensional migration/invasion.    
6.10. Concluding remarks 
This study coupled live-cell imaging approach with pharmacology, taking advantage of 
novel, genetically-encoded FRET based sensors to characterise the components of the cAMP 
signalling pathway in PANC-1 cells. There are over 20 different PDAC cell lines (Thu et al., 
2014), each with different origins, genotypes and adhesive, invasive and tumorigenic 
phenotypes, as comprehensively reviewed previously (Deer et al., 2010). PANC-1 cells were 
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originally derived from a primary tumour at the head of the pancreas that metastasised 
locally to the duodenal wall and the peripancreatic lymph node. It carries a heterozygous 
activating mutation in the KRAS gene, homozygous deletions to the p16 gene and mutations 
in the TP53 gene (Lieber et al., 1975). PANC-1 cells have the advantage over other cell lines 
for being easily transfectable with plasmids and loaded with dye for real-time, physiological 
experiments; whereas its weakness is its poor tumorigenicity; even when injected into 
immune-compromised mice, making translational in vivo studies using this cell line difficult 
(Momose et al., 2010). In the prior studies we have tested BxPC-3, Capan-2, SUIT-2 and 
MiaPaCa-2 cells in Boyden Chamber studies, all of which displayed significant inhibition of 
migration in response to increases in cAMP levels; which supports the notion that the 
inhibitory effects of cAMP on cell migration is genuine in PDAC (Burdyga et al., 2013).     
Our study identified PDE3 and PDE4 to be the main terminators of cAMP signalling in PANC-
1 cells, whereas isoproterenol is the main cAMP agonist. However, in terms of cell migration 
isoproterenol is not a good potential target for blocking metastasis, as it had very little 
effects on cell migration. Moreover, it appeared that combined PDE3/4 inhibition was the 
best target as for inhibiting migration; putting forward PDE3/4 inhibitors as a potential 
candidate for reducing metastasis formation. In the second part of the study it was Ca2+ 
signalling, especially SOCE, appeared to be able to activate cAMP signalling in PANC-1 cells, 
which effectively translated into PKA activity. Immunofluorescence data showed that 
phosphorylated PKA substrates are accumulated at the lamellipodia of migrating cells, 
where they colocalised with actin. ER-PM junctions under basal conditions are situated 
immediately behind the actin-rich areas in the leading edge. This implies that SOCE-
mediated PKA activity could have a role in PANC-1 cell migration, which warrants further 
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investigation. To further develop this study it would be advantageous to carry out 
biochemical characterisation of the cAMP cascade components, specifically the isoforms of 
AC, and the splice variants of PDE3 and PDE4 that are expressed in PANC-1 cells. 
Furthermore, with the observations that different components of the cAMP pathway 
expressed in the same cell can have differential effects on cellular growth and cell migration 
in PDAC cells, it would be very important to determine how the machinery of this signalling 
cascade is spatially coordinated. Lastly, there is extensive genetic and epigenetic 
heterogeneity present in PDAC tumors (Arensman et al., 2014, Thu et al., 2014). Therefore, 
to relate the results reported here from ‘PANC-1 cells’ to ‘PDAC’, some experiments 
reported in the thesis would need to be carried out on other PDAC cell lines, and then the 
specified interventions applied onto in vivo models such as the ‘KPC’ mice, which 
spontaneously develop aggressive PDAC (Guerra and Barbacid, 2013) to evaluate the role of 
cAMP signalling casual in more pathology-relevant conditions.    
I hope that this study will be a useful stepping stone for further research that will elucidate 
the mechanism regulating migration, invasion and the formation of metastases of PDAC 
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